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Abstract 
Investigation of the human folate gene MTHFD1L: polymorphisms and 
disease risk. 
Stefano Minguzzi 
The MTHFD1L gene encodes the mitochondrial monofunctional enzyme with proven 10-
formyltetrahydrofolate synthetase activity. MTHFD1L expression is upregulated in human 
colon cancer and breast cancer, and high levels of this protein are correlated with growth 
rate of human cancer cell lines. Genetic association studies demonstrated that MTHFD1L 
polymorphisms are associated with coronary artery disease, Alzheimer’s disease and 
neural tube defects (NTDs). Moreover, MTHFD1L knockout mice develop NTDs with 
100% penetrance. This project involves the characterization of MTHFD1L with a particular 
focus on genetic polymorphisms and disease risk. MTHFD1L polymorphisms have been 
studied in relation to cleft disease and Melting Curve Analysis was developed for 
genotyping the Deletion Insertion Polymorphism rs3832406. MicroRNA-9 and 197 were 
proven to downregulate MTHFD1L at mRNA and protein level. The impact of 
polymorphism rs7646 on miR-197 binding suggests a mechanistic explanation of the 
previous association of this SNP with NTD risk. Sequence analysis was performed to 
discover and characterize MTHFD1 and MTHFD1L similar sequences. MTHFD1L 
expression was proven to be affected by a 24 hour exposure to cycloleucine in 
lymphoblast. Finally, HEK293 stable cell lines with either MTHFD1L downregulated or 
overexpressed have been generated and the resulting proteomes have been assessed by 
Mass Spec.   
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CHAPTER 1 
     
Introduction 
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1.1 Introduction 
 
1.1.1 Overview 
 
Nutritional genomics is a branch of science that studies the relationship between the human 
genome, nutrition and health. In particular, it studies how individual differences in genes 
influence the body's response to diet and nutrition and how these genetic variations (called 
polymorphisms) play a role as risk factors of disease. Folate is an essential nutrient 
necessary for many cellular functions and folate deficiency has been correlated with 
numerous diseases. Genes that are involved in the transport and metabolism of this vitamin 
are currently considered the main candidates for disease association. 
 
This thesis consists of the characterization of the folate-related gene 
methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) with a particular focus on 
genetic polymorphisms and disease risk. Our laboratory previously investigated the 
association between MTHFD1L polymorphisms and Neural Tube Defects (NTDs) in the 
Irish population (Parle-McDermott et al. 2009). Following up on this study, MTHFD1L 
genetic variations have been considered in relation to another birth defect, Cleft disease. 
The impact of these genetic variations on microRNA regulation has also been investigated. 
The results of these studies have been corroborated by proteomic analysis on samples with 
different MTHFD1L expression levels. The other aspects covered by this manuscript are 
the role of alternative splicing on MTHFD1L expression and the potential function of 
additional homologous sequences.  
 
This introductive first chapter starts off by explaining the concept of nutritional genomics 
and illustrating the folate-mediated one-carbon metabolism along with the genes involved 
in it. It continues by presenting the literature on the MTHFD gene family and their disease 
association and concludes with the aims and objectives of this thesis.  
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1.1.2 Nutritional genomics  
 
Nutritional genomics is a highly innovative and fast-growing science that studies how 
dietary components interact with genes and how these genes are related to metabolism. 
This discipline includes nutrigenomics, which studies how nutrients interact with the 
genome, proteome and metabolome; and nutrigenetics, which studies the interaction 
between diet and health as a consequence of genetic variations with implications to 
susceptible populations (Debusk et al. 2005, Subbiah 2007). 
 
The completion of the Human Genome Project and the improvement of genetic tools to aid 
genome-wide association study (GWAS) have had a great impact on the development of 
these disciplines. A GWAS is where many thousands of genetic variations, called single-
nucleotide polymorphisms (SNPs), are genotyped in a large number of individuals and 
tested for association with disease risk (Ott et al. 2011). Thanks to these extensive studies 
it is becoming evident that specific SNPs (and other polymorphisms) can affect the 
function of genes and alter specific metabolic pathways. Dietary factors might 
differentially interact with these SNPs to increase or decrease disease risk. An elegant 
example of this is a diet–SNP interaction involving the methylenetetrahydrofolate 
reductase (MTHFR) gene, one of the main genes involved in folate metabolism (see Figure 
1.1). The common 677C>T SNP of this gene encodes for an amino acid substitution that 
generates a thermolabile and less active protein (Frost et al. 1995). This results in reduced 
capacity to use folate to remethylate homocysteine to methionine in individuals that are 
homozygote for the T allele. TT individuals, therefore, have elevated homocysteine levels, 
which are a risk factor for a number of common diseases including cardiovascular disease 
(CVD). In this example diet plays an important role in interacting with genotype, because 
the amount of folate (substrate of MTHFR) and riboflavin (a cofactor of MTHFR) modify 
the activity of MTHFR and subsequently increase or decrease the disease risk (Parle-
McDermott et al. 2006a). 
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1.1.3 Folate  
 
Folate and its synthetic form folic acid (also known as vitamin B9), are essential nutrients 
in the human diet providing 1-carbon units for DNA synthesis and methylation reactions 
within the cell. Folate belongs to a group of water-soluble B vitamins and it was isolated 
for the first time in 1941 by Mitchell et al. from spinach leaves.  The term folate comes 
from the Latin word folium, which means leaf, in fact leafy vegetables such as spinach, 
asparagus, turnip greens have high amount of folates. Other natural folate rich foods are 
yeast extract spread, liver, legumes, sunflower seeds and peanuts (USDA National 
Nutrient Database for Standard Reference, Release 24.)  
 
Folate is especially important during periods of rapid cell division and it is required to 
produce healthy red blood cells and to prevent anemia (Iyer and Tomar 2009). Folates 
consist of a 2-amino-4hydroxy-pteridine (pterin) group conjugated by a methylene group 
to -aminobenzoic acid, which in turn is linked to one or more glutamate units (Figure 1.2) 
(Damaraju et al. 2008). Even though the pteridine ring can be produced by mammalian 
cells, inability to couple it to -aminobenzoic acid makes folate an essential nutrient in 
mammals (Birn 2006). This vitamin, which is naturally present in certain types of food, is 
hydrolyzed to monoglutamates by folate conjugase in the brush border of the small 
intestine prior to absorption into the portal vein (Fitzpatrick 2003, Iyer and Tomar 2009). 
Monoglutamate form of folate, including synthetic folic acid, which is the fully oxidized 
and most stable variant, can be easily transported across cell membranes and circulated in 
blood serum (Damaraju et al. 2008, Fox and Stover 2009). The absorption of 
monoglutamate is approximately twice as efficient as polyglutamate form and as a 
consequence, in the human body the bioavailability of the former is significantly greater 
than the latter (Iyer and Tomar 2009). 
 
A modest lack of dietary folate leads to suboptimal folate levels that appear to play an 
important role in the pathogenesis of several disorders, including CVDs, neural tube 
defects (NTDs) (Chapter 4, Section 4.1.2) and other congenital defects like Cleft (Chapter 
3, Section 3.1.2), thromboembolitic processes, Alzheimer’s disease, osteoporosis, 
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increased risk of breast and colorectal cancer (Daly et al. 1995, Kim 2004). The large 
volume of evidence for a protective effect of periconceptional folic acid supplementation 
against NTDs led to mandatory folic acid fortification in several countries like the United 
States, Canada and Chile (Food and Drug Administration 1996, Health Canada 1997, 
Freire et al. 2000). In the European Union, where folic acid fortification is not mandatory, 
the Daily Recommended Intake for adults (DRI) is 400 μg/d, with this requirement 
increasing to 600 μg/d during pregnancy (FAO/WHO 2002, IOM 2004, McPartlin et al. 
1993). 
  
Apart from nutritional intake, polymorphisms or variations within specific folate genes are 
also known to contribute to human disease risk, particularly in the context of a poor 
nutritional diet. As in the example above, genes that are involved in the transport and 
metabolism of this vitamin are currently considered the main candidates for disease 
association (Subbiah 2007). 
 
1.1.4 Folate-Mediated One-Carbon metabolism  
 
Folate is involved in both the activation of single carbon units as well as in their oxidation 
and reduction. Figure 1.1 summarizes the main pathways of folate-mediated one-carbon 
(1C) metabolism that, in eukaryotes, is highly compartmentalized in the cytoplasm, 
mitochondria and the nucleus. Cytoplasmic pathway is responsible for the synthesis of 
purines and for converting homocysteine to methionine. The mitochondrial pathway is 
required for the synthesis of formylated methionyl-tRNA, the catabolism of choline, 
purines and histidine, and the interconversion of glycine and serine (Fox and Stover 2008). 
Although de novo thymidylate synthesis was thought to occur in cytoplasm, recent studies 
suggested that this pathway predominantly takes place in the nucleus (Anderson et al. 
2012) and the mitochondria (Anderson et al. 2011, McEntee et al. 2011). The cytoplasmic 
and mitochondrial compartments are connected by transport of 1C donors such as formate, 
serine and glycine across the mitochondrial membrane (Momb et al. 2013). Since 1C 
metabolism is mainly unidirectional in flow (clockwise in Figure 1.1), mitochondria are 
also the primary source of one-carbon units, converting serine to formate (Tibbetts and 
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Appling 2010). In fact, it appears that under most conditions, the majority of 1C units for 
cytoplasmic reactions are derived from mitochondrial formate. Metabolic experiments 
carried out in mouse embryonic fibroblasts showed that more than 75% of 1C units that 
enter the cytoplasmic methyl cycle derive from mitochondria (Pike et al. 2010).  
 
As explained above, folate is transported across cell membranes and in serum as 
monoglutamate form. Once folate is inside the cell folylpoly-gamma-glutamate synthetase 
(FPGS) catalyzes the addition of poly- -glutamate tails to the -aminobenzoic acid (Shane 
1995, Moran 1999). The number of added glutamate residues varies from one cell type to 
another, but in the majority of eukaryotic cells, the predominant forms are penta- and 
hexaglutamate (Tibbetts and Appling 2010). The polyglutamate tail prevents efflux of 
folate cofactors from the cell and intracellular organelles, and it increases their binding 
affinity for many folate-dependent enzymes (Schirch and Strong 1989).  
 
The active form of folate is tetrahydrofolate (THF) which is the carrier of one-carbon units 
on the N5 and/or N10. To produce this active cofactor, folate is first reduced to 7,8-
dihydrofolate and then to 5,6,7,8-tetrahydrofolate. The last step is catalyzed by 
dihydrofolate reductase (DHFR) in the presence of NADPH (reaction 13). This enzyme is 
present in both the cytoplasm and the nucleus and recent studies identified a homologous 
protein, DHFRL1 (dihydrofolate reductase like-1), which is localized to the mitochondria 
(Anderson et al. 2011, McEntee et al. 2011). In Figure 1.1 reaction number 1, 2, 3 and 4 
are both in the cytoplasmic and mitochondrial compartments. In reaction 4, 1C unit is 
transfered to THF by serine hydroxymethyltransferase (SHMT) generating 5,10-
methylene-THF (CH2-THF) and glycine. In mammals, there are two SHMT isozyme that 
are encoded by distinct genes. SHMT1 encodes a cytoplasmic/nuclear isozyme (SHMT1), 
while SHMT2 encodes the mitochondrial (SHMT2) isoform and the cytoplasmic/nuclear 
(SHMT2α) isoform through alternative promoter use (Garrow et al. 1993, Anderson and 
Stover 2009, Anderson et al. 2012). In the cytoplasm CH2-THF is required for 
homocysteine (Hcy) remethylation when converted to 5-methyl-THF by 
methylenetetrahydrofolate reductase (MTHFR) (reaction 6). 5-methyl-THF is the main 
circulating form of folate and it acts as methyl donor in the remethylation of Hcy to 
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methionine carried out by Methionine Synthase (reaction 7) (Thomas and Fenech 2008). 
Through the Methyl cycle (top left in Figure 1.1) methionine is converted to  S-
adenosylmethionine (AdoMet) which is the principal methyl donor, necessary for the 
methylation of DNA, RNA, histones, lipids and small molecules (MacFarlane et al. 2011).  
 
Depending on the cell needs CH2-THF may also be oxidized to 10-formyl-THF or used as 
cofactor for de novo thymidylate biosynthesis (TYMS) (reaction 10) which occurs in the 
nucleus (Anderson et al. 2012) and mitochondria (Anderson et al. 2011, McEntee et al. 
2011). CH2-THF is oxidized to 10-formyl-THF in two reactions catalyzed by NADP-
dependent CH2-THF dehydrogenase (reaction 3) and 5,10-methenyl-THF (CH
+
-THF) 
cyclohydrolase (reaction 2). At this stage, cytoplasmic 10-formyl-THF may be used for de 
novo purine biosynthesis, a 10-reaction pathway particularly important during rapid cell 
division (Fox and Stover 2008). On the other hand, mitochondrial 10-formyl-THF may 
either be converted to CO2 or serve as formyl donor to synthesize formyl-methionyl-tRNA 
(reaction 12), necessary as initiator for mitochondrial protein synthesis (Christensen and 
Mackenzie 2008). There is one other important fate of 10-formyl-THF in both 
mitochondria and cytoplasm: the synthesis of formate and THF catalyzed by 10-formyl-
THF   synthetase (reaction 1). While cytoplasmic reactions 1,2 and 3 are performed by the 
trifunctional enzyme 10-formyl-THF synthase (MTHFD1), its mitochondrial homolog 
MTHFD1-like (MTHFD1L) catalyzes only reaction 1 in mammals. The other two 
reactions are carried out by MTHFD2 and MTHFD2L (Belanger et al. 1989, Di Pietro et 
al. 2002, Bolusani et al. 2011). 
 
While the synthesis of cytosine and the de novo purines occurs in the cytoplasm, the folate-
dependent de novo synthesis of thymidylate occurs in mitochondria (Anderson et al. 2011, 
McEntee et al. 2011) and in the nucleus (Chen et al. 2010 and Anderson et al. 2012). 
Recent findings better elucidated the role of 1-C metabolism inside the nucleus. It has been 
shown that TYMS, DHFR and SHMT1 localize to the nucleus only during S and G2/M 
phases enabling nuclear de novo thymidylate synthesis during DNA replication and repair 
(Anderson et al. 2012). These enzymes, which normally localize to cytoplasm (TYMS also 
to mitochondria), are transported to the nucleus upon post-translational modification with 
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the small ubiquitin-like modifier (SUMO) (Anderson et al. 2007 and Anderson et al. 
2009). TYMS, DHFR and SHMT1 form a thymidylate biosynthesis complex associated 
with the nuclear lamina and the DNA replication machinery. SHMT1 proved to have an 
important scaffold function for complex formation (Anderson et al. 2012). MTHFD1 
protein, which was believed to be present only in cytoplasm, was also identified as 
component of the nuclear thymidylate biosynthesis complex (Anderson et al. 2012).   
1.1.5 MTHFD genes  
 
As explained before, the reversible conversion of 10-formyl-THF and ADP to formate, 
THF and ATP is carried out by the trifunctional enzyme MTHFD1, which requires 
monovalent cations (NH4
+
, Mg2
+
, K
+
 or Rb
+
) to achieve maximal activity (Appling 1991, 
Fox and Stover 2008). This 935-aa protein exists in mammals as a homodimer of about 
100 kDa subunits. Each subunit consists of a ~30 kDa N-terminal domain containing CH2-
THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities, and a ~70 kDa C-
terminal domain containing 10-formyl-THF synthetase activity (Figure 1.3) (Tibbetts and 
Appling 2010). Leaphart et al. (2002) demonstrated that MTHFD1 is inhibited by THF and 
purines, while it is transcriptionally upregulated when increased DNA synthesis is required 
(Christensen and MacKenzie 2006). In mammals MTHFD1 is ubiquitously expressed in 
embryos and adults with the highest expression in kidney and liver (Di Pietro et al. 2004, 
MacFarlane et al. 2009).  
 
The enzyme is encoded by the MTHFD1 gene that spans 72 kilobase pairs on chromosome 
14 at 14q24 and it is spliced into a 3,466-base transcript sequence composed of 28 exons. 
MTHFD1 is an essential gene as its homozygous knock-out is lethal in mouse embryos, 
probably due to inadequate de novo purine synthesis. Heterozygous disruption of 
MTHFD1 results in viable mice with lower hepatic AdoMet levels which is consistent with 
formate serving as a 1C source for cellular methylation reactions (MacFarlane et al. 2009). 
On the other hand MTHFD1
+/-
 mice exhibited decreased levels of uracil misincorporation 
into liver nuclear DNA, indicating enhanced de novo thymidylate synthesis and suggesting 
a competition between SHMT1 and MTHFD1 for a limited pool of THF (MacFarlane et al. 
2009). Another study also showed that azoxymethane-induced colon cancer in MTHFD1
+/-
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mice increased tumour incidence 2.5-fold (MacFarlane et al. 2010). In a recent study, 
Christensen et al. (2013) generated a mouse model in which the MTHFD1 synthetase 
activity was inactivated without affecting protein expression or the other activities of this 
enzyme. Mthfd1S
-/-
 mouse embryos died shortly after 10.5 days gestation, and showed a 
delayed or abnormal development. On the other hand, in Mthfd1S
+/-
 heterozygote mice de 
novo purine synthesis was impaired and the proportion of 10-formylTHF in the plasma and 
liver was reduced. The authors, therefore, suggested that synthetase deficiency may lead to 
pregnancy complications through decreased purine synthesis and reduced cellular 
proliferation (Christensen et al. 2013). Indeed, MTHFD1 has been widely investigated in 
relation to birth malformations. A common variant of MTHFD1, 1958G→A, results in an 
arginine to glutamine substitution (R653Q) in the active site of the enzyme. MTHFD1 
1958G→A has been associated with increased risk of NTDs (Brody et al. 2002, Parle-
McDermott et al. 2006b, De Marco et al. 2006), cleft lip and palate (Mills et al. 2008), 
congenital heart defects (Christensen et al. 2009), placental abruption (Parle-McDermott et 
al. 2005a), unexplained second-trimester pregnancy loss (Parle-McDermott et al. 2005b) 
and intrauterine growth restriction (Furness et al. 2008). In 2012, Beaudin et al. generated 
another Mthfd1 knock-out mouse model that resulted in impaired fetal growth. MTHFD1
+/-
 
mice exhibit the same range of birth malformations mentioned above.      
 
A mitochondrial isozyme of MTHFD1 was first identified in Saccharomyces cerevisiae by 
Paukert and coworkers in 1977 and subsequently cloned and characterized by Shannon and 
Rabinowitz (1986 and 1988). In yeast both cytoplasmic and mitochondrial isozymes are 
trifunctional showing dehydrogenase, cyclohydrolase and synthetase activities 
(Christensen and MacKenzie 2008). Differently from yeast, mammalian mitochondria do 
not exhibit a unique trifunctional enzyme. Mammalian mitochondria contain a bifunctional 
NAD-dependent CH
2
-THF dehydrogenase/CH
+
 cyclohydrolase encoded by MTHFD2 gene 
(Christensen and MacKenzie 2006). This essential gene is located on chromosome 2 at 
2p31.1 and it is believed to have evolved from trifunctional MTHFD1 through gene 
duplication. It subsequently lost the synthetase domain and changed the redox cofactor 
specificity from NADP
+
 to NAD
+
 (Patel et al. 2002). Homozygous knockout of Mthfd2 is 
embryonic lethal in mice. Embryos develop to about E15.5 and display no evident 
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developmental abnormalities, but they are smaller and paler than WT and heterozygous 
littermates (Di Pietro et al. 2002). In mice, MTHFD2 expression has been detected in all 
the embryonic tissues as well as in cancer and transformed cell lines, but it was not found 
in any adult tissue (Christensen et al. 2008). This lack of  CH
2
-THF dehydrogenase and 
CH
+
 cyclohydrolase activities has left a gap in the mitochondrial 1C metabolism of adult 
mammals until MTHFD2L gene was recently discovered by Bolusani and colleagues 
(2011). They demonstrated that MTHFD2L is ubiquitously expressed in adult tissues of 
humans and rodents and it carries out the same 2-step reaction of MTHFD2 (although the 
cyclohydrolase step still has to be confirmed). In humans MTHFD2L is localized on 
chromosome 4 at 4q13.3 and it contains 9 exons encoding a protein of 347 aa. Like its 
homolog MTHFD2, MTHFD2L possesses only a cyclohydrolase/dehydrogenase domain 
that is similar to N-terminal domain of MTHFD1 (Figure 1.3).  
 
The monofunctional enzyme that completes the mitochondrial 1C pathway and possesses 
10-formyl-THF synthetase activity is encoded by the MTHFD1L gene. MTHFD1L protein 
retains the size and the two structural domains of its cytoplasmic homolog but due to non-
conservative mutation of critical residues, both the dehydrogenase and cyclohydrolase 
activities are not functional (Figure 1.3) (Christensen and MacKenzie 2008). In fact 
MTHFD1L shares about 61% amino acid identity with MTHFD1, but the sequence 
identity in the N-terminal domain (33%) is substantially lower than in the C-terminal 
synthetase domain (77%). In particular, four critical mutated amino acids (aa) (K93, R206, 
G211 and R283) are believed to be responsible for the lack of activity of the N-terminal 
domain (Christensen et al. 2005). Differently from its cytoplasmic homolog, MTHFD1L 
also contains 62 N-terminal residues with a predicted mitochondrial targeting sequence and 
a cleavage site between residues 31 and 32. The function of the next 31 aa including an 
unusual sequence of 9 consecutive glycine residues, is still unknown. MTHFD1L also 
lacks 12 aa near the junction between the two domains (Prasannan et al. 2003).  
 
MTHFD1L acts as peripheral membrane protein, associated with the matrix side of the 
mitochondrial inner membrane (Prasannan et al. 2008). MTHFD1L is more efficient with a 
longer THF polyglutamate chain length as substrate, similar to other enzymes of the same 
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family. From monoglutamate to pentaglutamate  the Km for THF decreases at least 100-
fold and the Km for ATP and formate reacts in a similar way (Tibbets and Appling 2010). 
Like MTHFD1 the mitochondrial isozyme is expressed ubiquitously in mammalian cells, 
however the expression pattern is different; high levels of MTHFD1L were detected in the 
thymus, spleen, brain and placenta while in liver and kidney were relatively low 
(Prasannan et al. 2003, Walkup et al. 2005, Prasannan et al. 2009). Sugiura et al. (2004) 
also reported the highest levels of MTHFD1L expression in ovary, lung and thymus, 
whereas the expression levels were the lowest in white blood cells, muscle and 
lymphocytes. The MTHFD1L gene is also ubiquitously expressed throughout the embryo 
during all stages of mammalian embryogenesis, but with localized regions of higher 
expression along the neural tube, the brain, craniofacial structures, the tail bud and the limb 
buds (Pike et al. 2010).  
 
1.1.6 MTHFD1L and disease 
 
The relevance of MTHFD1L is increasing given its identification in genome wide 
association screens as being associated with several diseases. In 2007, a GWAS carried out 
by Samani et al. found an association between coronary artery disease risk and many 
intronic MTHFD1L polymorphisms in the European population. The lead SNP 
(rs6922269) is present in intron 9 and its risk allele (A) has a prevalence of approximately 
25% in the European population, with the coronary artery disease risk increased by 23% 
per copy (95% CI, 15 to 33). Haplotype analysis showed that only the two haplotypes 
carrying the A allele tended to be more frequent in cases than in controls, confirming the 
increased odds ratio for coronary artery disease with the A allele in the single locus 
analysis (Samani et al. 2007). These findings were later confirmed by an independent 
GWAS performed in the German population (Bressler et al. 2010).  
 
Another GWAS demonstrated that SNP rs11754661, in MTHFD1L intron 6, and other 
intronic SNPs are associated with Alzheimer’s disease risk (Naj et al. 2010). This finding 
was confirmed by two independent studies in the in the Chinese Han population (Ren et al. 
2011, Ma et al. 2012). As the 1C metabolism is important for homocysteine conversion to 
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methionine a potential mechanism that can explain Alzheimer’s disease connection with 
MTHFD1L is hyperhomocysteinaemia. Elevated plasma homocysteine levels have been 
implicated in Alzheimer’s disease (Van Dam et al. 2009, Morris 2003) and in other 
neurodegenerative disease (Herrmann et al. 2002). Decreased levels of MTHFD1L protein 
have been reported in the hippocampus in a mouse model of Alzheimer’s disease using a 
proteomic approach (Martin et al. 2008). Homocysteic acid, derived from homocysteine 
and methionine, is elevated in these mice and treatment with anti-homocysteic acid 
antibodies reduced amyloid presence and inhibited cognitive decline in these animals 
(Hasegawa et al. 2010). B6-deficient diets lead to further increases in homocysteic acid in 
these mice. 
 
Moreover, Sugiura et al. (2004) have shown that MTHFD1L and SHMT2 are upregulated 
in human colon adenocarcinoma. The expression level of MTHFD1L mRNA was 
increased to some degree (1.45-fold) in benign adenoma tissues but the increase was higher 
(2.38-fold) in colon adenocarcinomas. In addition to colon cancer, the increased expression 
of MTHFD1L was denoted in other tumours such as stomach (1.97-fold) or pancreatic 
cancer (1.44-fold) (Sugiura et al. 2004). The authors also demonstrated that the 
overexpression of MTHFD1L stimulated the cell growth and the colony formation of 
HEK293 cells. The authors suggested that mitochondrial folate genes could be connected 
to cancer through the c-myc oncogene, which is a crucial transcription factor in the control 
of cell proliferation, differentiation, and apoptosis (Sugiura et al. 2004). Both SHMT2 
(Nikiforov et al. 2002) and MTHFD1L (Tavtigian et al. 1994, Sugiura et al. 2004) seemed 
to be responsive to the expression of c-myc oncogene in mammalian cells. A myc 
consensus sequence (CACGTG) is also present in the first intron of both SHMT2 and 
MTHFD1L genes.  
 
Consistently with Sugiura et al. findings, it has been recently demonstrated that high 
expression levels of MTHFD1L, along with other mitochondrial folate proteins like 
SHMT2 and MTHFD2, were significantly correlated with the growth rates of human 
cancer cell lines (Jain et al. 2012, Tomita et al. 2012). Interestingly, the authors did not 
find such correlation with their cytosolic homologues SHMT1 and MTHFD1. It has been 
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shown that breast cancer patients with above-median expression levels of MTHFD1L, 
SHMT2 and MTHFD2, but not their cytosolic homologues, had higher mortality (Jain et 
al. 2012). The authors also found a strong association between growth rate of tumour cells 
and demand of glycine which is produced from serine by SHMT enzymes. Intriguingly, in 
contrast to the cancer cell lines, they found that rapidly proliferating nontransformed cells 
release rather than consume glycine (Jain et al. 2012). These data are relevant for cancer 
therapeutics as it may be possible to tackle aggressive cancer cells specifically by 
inhibiting glycine influx, synthesis, or consumption (Jain et al. 2012). Altogether, these 
findings match with the view that changes in the mitochondrial metabolism play an 
important role in cancer cell proliferation. 
 
 
1.1.7 MTHFD1L and NTDs 
 
In a recent publication, Mthfd1l knockout mice were analysed and the loss of the protein 
was found to be lethal to developing embryos, causing fetal growth restriction and aberrant 
neural tube phenotypes with 100% penetrance (Momb et al. 2013). All the Mthfd1l 
knockout embryos developed a clear NTD phenotype failing to close the neural tube 
(exencephaly or craniorachischisis) or displaying a wavy neural tube with a small, 
aberrantly formed head (Momb et al. 2013). Maternal supplementation with sodium 
formate significantly decreased the incidence of NTDs and partially rescued the growth 
defects in mouse embryos lacking Mthfd1l. Although there are other folate related mouse 
models that show NTDs, this Mthfd1l knockout mouse model is fully penetrant and does 
not require a folate-deficient diet to cause this phenotype (Momb et al. 2013).  
 
Moreover, in humans MTHFD1L variants have been shown to be associated with risk of 
NTDs (Parle-McDermott et al. 2009). MTHFD1L gene spans 236 kilobase pairs on human 
Chr 6 at 6q25.1 and consists of 28 exons plus one alternative exon. To date four different 
MTHFD1L transcript variants have been identified in humans: transcript variant number 1 
(3490 bases) and 3 (3174 bp) share the same coding region, but the latter has a shorter 
5′UTR. Transcript variant 2 (3437 bp) has the same exact sequence of transcript 1 with the 
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only exception of a lacking codon at the end of exon 6. Instead transcript variant 4 (1072 
bp) is a shorter isoform which lacks enzymatic activity (Prasannan et al. 2003) This short 
transcript is caused by a premature stop codon in the alternatively spliced exon 8a and just 
upstream of this exon there is a polypyrimidine tract which is a well known cis-acting 
factor required for splicing (Sawicka et al. 2008) (Figure 1.4). Within this polypyrimidine 
tract there is the Deletion/Insertion Polymorphism (DIP) rs3832406 composed of several 
ATT repeats: Allele 1 has 7 ATT repeats, allele 2 has 8 repeats and allele 3 has 9 repeats. 
 
Our laboratory previously investigated the association between MTHFD1L polymorphisms 
and Neural Tube Defects (NTDs) in the Irish population (Parle-McDermott et al. 2009). 
Common genetic variations and low maternal folate levels are important risk factors for 
this kind of birth malformation. It has been reported that the Allele 1 of the DIP and 
numerous Single Nucleotide Polymorphisms (SNPs) of MTHFD1L are associated with the 
risk of NTDs and suggested that the DIP could affect the alternative splicing of the gene. 
In fact, it has been demonstrated that in Coriell lymphoblast cells the ratio between Long 
(variants 1, 2 and 3) and Short (variant 4) transcripts is higher in cells homozygous for 
allele 1 than in cells homozygous for allele 2 (Figure 1.5). 
 
Figure 1.6 shows the Linkage Disequilibrium (LD) plot of pairwise values of D’ for 119 
MTHFD1L genetic markers. Brackets (a, b) mark two regions in which single markers 
were found to be associated with NTD risk. These regions represent two different signals 
of disease association and DIP rs3832406 is included in region ‘‘a’’. All the 
polymorphisms associated with NTD risk in region “a” were intronic, so the best candidate 
for driving the haplotype risk of this region is the DIP. As a consequence, it has been 
proposed that the DIP polymorphism is the direct disease causing variant within the 
associated LD region “a” by affecting alternative splicing of the gene. In this scenario, 
higher MTHFD1L protein levels would be associated with an increased NTD risk (Parle-
McDermott et al. 2009). However, how the other polymorphisms that independently 
increase NTD-risk impact on MTHFD1L remain to be elucidated.  
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Moreover, unpublished results from our laboratory showed that MTHFD1L Long transcript 
is significantly upregulated in HEK293 cells cultured in the absence of folate (Figure 1.7). 
These findings suggest that a high level of MTHFD1L Long transcript might be an 
indicator of folate deficiency.  
 
1.1.8 Summary 
 
Nutritional genomics aims to identify genetic susceptibility to diseases related to diet 
factors. Folate, or vitamin B9, is an essential nutrient in our diet. Folate deficiency and 
polymorphisms within folate-related enzymes have been extensively associated with a 
number of common diseases and disorders, particularly, NTDs. The MTHFD gene family 
play an important role in folate-dependent 1C metabolism. MTHFD1L, in particular, is 
responsible for supplying the cytoplasm with 1C units in the form of formate. This key role 
puts MTHFD1L under the spotlight for its possible involvement in human disease. Indeed, 
several studies have reported its upregulation in cancer cells and its association with 
coronary artery disease, Alzheimer’s disease and NTD risk. Despite these studies, the 
mechanism of MTHFD1L’s association with disease is not yet known and many aspects of 
this essential gene remain to be elucidated. Taking the cue from previous studies, this 
project further investigates the role of MTHFD1L and its genetic variants in a bid to better 
understand its involvement in disease.  
 
1.1.9 Aims and objectives 
 
This project involves the characterization of MTHFD1L with a particular focus on genetic 
polymorphisms and the role of MTHFD1L levels in disease risk. The project will also 
involve an analysis of the potential function of additional homologous sequences. The key 
questions/aims that are being addressed are: 
1. Development of a new genotyping assay for the technically challenging MTHFD1L 
DIP polymorphism rs3832406. 
2. Is MTHFD1L a genetic risk factor for cleft disease in Ireland? 
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3. Do NTD-associated polymorphisms in the 3′UTR of MTHFD1L have a functional 
impact on miRNA regulation? 
4. Investigation of why altered expression of MTHFD1L has a role to play in disease 
risk. 
5. What is the functional role of other human MTHFD-like sequences? 
 
The above aims will be met by achieving the following objectives:  
1) Development of a Melting Curve genotyping assay for the triallelic DIP rs3832406 
using Melting Curve analysis on the Roche Lightcycler 480 instrument.  
2) Genotyping of key MTHFD1L polymorphisms in an Irish Cleft cohort and 
subsequent statistical analysis to test for an association.  
3) Investigation of the NTD risk associated polymorphisms in the 3′ UTR of 
MTHFD1L for a potential impact on micro RNA (miRNA) regulation.  This 
objective will involve the development of luciferase constructs and the utilisation 
of a cell culture model.  
4) The role of altered MTHFD1L expression in disease will be assessed by further 
investigation of the Long and Short transcripts of MTHFD1L and by a proteomic 
analysis. Assessment of the impact of folate metabolism disruption on the relative 
ratio of the Long and Short transcripts of MTHFD1L will be assessed using a 
cycloleucine cell culture model and RT-qPCR. A proteomic analysis on cells that 
have been manipulated to inhibit the expression of MTHFD1L and to overexpress 
it will be carried out to provide an understanding of how the expression level of 
MTHFD1L is significant in disease.  
5) Analysis of genomic sequences similar to MTHFD1 and/or MTHFD1L to find any 
evidence of expression and to determine if these sequences have a functional 
relationship with their parent genes. Expression of candidate sequences will be 
assessed by carefully designed RT-qPCR assays with subsequent cloning and 
expression for functional characterisation.  
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Figure 1.1 Compartmentalization of mammalian one-carbon metabolism (adapted 
from Tibbetts and Appling 2010).  
End products of one-carbon metabolism are in red. One-carbon donors are in blue. 
Activated one-carbon units carried by tetrahydrofolate (THF) are in green. Reactions 1–4 
and 13 are in both the cytoplasmic and mitochondrial (m) compartments. Reactions 4, 10 
and 13 are also present in the nucleus (n). Reactions 1, 2, and 3: 10-formyl-THF 
synthetase, 5,10-methenyl-THF (CH
+
-THF) cyclohydrolase, and 5,10-methylene-THF 
(CH2-THF) dehydrogenase, respectively, are catalyzed by trifunctional C1-THF synthase 
in the cytoplasm (MTHFD1). In mammalian mitochondria, reaction 1m is catalyzed by 
monofunctional MTHFD1L and reactions 2m and 3m by bifunctional MTHFD2 or 
MTHFD2L. The other reactions are catalyzed by the following enzymes: 4, 4n and 4m, 
serine hydroxymethyltransferase (SHMT); 5, glycine cleavage system; 6, 5,10-methylene-
THF reductase; 7, methionine synthase; 8, dimethylglycine (DMG) dehydrogenase; 9, 
sarcosine dehydrogenase; 10n and 10m, thymidylate synthase (TYMS); 11, 10-formyl-
THF dehydrogenase (only the mitochondrial activity of this enzyme is shown, but it has 
been reported in both compartments in mammals); 12, methionyl-tRNA formyltransferase; 
13, 13n and 13m,  dihydrofolate (DHF) reductase; 14, betaine-homocysteine 
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methyltransferase. AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; 
Hcy, homocysteine. 
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Figure 1.2 Folic acid and folate (modified from Forssén et al. 2000).  
Structures of synthetic folic acid (up) and natural folates including reduced one-carbon 
substituted forms of polyglutamates (down).  
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Figure 1.3 Domain structures of mammalian one-carbon interconverting enzymes 
(figure drawn with Microsoft PowerPoint).  
MTHFD1 expresses a cytoplasmic trifunctional enzyme  of 935aa composed of two 
domains, a ~30 kDa N-terminal D/C domain (green), which contains NADP-dependent 
CH2-THF dehydrogenase and CH+-THF cyclohydrolase activities, connected to a ~70 kDa 
C-terminal domain (red), which contains the 10-formyl-THF synthetase activity. 
MTHFD1L encodes a mitochondrial protein of 978aa with the same two-domain structure, 
but with an N-terminal mitochondrial targeting sequence (blue). The D/C domain of 
MTHFD1L is not functional. MTHFD2 and MTHFD2L both encode bifunctional NAD-
dependent CH2-THF dehydrogenase/CH+-THF cyclohydrolase and present an N-terminal 
mitochondrial targeting sequence. 
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Figure 1.4 MTHFD1L Short and Long isoforms and DIP rs3832406 position (adapted 
from Parle McDermott et al. 2009). 
The potential proteins resulting from translation of the MTHFD1L Long and Short 
mRNAs. The longer transcript encodes a monofunctional mitochondrial protein with a 
synthetase domain localized to the C-terminal end (black bar). The shorter transcript is 
caused by the inclusion of the alternative exon 8a which contains a premature stop codon. 
The shorter protein lacks a catalytic domain. DIP rs3832406 position is highlighted in red. 
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Figure 1.5 The ratio of MTHFD1L Long and Short transcripts differs by rs3832406 
genotype in Coriell lymphoblast cell lines (Parle-McDermott et al. 2009).  
Homozygotes for Allele 1 have a significantly greater proportion (mean is 35% more) of 
the Long transcript relative to the Short transcript compared to homozygotes for Allele 2 as 
assessed by Mann-Whitney U test (two tailed; P=0.006). 
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Figure 1.6 Linkage Disequilibrium (LD) plot of pairwise values of D’ for 119 markers 
within and adjacent to MTHFD1L (Modified from Parle-McDermott et al. 2009). 
The LD plot was constructed using genotype data from 338 Irish controls. Brackets (a, b) 
mark the two regions in which single markers were found to be associated with NTD risk. 
Region ‘‘a’’ contains the rs3832406 DIP. Each individual polymorphism that showed an 
association with NTD are indicated by an asterisk (*).  
 
a b 
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Figure 1.7 MTHFD1L gene expression was compared between samples from seven 
different time-points in a folate depletion time course analysis in HEK293 cells 
(experiment performed by Nicola Carroll).  
The Day 0 sample is the calibrator for the relative quantification of gene expression. A 
significant difference in MTHFD1L mRNA levels between different samples was 
identified by one-way ANOVA, p-value = 0.0012. A post-hoc test determined samples at 
Day 6 and Day 8 (red data points) were those contributing to this difference when 
compared to the Day 0 sample. 
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 Material and Methods 
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2.1 Materials 
 
2.1.1  Reagents 
 
Ambion (Applied Biosystems): Placental RNA (Cat. No. AM7950), mir9 and mir197 
Pre-miR
TM
 precursor molecules (Cat. no. AM17100), negative control #1 Pre-miR
TM
 
precursor molecule (Cat. no. AM17110), miR-9, miR-197 and RNU6B TaqMan
®
 assays 
(Cat. no. 4427975), anti-9 and anti-197 Anti-miR™ miRNA Precursor (Cat. no. 
AM17005), Anti-miR™ miRNA Inhibitor Negative Control #1 (Cat. no. AM17010),  
Taqman RT-qPCR assay (Cat. no. 4331182) for DHFR (Hs00758822_s1), TYMS 
(Hs00426591_m1), SHMT1 (Hs00244618_m1), MTHFD1 (Hs01068268_g1) .  
Agilent Technology: QuikChange II Site-Directed Mutagenesis Kit (Cat. no. 200523). 
Biological Resource Centre National Institute of Technology and Evaluation, Chiba, 
Japan: AK097152 and AK074198 sequences in pME18SFL3 vector (Appendix A). 
Bioline: BioScript (Cat. no. BIO-27036), ISOLATE Plasmid Mini Kit (Cat. no. BIO-
52026), ISOLATE RNA Mini Kit (Cat. no. BIO-52043), Oligo dT (Cat. no. BIO-38029), 
Random Hexamers (Cat. no. BIO-38028), SensiFast™ Probe One Step Kit (Cat. no. BIO-
76001). 
Biosera: Fetal Bovine Serum (FBS) (Cat no S1900). 
Bio-Rad: Quick Start Bradford Protein Assay Kit (Cat. no. 500-0201). 
Coriell Institute: human variation panel – Caucasian panel of 100 genomic DNA (Cat. no. 
HD100CAU ), African Americans panel of 100 genomic DNA (Cat. no. HD100AA ). 
Coriell lymphoblast cells: 17158 (Cat. no. GM17158), 17229 (Cat. no. GM17229), 17240 
(Cat. no. GM17240), 17291(Cat. no. GM17291), 17189 (Cat. no. GM17189), 17205 (Cat. 
no. GM17205), 17220 (Cat. no. GM17220). 
GE Healthcare: ExoSap-IT (Cat. no. US78200). 
Greiner Bio-One: 75cm
3
 flasks (Cat. no. 658175CI), 25cm
3
 flasks (Cat. no. 690175CI), 
Cell Scrappers (Cat. no. 541070G), 6-well plates (Cat. no.657160), 24-well plate (Cat. no. 
662160). 
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Gibco:  Dulbecco’s Modified Eagle Medium (DMEM) 1X (Cat. no. 41965), Trypan Blue 
Stain 0.4% (Cat. no. 15250-061). RPMI (Roswell Park Memorial Institute) 1640 (Cat. no. 
12633-012). 
Invitrogen: Gateway® pDEST™15 Vector (Cat. no. 11802-014) (Appendix D), 
Gateway® BP Clonase® II Enzyme mix (Cat. no. 11789-020), Gateway® LR Clonase® II 
Enzyme mix (Cat. no. 11791-020), Lipofectamine 2000 reagent (Cat. no. 11668500), 
SuperScript II (Cat. no. 18064), NuPAGE® 3-8% Tris-Acetate Gels 1.0 mm/12 well (Cat. 
no. EA03752BOX ), NuPAGE® Tris-Acetate SDS Running Buffer (20X) (Cat. no. 
LA0041), HiMark™ Pre-Stained HMW Protein Standard (Cat. no. LC5699), iBlotR Gel 
Transfer Device (Cat. no. IB1001), iBlotR Gel Transfer Stacks, Regular Nitrocellulose 
(Cat. no. IB3010-01), NuPAGE
® 
4X LSD sample buffer (Cat. no. NP0007), pDONR™211 
(Cat. no. 12536-017) (Appendix B),  pcDNA™3.2-DEST(Cat. no. 12489-019) (Appendix 
C).  
Lennox: Puromycin Dihydrochloride (Cat. no. CA2856.0010).  
MitoSciences: monoclonal antibody anti PDH subunit E1 alpha (Cat. no. MSP03). 
New England Biolabs: 100bp Ladder (Cat. no N3231L), Dnase I (Cat. no. M0303S). 
Promega: ProteaseMAX™ Surfactant (Cat. no. V2071), Trypsin Gold, Mass 
Spectrometry Grade (Cat. no. V5280), Endoproteinase Lys-C Sequencing grade (Cat. no. 
V1071). 
Qiagen: IPA Ingenuity software (Cat. no. IPA-NUL-00002), QIAamp DNA Blood Mini 
Kit (Cat. no 51106), RNeasy Mini Spin Columns (Cat. no. 74104), Qproteome 
Mitochondria Isolation Kit (Cat. no. 37612). 
Roche: LightCycler 480 Genotyping Master (Cat. no. 04707524001).  
Sigma-Aldrich: Acetonitrile (Cat. no. 271004), Agar (Cat. no. A5306), Ampicillian (Cat. 
no. A0166), Ammonium Bicarbonate (Cat. no. 09830)Agarose (Cat. no. A9539), CHAPS 
hydrate (Cat. no. C9426), Cycloleucine (Cat. no. A48105), DTT (Cat. no. D0632), Formic 
Acid (Cat. no. F0507), G418 disulfate salt (Cat. no. A1720),  Hexadimethrine bromide 
(Cat. no. H9268-5G), Iodoacetamide (Cat. no. I1149), Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Cat. no. I6758), Magnesium Chloride (Cat. no. M8787), 
NaCl (Cat. no. S7653), Orange G (Cat. no. O3756),  Penicillin-Streptomycin (Cat. no. 
P4333), RNA Loading Buffer (Cat. no. R1386), Sodium Pyruvate (Cat. no. S8636), Taq 
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Polymerase 5U/µl (D4545), Trypsin-EDTA (Cat. no. T4049), Tryptone (Cat. no. T7293), 
Yeast Extract (Cat. no. Y1333), 10X PCR buffer without Magnesium Chloride (Cat. no. 
P2317), Non-target shRNA (Cat. no. SHC002) (Appendix E), MTHFD1L shRNA 
(SHCLNV-NM_015440) (Appendix F, Appendix G), Thiourea (Cat. no. T8656), 
Trifluoroacetic Acid (TFA) (Cat. no. T6508), Tris (Cat. no. T1503) UREA (Cat. no. 
U5378). 
Switch Gear Genomics: LightSwitch Luciferase Assay System (Cat. no. LS010), 
MTHFD1L 3′UTR reporter construct (Cat. no. S890005).  
Thermo Scientific: SuperSignal
®
 West Femto Trial Kit (Cat. no. 34094), RestoreTM
 
PLUS 
Western Blot Stripping Buffer (Cat. no. 46430), BCA Protein Assay Reagent A (Cat. no. 
23228) and Reagent B (Cat. no. 23224), Immuno Pure Goat Anti-Mouse IgG, (H+L) 
Peroxidase conjugated (Cat. no. IG1082801), Immuno Pure Goat Anti-Rabbit IgG, (H+L) 
Peroxidase conjugated (Cat. no. IE10656916), Pep-clean C18 spin columns (Cat. no. 
89870), PepMap C18, 75 μm ID × 500 mm, 3 μm particle and 100 Å pore size (Cat. no. 
164570), PepMap C18, 300 μm ID × 5 cm, 5 μm particle size, 100 Å pore size (Thermo 
Fisher Cat. no. 160292), protease inhibitors cocktail (Cat. no. BPE9706-1).  
 
2.1.2 Solutions 
 
Detergent free buffer for protein resuspension: 6M Urea, 2M  thiourea, 10mM tris, pH 
8.0 
LB Agar: 15g of agar per litre of LB Broth 
LB Broth: 2.5g Tryptone, 2.5g NaCl, 1.25g Yeast Extract, 250ml Deionised H2O 
Orange G (10X): 0.1 g Orange G, 20 g Sucrose, 50 mL H2O 
PBS (10X): 80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4, 1L H2O (pH7.4) 
Mammalian Protein Extraction Buffer: 50mM Tris, pH 7.8, 1mM EDTA, 0.1% v/v 
Triton X-100, 10mM β-mercapthoethanol, 0.5% v/v protease inhibitors cocktail, 0.07% v/v 
ß-mercaptoethanol. 
Protein Extraction Buffer used for Mass Spec experiments: 7 M urea, 2  M thiourea, 30 
mM Tris, 4% CHAPS, pH 8.5 
TBE (10X): 48.44gTris HCl, 12.37g Boric Acid, 1.5g EDTA, 500ml H2O 
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TBS (10X): 24.23g Tris HCl, 80.06g NaCl, 1L H2O (pH 7.6) 
TBS-T: TBS + 1% Tween 
 
2.1.3 Cell Lines 
 
HEK 293 (Human Embryonic Kidney): ATCC (Cat. no. CRL-1573) 
MCF7 (Breast cancer cell line): ATCC (Cat. no. HTB-22)  
MAX Efficiency® DH5Alpha (Escherichia coli): Invitrogen (Cat. no. 12034013) 
 
 
2.2  Methods 
 
2.2.1 Tissue culture methods 
 
2.2.1.1 HEK 293 and MCF-7 cell culture  
Human Embryonic Kidney 293 (HEK 293) and human breast adenocarcinoma (MCF-7) 
cell lines were cultured in Dulbecco’s modified Eagle medium (DMEM) (Gibco) 
supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) Penicillin-streptomycin 
solution (PenStrep) in a 5% CO2 incubator at 37°C. Cells were usually cultured in 12 ml of 
media 75cm
3
 flasks. Cell passages were performed by incubating with 3ml of Trypsin-
EDTA (Sigma-Aldrich) at 37
o
C for 5 minutes after washing cells with phosphate-buffered 
saline (PBS). Trypsin was then in-activated by adding twice the volume of DMEM. Cells 
were collected by centrifugation at 500 g for 5 minutes.  
 
2.2.1.2 Coriell lymphoblast cell culture 
Coriell lymphoblast cells were cultured in suspension in RPMI (Roswell Park Memorial 
Institute) 1640 supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) Penicillin-
streptomycin solution (PenStrep) in a 5% CO2 incubator at 37°C. Cells were usually 
cultured in 12ml of media in 75cm
3 
flasks. Cell passages were performed by centrifugation 
at 500 x g for 5 minutes. Cells were then resuspended in new media.  
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2.2.1.3 Cell counts 
Cells were collected by centrifugation and pellet was resuspended in 1ml of complete 
media. Cell suspension (100µl) was then added to 400µl of trypan blue in a 1:5 dilution 
and left at R.T. for 5 minutes. The solution was then loaded to a chamber of the 
hemocytometer and observed under a microscope at 100x magnification. Viable cells were 
counted in the four corners (each corner has 16 squares). The same procedure was repeated 
for the other chamber of the hemocytometer. The coefficient of variation was calculated. 
The average cell count was then calculated and multiplied by the dilution factor and then 
by 10
4
. 
 
2.2.1.4 Cell transfection 
Cells were counted and seeded in a 6 well plate at a density of 1-2 x 10
5
 cells/ml in 
complete media without antibiotic and incubated at 37
o
C for about 24 hours until 70%-
90% confluency was obtained. The media was removed from the cells and replaced with 
1ml of incomplete media (without FBS). For each well, 2-4µg of plasmid DNA or miRNA 
precursor/anti-miR inhibitor at a final concentration of 50 nM were mixed with 10ul of 
Lipofectamine 2000 transfection reagent and added to 1ml of incomplete media. 
Transfecting solution was then incubated for 30 minutes at R.T. and finally added to cells. 
Two negative controls were also performed: the first adding only 1ml of incomplete media 
and the second adding 1ml of incomplete media and 10ul of Lipofectamine 2000 (-CTR). 
Cells were incubated in a 5% CO2 incubator at 37°C for 24-48 or 72 hours.  
 
2.2.2 DH5 transformation 
 
AK097152 and AK074198 clones containing ncRNA sequences (Chapter 5, Section 5.2.3) 
were transformed in DH5  competent cells by heat shock method. About 100 ng of 
plasmid were added to a 50 µl vial of DH5  competent cells. Cells were incubated on ice 
for 30 minutes and then heat shocked for 30 seconds at 42°C without shaking. Vial was 
immediately transferred to ice and 250 μl of room temperature S.O.C. medium was added. 
Vial was shaken horizontally at 37°C for 1 hour at 225 rpm in a shaking incubator. Cells 
were then spread on a LB agar plate 100 μg/ml ampicillin. After overnight incubation at 
31 
 
37ºC single colonies were selected and grown in liquid LB containing 100 μg/ml 
ampicillin.  
 
2.2.3 Plasmid Mini Prep  
 
Bacteria were cultured overnight and then they were centrifuged at 1500 x g for 10 minutes 
to pellet cells. The supernatant was removed and the pellet was resuspended in lysis buffer 
from ISOLATE Plasmid Mini Kit (Bioline). The plasmid DNA was then isolated as per 
manufacturer’s protocol.  
 
2.2.4 RNA Extraction and Reverse Transcription 
 
Culture cells were centrifuged and the cell pellet was washed in 1ml of PBS buffer. RNA 
was extracted using either Qiagen or Bioline RNA extraction kit. Quantity and quality of 
RNA samples were analyzed by Nanodrop (Thermo Scientific) measuring at A260 and by 
gel electrophoresis methods (Chapter 2, Section 2.2.8). RNA samples (5-20 µg) were 
treated with 2-4 units of DNase I (NEB) at 37°C for 10 minutes. Upon addition of 1 µl of 
EDTA to a final concentration of 5 mM Dnase was heat inactivated at 75°C for 10 
minutes. Samples were then reverse transcribed to cDNA using Bioscript (Bioline) reverse 
transcriptase and a mix of random Hexamers (Bioline) and Oligo dT primers (Bioline) as 
follows. RNA (2-4 µg) was mixed with 0.2 µg of random Hexamers and 0.5 µg of Oligo 
dT primers and incubated for 5 minutes at 70 °C then chilled on ice for at least 1 minute. 
Samples were then mixed with 1X RT buffer, 0.2 mM of each dNTP and 200U of 
Bioscript reverse transcriptase in a final volume of 20µl and incubated at 25°C for 10 
minutes, 42°C for 30 minutes and 85°C for 5 minutes. A control reaction (-RT), without 
the addition of reverse transcriptase, was carried out in parallel for each sample to act as a 
control to ensure genomic DNA was adequately removed. All the cDNAs obtained were 
used as template in the PCR and qPCR reactions described below.  
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2.2.5 DIP rs35337982 validation assay 
 
A PCR assay was designed to amplify 282 bp containing DIP rs35337982 in twenty 
different genomic DNA samples. Ten random samples were selected from Coriell 
Caucasian panel and ten from cleft study samples (Chapter 3, Section 3.2.1). PCR methods 
are described below. PCR samples were sequenced and then analyzed by BLAST (an 
example of sequenced sample is reported in Appendix S). 
 
2.2.6  PCR 
 
Unless indicated differently all PCR assays were carried out using 0.2 µM of each primer, 
0.2 mM of each dNTP, 1.5 mM of MgCl2, 1X PCR buffer without MgCl2, 1U of Taq 
Polymerase and 1µl of cDNA in a final volume of 50 µl at the following conditions: 5 
minutes pre-incubation at 95ºC, amplification 35 cycles of 30 seconds at 95ºC, 30 seconds 
at 55ºC, 1 minute at 72 ºC, final elongation for 5 minutes at 72 ºC. Primers were purchased 
from either Eurofins or IDT. All the primers used for RT-PCR analysis in Chapter 5 were 
designed to have at least 5-base mismatches with parental sequences. Primer positions are 
shown in Appendix Z, AA, and BB while primer sequences are shown in Table 2.1.  
 
2.2.7 Genomic DNA contamination test 
 
All cDNA products were also tested for genomic contamination by an intron spanning 
PCR assay designed to amplify the MTHFD1 gene. Resulting bands are 232 bp for cDNA 
amplification and 330 bp for gDNA amplification. The difference in size is due to the 
presence of an intron in the genomic sequence and its absence in the spliced reverse 
transcribed mRNA. 
PCR reaction were carried out with 0.5 µM of each primer, 0.5 mM of each dNTP, 1.5 mM 
of MgCl2, 1X PCR buffer without MgCl2, 1U of Taq Polymerase and 1µl of cDNA in a 
final volume of 50 µl 10 at following conditions: 3 minutes of pre-incubation at 95ºC, 
amplification 35 cycles of 30 seconds at 95ºC, 1 minute at 58ºC, 1 minute at 72 ºC, final 
elongation for 10’ at 72 ºC. 
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Primer sequences are: 
MTHFDRQ For  5′-CAC TCC AGT GTT TGT CCA TG -3′ 
MTHFDRQ Rev  5′-GCA TCT TGA GAG CCC TGA C -3′ 
 
2.2.8 Agarose gel 
 
Agarose gels were made by boiling 1% agarose (w/v) in 30ml of 1xTBE. Liquid solution 
was then cooled to 55°C and mixed with 2µl of 500µg/ml ethidium bromide before 
pouring into mould. The electrophoresis buffer was also 1xTBE. PCR product (10 µl) was 
mixed with 2 µl of orange G loading dye and electrophoresised at 90 volts for 30-45 
minutes. Gels were visualized under UV light using DNR Mini-Bis Pro Bio-Imaging 
System. Alternatively, extracted RNA quality was verified through the same procedure 
after heating it to 65
o
C in RNA denaturing buffer for 5 minutes.  
 
2.2.9 Sequencing 
 
Samples were cleaned-up for Sanger sequencing as follows: 15 µl of sample were mixed 
with 5 µl of ExoSap-IT (GE Healthcare) and incubated at 37 °C for 15 minutes followed 
by enzyme inactivation at 80°C for 15 minutes. About 5-10 ng of PCR products were then 
sequenced by either Eurofins or Source Bioscience. 
 
2.2.10 RT-qPCR  
 
cDNA was obtained by reverse transcription as described in Chapter 2, Section 2.2.4 . All 
the assays were designed using the Universal Probe Library (Roche). For primers, probes 
and their concentrations see Table 2.2. Primers were obtained from Eurofins MWG or 
Integrated DNA Technologies (IDT) while the probes were from Roche. Taqman
®
 Gene 
Expression assays were used for the following genes: MTHFD1, DHFR, TYMS and 
SHMT1 (Ambion). Specific reverse transcription and qPCR analysis of miR-9, miR-197 
and RNU6B were conducted using TaqMan microRNA assays (Ambion). In all the 
experiments samples were run in triplicates. All assays and analysis were performed using 
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Sensimix™ II Probe Kit (Bioline) on the Roche Lightcycler® 480 instrument at following 
conditions: 5 minutes pre-incubation at 95ºC, amplification 45 cycles of 30 seconds at 
95ºC, 30 seconds at 60ºC, 1 second at 72 ºC with signal acquisition. Results were 
calculated by applying the comparative E-method to measure the fold change in target 
gene expression relative to reference gene. Statistical significance was determined by 
Student’s t-test or ANOVA. 
 
2.2.11 Cycloleucine time course  
 
17158 Coriell lymphoblast cell line was used for this experiment which was performed in 
triplicate. Cells were treated with cycloleucine dissolved in PBS at the following 
concentrations: 5mM, 7.5mM and 10mM. An untreated negative control was carried out in 
parallel. RNA was collected at the following time points for each concentration: 24hours, 
48hours and 72hours. Cell cultures and RNA extraction were previously performed by 
Nicola Carroll (Carroll et al. 2012).  
 
2.2.12 Invitrogen® Gateway cloning 
 
The vectors used in Chapter 5, Section 5.2.4 and Chapter 7, Section 7.2.3 were generated 
using the Invitrogen Gateway cloning system 
(http://www.invitrogen.com/site/us/en/home/Products-and-
Services/Applications/Cloning/Gateway-Cloning/Protocols.html). ChrX 3′UTR and ChrX 
750 ORF sequences were PCR amplified from HEK293 cDNA (Chapter2, Section 2.2.4) 
using attB-flanked primers (Table 2.3). A modified version of MTHFD1L coding sequence 
with attB-flanking regions in pMA-RQ vector  was purchased from Invitrogen
® 
(Appendix 
H). MTHFD1L coding sequence was modified without changing the resulting aa sequence, 
in order to optimize the protein expression in mammalian cells. 
 
Entry clones were generated from the above attB-flanked sequences through BP 
recombination reaction with pDONR™211 (Appendix B) vector following manufacturer’s 
procedures (Invitrogen). A destination vector was then created by performing an LR 
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recombination reaction (Invitrogen) between the entry vector and the respective destination 
vectors. ChrX 3′UTR and MTHFD1Lopt sequences were cloned in the mammalian 
expression vector pcDNA™3.2/V5-DEST (Appendix C), while ChrX 750 ORF sequence 
was cloned in the E.Coli protein expression vector Gateway
®
 pDEST™15 (Appendix D). 
pcDNA3.2-MTHFD1Lopt (Appendix I, J, K and L), pDEST15-750ORF (Appendix M and 
N) and pcDNA3.2-ChrX 3′UTR (Appendix O)  sequences were completely verified by 
Sanger sequencing using Source Biosciences service based in Dublin. Primers used for 
Sanger sequencing are shown in Table 2.4. 
 
2.2.13 Protein Analysis Methods 
 
2.2.13.1 Mitochondrial and cytosolic protein extraction. 
Cytosolic and mitochondrial fractions were isolated using Qproteome Mitochondria 
Isolation kit (Qiagen) following manufacturer’s instruction. Protein acetone precipitation 
was performed to concentrate cytosolic fraction. Four volumes of ice-cold acetone were 
added to the protein fraction and incubated for 15 min on ice. Sample was centrifuged for 
10 min at 12,000 x g in a pre-cooled centrifuge at 4°C. Supernatant was discarded and the 
pellet was washed with 1 ml of 80% acetone. Pellet was then let air dry. Cytosolic proteins 
were resuspended in 50 µl of H2O. Mitochondrial fraction obtained following 
manufacturer’s instruction were resuspended in 50 µl of protein extraction buffer and 
incubated on ice for 10 minutes after vortexing.  Proteins were either used directly for SDS 
Page electrophoresis or stored for brief periods at -20°C.  
 
2.2.13.2 Protein Concentration Estimation 
Bicinchoninic acid assay (BCA) was used to determine protein concentration. Standards 
were prepared using Bovine Serum Albumen (BSA) diluted in sterile H2O to 
concentrations of 25 g/ml, 125 g/ml, 250 g/ml, 500 g/ml, 750 g/ml, 1000 g/ml, 
1500 g/ml and 2000 g/ml. Unknown samples were diluted 1/10 in sterile H2O. The 
working reagent was prepared making a solution of reagent A and reagent B (1:50). Ten µl 
of either standard or sample were added in triplicate on a suitable 96-well plate and 100µl 
of the working reagent were added to each well. The plate was then incubated at 37
o
C for 
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30 minutes. Samples were then measured at 562 nM using Tecan i600 spectrophotometer. 
BSA standard values were used to make the standard curve from which unknown sample 
concentrations were then calculated.  
 
2.2.13.3 Sample Preparation, Electrophoresis and iBlot Dry Tranfer. 
Samples were diluted with 0.5 volume of NuPAGE
® 
4X LSD sample buffer and boiled for 
5 minutes on a heating block. Samples could then be stored at -20
o
C until required. 
Proteins (25 µg)  were loaded into precast NuPAGE
®
 3-8% Tris-Acetate Gel (1.0 mm/12 
well) and proteins were separated by the application of a 140 volts current to the gel 
apparatus filled with NuPAGE
®
 Tris-Acetate SDS Running Buffer. Five µl of HiMark™ 
Pre-Stained HMW Protein Standard were used to confirm the molecular weight of protein 
bands. The migration of bromophenol blue was monitored and the current switched off 
when the dye band reached the bottom of the gel (approximately 90 minutes). The gel was 
then removed from the apparatus and transfered to nitrocellulose membrane for 10 minutes 
using iBlotR Gel Transfer Device.  
 
2.2.13.4 Western Blotting for MTHFD1L 
The nitrocellulose membrane was stained with ATX Ponceau S red staining solution to 
ensure successful transfer and then washed several times in dH2O. The nitrocellulose 
blotting paper was blocked by incubating in tris buffered saline (TBS) containing 5% non 
fat dried milk for 1 hour at R.T., with gentle shaking. The membrane was washed twice for 
5 minutes in TBS containing 0.05% Tween (TBS-T) and probed with the primary 
antibody. The primary antibody was a rabbit polyclonal antibody raised against 
MTHFD1L protein (gifted from Prof. Dean Appling, University of Texas at Austin) and 
was used at a 1:500 dilution in TBS-T. The membrane was incubated with the primary 
antibody overnight at 4
o
C with gentle shaking and then washed 4 times for 5 minutes in 
TBS-T. An anti-rabbit secondary antibody conjugated to horseradish peroxidase (HRP; 
anti-rabbit IgG-HRP) was used at a 1:20000 dilution in TBS-T. The membrane was 
incubated with the secondary antibody at 4
o
C for 1hour at room temperature and washed 5-
6 times for 5 minutes with TBS-T. The substrate Working Solution was prepared mixing 
the two components of Signal
®
 West Femto kit at a 1:1 ratio. The membrane was then 
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incubated at room temperature for 5 min in 1 ml of substrate Working Solution before 
image was taken using Gene Gnome instrument (SynGene). 
 
2.2.13.5 Western Blotting for PDH 
After Western blotting for MTHFD1L, the membrane was stripped using Restore
TM 
PLUS 
Western Blot Stripping Buffer. It was then probed using a mouse monoclonal primary 
antibody raised against PDH (Pyruvate Dehydrogenase) subunit E1 alpha at a 1:1,000 
dilution. The membrane was incubated and washed as before and then probed with the 
HRP-linked anti-mouse secondary antibody. Again, 1ml of substrate Working Solution 
was added to membrane and incubated for 5 minutes before image was taken using Gene 
Genome instrument. 
 
2.2.13.6 Image J density comparison 
ImageJ software (http://rsb.info.nih.gov/ij/index.html) was used to compare the density of 
Western blot bands. A complete tutorial to use this software is present at this link 
http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-image-j/. 
 
2.2.14 Bioinformatics Resources 
 
2.2.14.1 BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
The Basic Local Alignment Search Tool (BLAST) finds regions of local similarity 
between sequences. The program compares nucleotide or protein sequences to sequence 
databases and calculates the statistical significance of matches. Nucleotide BLAST was 
used to find sequences similar to MTHFD1L and MTHFD1. All the sequences analysis and 
sequence similarity localization were made using mRNA transcript variant 1 of MTHFD1L 
(accession number: NM_001242767) and MTHFD1 mRNA (accession number: 
NM_005956) using default parameters. Database research was carried out in Ref seq 
(RNA entries from NCBI's Reference Sequence project) and EST database that contains 
sequence data and other information on cDNA sequences, or "Expressed Sequence Tags". 
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2.2.14.2  ORF FINDER (http://www.ncbi.nlm.nih.gov/projects/gorf/)  
The ORF Finder (Open Reading Frame Finder) is a graphical analysis tool that finds all 
open reading frames of a selectable minimum size in a user's sequence or in a sequence 
already in the database. This tool identifies all open reading frames using the standard or 
alternative genetic codes. Default parameter values were used for all analyses. 
 
2.2.14.3 CLUSTALW (www.ebi.ac.uk/clustalw) 
CLUSTALW is a multiple sequence alignment program for DNA or proteins. Default 
parameter values were used for all analysis. 
 
2.2.14.4  miRBase Version 19 (http://www.mirbase.org)  
Database of published miRNA sequences and annotation. Each entry in the miRBase 
Sequence database represents a predicted hairpin portion of a miRNA transcript  with 
information on the location and sequence of the mature miRNA sequence. 
 
2.2.14.5 miRANDA (http://www.microrna.org) 
miRANDA is a microRNA binding prediction tool that uses an algorithm which incorporates 
current biological knowledge on target rules and on the use of an up-to-date compendium of 
mammalian miRNAs.  The web resource provides users with functional information about the set 
of genes that are potentially regulated by a particular miRNA, the implied cooperativity of multiple 
microRNAs on a particular mRNA and microRNA expression profiles in various tissues.    
 
2.2.14.6 Target Scan (http://www.targetscan.org) 
TargetScan predicts biological targets of miRNAs by seeking for the presence of conserved 
8mer and 7mer sites that match the seed region of each miRNA. Nonconserved sites can also 
be predicted. In mammals, predictions are ranked based on the predicted efficacy of 
targeting as calculated using the context+ scores of the sites. As an option, predictions are 
ranked by their probability of conserved targeting. 
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2.2.14.7 RNAfold (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) 
The RNAfold web server (Vienna RNA Package) predicts secondary structures of single 
stranded RNA or DNA sequences. 
 
2.2.14.8 RNAcofold (http://rna.tbi.univie.ac.at/cgi-bin/RNAcofold.cgi) 
The RNAcofold web server will predict secondary structures of single stranded RNA or 
DNA sequences upon dimer formation. 
 
2.2.14.9 EST database (http://www.ncbi.nlm.nih.gov/nucest/) 
EST The EST database is a collection of short single-read transcript sequences from 
GenBank. These sequences provide a resource to evaluate gene expression, find potential 
variation, and annotate genes. 
 
2.2.14.10 RefSeq: NCBI Reference Sequence Database  
(http://www.ncbi.nlm.nih.gov/refseq/) 
A comprehensive, integrated, non-redundant, well-annotated set of reference sequences 
including genomic, transcript, and protein. 
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Table 2.1 Primers used for RT-PCR assays. 
 
Assay Primer Name Primer Sequence 
   
Chr11seq 
CHR11 A  For    5′- GTT GTG AAT AGG ATA CAC CTT CAA TGA GG -3′ 
CHR11 A  Rev    5′- GGC TTT CAT AGG AAT TGA TTC AGG TTC -3′ 
   
Chr2seq 
and 
Chr9seq 
NCBI 2 For  5′- TGC CCA TCT GCA TGG CAA AGA CC -3′ 
NCBI 2 Rev    5′-  CCC CAC CCG GCA TTC GTA GC -3′ 
NCBI ALL For  5′- GCT GGT GCC ACT TGA ACC AAG T -3′ 
NCBI 5 For  5′- CCT CGT CCC ACC CCC ATG GT -3′ 
   
 CHRX 1 For   5′- AGC AGA CAA CAT TGA ATT ACT CCT CAA -3′ 
 CHRX 3′UTR For   5′- TGA ATG GAT CAT TCT AAA CAG ATC ATC AT -3′ 
 CHRX 3′UTR 2
nd
 Rev 5′- AAA ATG ACA TCC GGG AAA ACT CCT A -3′ 
ChrXseq 
CHRX 2 For   5′- AGT ATT CCG GTC TCC ACC CT -3′ 
CHRX 2 Rev  5′- TTG AGG AGT AAT TCA ATG TTG TCT GCT -3′ 
CHRX 3 For  5′- AAG TCA CAC ACA GAC GGT CCA C -3′ 
CHRX 3 Rev  5′- AGG GTG GAG ACC GGA ATA CT -3′ 
CHRX 4 Rev  5′- GTG GAC CGT CTG TGT GTG ACT T -3′ 
CHRX 5 For  5′- GAC TCA GAC AAT ACA CTG AAG GAG -3′ 
CHRX 5 Rev  5′- GAA CGG GCC TCG TCG ATG -3′ 
CHRX 6 For  5′- CAT ACG ACG AGG CCC GTT C -3′ 
CHRX 6 Rev  5′- CGC ACA CAC ATA AAA AAG TTC TGG -3′ 
CHRX 7 For  5′- CCA GAA CTT TTT TAT GTG TGT GCG -3′ 
   
DIP 
rs35337982 
validation 
A insertion For  5′- GGG ACG CCC ACC CAA GAA -3′ 
A insertion Rev  5′- ACA CTG CTG CCC CAG GCA T -3′ 
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Table 2.2 Primers and probes used for qPCR assays. 
Assay 
Primer / 
Probe Name Primer Sequence 
Final 
Conc.  
     
MTHFD1L 
Long Isoform 
Forward  MTHFD1LuplLoHF 5′ - GAGCTCTGAAGATGCATGGAG - 3′ 0.2 µM 
Reverse  MTHFD1LuplLoHR 5′ - TGCTTCTGGAGGTTACAGCA - 3′ 0.2 µM 
Probe #42         
        
MTHFD1L 
Short Isoform 
Forward  MTHFD1LuplShrtFo 5′ - ACGCCAGCTTCAAAGCAA - 3′ 0.2 µM 
Reverse  MTHFD1LuplShrtRe 5′ - TCACAGGAGAATCACTTCAACC - 3′ 0.2 µM 
Probe #13         
        
MTHFD1L opt* Forward MTHFD1LoptFor  5′- CGAGTTCAGCGAGATCCAG -3′ 0.2 µM 
 Reverse MTHFD1LoptRev  5′- CTGGGGTCGGTCTTGTTG -3′ 0.2 µM 
 Probe #41    
        
Beta-
Glucuronidase 
(GUS) 
Forward  GUSupl(HPLC)F 5′ - ACGCCAGCTTCAAAGCAA - 3′ 0.2 µM 
Reverse  GUSupl(HPLC)R 5′ - TCACAGGAGAATCACTTCAACC - 3′ 0.2 µM 
Probe #57         
        
ncRNAChr9  
Forward  NCBI5For 5′- GACTCAGACAATACACTGAAGGAG -3′ 0.5 µM 
Reverse  NCBI5Rev 5′- GAACGGGCCTCGTCGATG -3′ 0.5 µM 
Probe #23         
        
ncRNAChr2  
Forward  NCBIALLFor 5′- GCT GGT GCC ACT TGA ACC AAG T -3′ 0.5 µM 
Reverse  NCBI5Rev 5′- GAACGGGCCTCGTCGATG -3′ 0.5 µM 
Probe #61         
        
40S ribosomal 
protein S13 
gene (RPS13)  
Forward  RPS13For 5′- GGT TGA AGT TGA CAT CTG ACG A -3′ 0.2 µM 
Reverse  RPS13Rev 5′- TGT GCA ACA CCA TGT GAA TCT -3′ 0.2 µM 
Probe #68         
     
 Forward  MTR upl For 5′- ACAGCAGCATCATGGTCAAG -3′ 0.2 µM 
MTR Reverse  MTR upl Rev 5′- TTCATGGAGCTCTTCTGCAA -3′ 0.2 µM 
 Probe #53   
     
DHFRL1 Forward  DHFRL1uplFor 5′ - CGGACCTTAGAAAGTCACACATC- 3′ 0.2 µM 
 
Reverse  DHFRL1uplRev 5′ - TCACAGGAGAATCACTTCAACC - 3′ 0.2 µM 
Probe #89         
        
GAPDH  
Forward  gapdh-for 5′- CTCTGCTCCTCCTGTTCGAC -3′ 0.2 µM 
Reverse  gapdh-rev 5′- ACGACCAAATCCGTTGACTC -3′ 0.2 µM 
Probe #60         
        
TBT (TATA 
Binding 
Protein)  
Forward  tbt-for 5′- TTGGGTTTTCCAGCTAAGTTCT -3′ 0.2 µM 
Reverse  tbt-rev 5′- CCAGGAAATAACTCTGGCTCA -3′ 0.2 µM 
Probe #24         
        
ACTB (Actin 
Beta) 
Forward  acbt-for 5′- CCAACCGCGAGAAGATGA -3′ 0.2 µM 
Reverse  acbt-rev 5′- TCCATCACGATGCCAGTG -3′ 0.2 µM 
Probe #64         
*MTHFD1L sequence optimized for protein expression in mammals (Chapter 2, Section 
2.2.12). 
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Table 2.3 Primers used for Invitrogen
®
 Gateway cloning. 
 
Assay Primer Name Primer Sequence 
ChrX 3′UTR 
CHRX attB 3′UTR For 
 5′- GGGGACAAGTTTGTACAAAAAAGCAGGCTCC 
TGAATGGATCATTCTAAACAGATCATCAT -3′ 
attB 3′UTR 2nd  Rev   
 5′- GGGGACCACTTTGTACAAGAAAGCTGGGTCCTA 
AAAATGACATCCGGGAAAACTCCTA -3′ 
   
ChrX 750 ORF 
attBCHRX750 For Good  
5′- GGGGACAAGTTTGTACAAAAAAGCAGGCTCC 
ATGTGTGTGCGACAGCCTTCTCAG -3′ 
attB Long ORF Rev    
5′- GGGGACCACTTTGTACAAGAAAGCTGGG 
TCCTAGAGTGTGATCCGGTCTGCAATGATA -3′ 
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Table 2.4 Sequencing Primers.  
 
Primer Name Primer Sequence 
T7 Promoter For  5′- TAATACGACTCACTATAGGG -3′ 
T7 Terminator Rev     5′- GCTAGTTATTGCTCAGCG G -3′ 
MTHFD1Lopt For  5′- CGAGTTCAGCGAGATCCAG -3′ 
MTHFD1Lopt2 For 5′- GAACGCCCTGAAGCCCGAGAAG -3′ 
MTHFD1Lopt4 For 5′- TCGCCAATATCGCCCACGGC -3′ 
NCBI 2 For  5′- TGCCCATCTGCATGGCAAAGA CC -3′ 
NCBI ALL For  5′- GCTGGTGCCACTTGAACCAAG T -3′ 
NCBI 5 For  5′- CCTCGTCCCACCCCCATGGT -3′ 
A insertion For  5′- GGGACGCCCACCCAAGAA -3′ 
CHRX 1 For   5′- AGCAGACAACATTGAATTACTCCTCAA -3′ 
CHRX 2 For   5′- AGTATTCCGGTCTCCACCCT -3′ 
CHRX 3 For  5′- AAGTCACACACAGACGGTCCAC -3′ 
CHRX 5 For  5′- GACTCAGACAATACACTGAAGGAG -3′ 
CHRX 6 For  5′- CATACGACGAGGCCCGTTC -3′ 
CHRX 7 For  5′- CCAGAACTTTTTTATGTGTGTGCG -3′ 
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3.1  Introduction 
 
3.1.1 Cleft lip with or without cleft palate 
 
Cleft lip with or without cleft palate (CLP) and cleft palate only (CPO) are common birth 
defects of complex and heterogeneous aetiology and they are characterized by disruptions 
of normal facial structure (Figure 3.1) (Dixon et al. 2011). While these pathologies can 
occur in numerous Mendelian or teratogenic syndromes, the isolated, non-syndromic form 
represents 70% of all CPL cases and 50% of all CPO cases (Jugessur et al. 2009, Marazita 
et al. 2002). CLP and CPO, with an average birth occurrence ranging from 1 in 700 to 1 in 
1,000 among European populations, are a cause of substantial morbidity and mortality. The 
frequency differs widely across geographical origin, with a prevalence as high as 1 in 500 
in Asian and Native American population, and as low as 1 in 2,500 in African derived 
populations. These data suggest that the contribution given by individual risk factors may 
vary across different populations (Mossey et al. 2009). Furthermore, also the gender may 
influence the frequency: CLP have a 2:1 male to female ratio while CPO have around 1:2 
male to female ratio. Since CLP and CPO are aetiologically heterogeneous, many efforts 
have been done in order to identify distinct risk factors spanning genetics and environment. 
The important role played by genetic factors is indicated by several twin and family studies 
(Mitchell et al. 2002) and by recurrence risk, which is 20-30 times greater than population 
prevalence (Mangold et al. 2010). Nevertheless, CLP and CPO are well known to be 
associated with several environmental risk factors, like, for example, maternal smoking 
(Little et al. 2002, Shi et al. 2008, Butali et al. 2013).    
  
3.1.2 Cleft and folic acid  
 
Many studies suggest that folate deficiency before or during pregnancy can be another 
environmental risk factor (Boyles et al. 2008; van Rooij et al. 2004, Wehby and Murray 
2010, Blanton et al. 2011). Folate supplementation in pregnancy has been shown to reduce 
the recurrence of CLP in families (Chevrier et al., 2007; Wilcox et al., 2007; Jia et al., 
2011; Kelly et al., 2012, Butali et al. 2013). Nevertheless this association is still 
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controversial (Ray et al. 2003, Wehby and Cassell 2010) as demonstrated by the mixed 
results of numerous association studies  between cleft occurrence and folate related genes, 
including MTHFR (Shaw et al. 1998, Martinelli et al. 2001, Blanton et al. 2002, Prescott et 
al. 2002, Jugessur et al. 2003, Shotelersuk et al. 2003, van Rooij et al. 2003, Vieira et al. 
2005, Mills et al. 2008, Butali et al. 2013), MTHFD1 (Mostowska et al. 2010, Boyles et al. 
2008, Mills et al. 2008), 5,10-methenyltetrahydrofolate synthetase (MTHFS) and  5-
methyltetrahydrofolate-homocysteine methyltransferase (MTR) (Martinelli et al. 2006, 
Mostowska et al. 2010,  Bufalino et al. 2010, Blanton et al. 2011).  
 
To our knowledge, so far, genetic variants of the folate related gene MTHFD1L have never 
been tested for cleft association. As explained in Chapter 1, Sections 1.1.6-7, this gene is 
gaining relevance as a target for disease association studies as more and more 
investigations are reporting polymorphisms associated with illnesses like coronary artery 
disease (Samani et al. 2007, Bressler et al. 2010) and Alzheimer disease (Naj et al., 2010). 
Sugiura et al. (2004) have also shown that MTHFD1L is upregulated in human colon 
adenocarcinoma. In a recent publication, it has been also proved that deletion of Mthfd1l 
causes embryonic lethality and neural tube and craniofacial defects in mice (Momb et al. 
2013). 
 
Moreover, it has been previously reported that numerous MTHFD1L polymorphisms are 
associated with the risk of NTDs in the Irish population (Chapter 1, Section 1.1.7, Parle-
McDermott et al. 2009). MTHFD1L gene encodes the mitochondrial C1-THF Synthase 
protein which has a monofunctional 10-formyl-THF synthetase activity lacking the 5,10-
methylene-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities typically 
found in the trifunctional cytoplasmic protein encoded by MTHFD1 (Prasannan and 
Appling 2008). The short MTHFD1L isoform of 1.1 kb (transcript variant 4), that lack 
enzymatic activity (Prasannan et al. 2003), is caused by the alternatively spliced exon 8a.  
Just upstream this exon there is a polypyrimidine tract containing the triallelic 
deletion/insertion polymorphism (DIP) rs3832406 which has been shown to be associated 
with NTDs (Chapter 1, Section 1.1.7). DIP rs3832406 is composed of several ATT repeats: 
Allele 1 has 7 ATT repeats, allele 2 has 8 repeats and allele 3 has 9 repeats. The DIP is 
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within the region “a” of the MTHFD1L LD map (Chapter 1, Figure 1.6). In this scenario 
DIP polymorphism could be the direct disease causing variant within the associated LD 
region “a” by affecting alternative splicing of the gene (Parle-McDermott et al. 2009).  
 
Based on its association with neural tube defects (NTDs) (Parle-McDermott et al. 2009), 
and the previously detected association of its cytoplasmic homologue MTHFD1 in our 
cleft cohort, in this chapter of the project, we considered the mitochondrial enzyme 
MTHFD1L to be a prime candidate for consideration for association with cleft. We tested 
the DIP and another SNP within region “a” for a possible association with cleft disease 
(Figure 3.2). We genotyped MTHFD1L DIP rs3832406 and the most statistically 
significant NTD-associated SNP from that study i.e., rs17080476, in 981 Irish case-parent 
trios affected by CPL or CPO. We also adapted a melting curve method capable of 
genotyping deletion/insertion polymorphisms without the need for capillary 
electrophoresis. Finally, another MTHFD1L DIP rs35337982 was reported in NCBI 
database, but it has not been validated; here we carried out a brief investigation to validate 
it.  
 
The results of this chapter have been published:  
Minguzzi S, Molloy AM, Peadar K, Mills J, Scott JM, Troendle J, Pangilinan F, Brody L, 
Parle-McDermott A: Genotyping of a tri-allelic polymorphism by a novel melting curve 
assay in MTHFD1L: an association study of nonsyndromic Cleft in Ireland. BMC Med 
Genet 2012; doi:10.1186/1471.  
 
3.2 Methods 
 
3.2.1 Subjects and Ethic Statement 
 
Cleft samples were obtained at the Dublin Cleft Centre in Ireland as previously described 
(Mills et al. 2008) from subjects with CPO or CLP along with their mothers and fathers. 
Not all triad families were complete because samples from all three family members were 
not always available. A total of 2688 samples including 758 complete triads and 223 
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incomplete triads were collected for this work. Medical information was provided by the 
attending surgeons for 87% of the cleft cases.  
 
Following complete description of the study to the subjects, written informed consent was 
obtained from all participants. Ethical approval was granted by the hospitals, and the 
Institutional Review Board at NIH. Control samples were collected from a population of 
56,049 pregnant women attending the three main maternity hospitals in the Dublin area 
between 1986 and 1990 as previously described (Mills et al. 2008 and Parle-McDermott et 
al. 2006b). 
 
For this study a random sample, (n = 1,008), were selected after all mothers who had given 
birth to a child with a known malformation, including NTD, orofacial cleft, congenital 
heart defect, Down syndrome, or limb deformity had been removed. Mothers with a 
previous history of an NTD affected pregnancy were also excluded. Subjects gave consent 
for all the samples. 
 
3.2.2 Genotyping Methods 
 
Genomic DNA was extracted from blood or buccal swab collected samples using a 
QIAamp DNA Blood Mini Kit (Qiagen, UK). HybProbe melting curve assays were 
designed to genotyped DIP rs3832406 and SNP rs17080476 on a LightCycler 480 Real 
Time PCR machine (Roche) using LightCycler 480 Genotyping Master and are described 
in more detail below. Genotyping quality was verified by repeat genotyping of at least 10% 
of samples. The success rates and agreement rates for repeat genotyping were, 
respectively, 99.2% and 99.1%   for DIP rs3832406, 99.7% and 100% for SNP 
rs17080476.  
 
SNP rs17080476 assay 
SNP rs17080476 reagents and analysis conditions are: Forward Primer 5′-
GCAACTTTGTTTAGTATGAAAATTTGAT-3′ (4µM), reverse primer 5′-
TCTGTCTTCACCCAGCC (2µM), anchor probe 5′-Bodipy630/650-
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AAGAGGGGAAAAAAAACCTTTCTCCATTATTCCTA-PHO-3′ (0.4 µM), sensor 
probe 5′-ATTCATTTCTTTACAGCAGTGGGATTATGAAA-Fluorescein 3′ (0.2 µM), 
pre-incubation 10 minutes at 95ºC, amplification 45 cycles of 15 seconds at 95ºC, 15 
seconds at 56ºC, 15 seconds at 72 ºC, melting curve 1 minute at 95 ºC,   2 seconds at 50 ºC, 
acquisition ramp till 80 ºC  (0,11ºC/s, 5 acquisitions per ºC). 
 
DIP rs3832406 assay 
DIP rs3832406 reagents and analysis conditions are: forward primer 5′-
AAGCTTCCTGTTACCAC-3′ (4µM), reverse primer 5′-AGGAGAATCACTTCAACC-3′ 
(2µM), anchor probe: 5′-AGCCCCACGTTTGAATTTTATGTTTTTCCTAAAGT-
Fluorescein-3′ (0.2µM). Sensor probe: 5′BODIPY630/650-AGGGAAGATTATTATTATT 
ATTATTATTATTATTTTCTTTTTCAGACGGA-Phosphate-3′ (0.2µM), pre-incubation 
10 minutes at 95 ºC, amplification 45 Cycles of 10 minutes at 95 ºC, 10 seconds at 56 ºC, 
10 seconds at 72 ºC, melting curve 1 minute at 95 ºC, 2 seconds at 50 ºC, acquisition ramp 
till 70 ºC  (0,02 ºC/s, 30 acquisitions per ºC). 
 
3.2.3 Statistical Methods 
 
Our primary analysis was made with isolated nonsyndromic cases of CLP and CPO and 
their parents were included. A secondary analysis was then carried out including 
nonsyndromic cleft cases with other defects. Hardy-Weinberg equilibrium (HWE) was 
tested within each subject class (case, mother, father and controls) for SNP and DIP by chi-
squared test. Associations with CLP and CPO were tested for SNP and DIP in 
cases/controls and separately in mothers/controls by logistic regression and odds ratios 
using either a dominant or recessive disease model. Triads (case, mother, and father) were 
used to perform the Transmission Disequilibrium Test (TDT) of Spielman et al. (1993) for 
each allele separately. Case and maternal effects were also assessed by log-linear modeling 
using 2 degrees of freedom.  
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3.3 Results 
 
3.3.1 Development of a novel assay to genotype DIP rs3832406 by Melting Curve 
Analysis 
 
A single assay which is able to distinguish 3 alleles contemporaneously was developed 
taking advantage of the GC-rich regions flanking the DIP (Figure 3.3). As described 
above, this polymorphism is a repeated “ATT” sequence which has three common alleles, 
Allele 1 (ATT7) Allele2 (ATT8) and Allele 3 (ATT9). A wide 50-bases sensor probe was 
designed to perfectly match allele 3 with 9 ATT repeats and its flanking regions, producing 
a melting temperature (Tm) of 63°C (Figure 3.3c). The same probe, starting the annealing 
from GC-rich regions, produces a 3-base mismatched bubble on allele 2 and a 6-base 
mismatched bubble on allele 1 causing a Tm of 60.3°C and 58.8°C respectively (Figure 
3.3a-b). As a result the peaks produced by each allele are clearly distinguishable (Figure 
3.4). This assay can be easily adopted by any laboratory with a Real-Time PCR machine 
with melting curve capacity. This is a valid alternative to capillary electrophoresis for the 
genotyping of multiple allele DIPs.  
 
3.3.2  DIP rs3832406 showed an associated with CLP  
 
CPL and CPO triad (mother, father and affected case) and control samples necessary for 
this association study were collected from the Irish population. Primary analysis was 
carried out on triads with isolated cases of CLP and CPO, while in secondary analysis 
nonsyndromic cases with other defects were included. DIP rs3832406 and SNP 
rs17080476 were genotyped in 2688 samples including 758 complete triads and in 1008 
controls. 
 
 SNP and DIP genotype frequencies for all groups are shown in Table 3.1 Genotype 
distributions in all groups were in HWE. The DIP showed an association with CLP case 
status based on TDT and log-linear analysis (Table 3.2). Based on TDT Allele 1 is 
transmitted to the offspring 55% of times (p= 0.017) in isolated CLP cases, carrying an 
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increased risk of having this disease. When the multiple case families were added to the 
analysis this value becomes more significant (56% transmission, p= 0.006). Allele 3 which 
has the lowest frequency, was passed to the offspring only 42.9% of times (p= 0.045) in 
multiple CLP cases, appearing to have a protective role against the disease. A Log-linear 
analysis with 2 degrees of freedom based on a recessive disease model confirmed the case 
association for Allele 1 (p= 0.039) in multiple CLP cases (Table 3.2). However, correction 
of these significant p-values using permutational adjustment resulted in loss of statistical 
significance. All the other analysis performed for DIP and SNP in CLP or CPO cases did 
not exhibit a significant association with the disease (Table 3.3, 3.4 and 3.5). 
 
 
 
3.3.3 DIP rs35337982 validation 
 
Deletion/insertion polymorphism rs35337982 is reported on dbSNP Short Genetic 
Variations database, but it has not been validated. DIP rs35337982 is reported as an 
insertion of a single adenosine nucleotide in exon 19 of MTHFD1L which leads to a 
premature stop codon in exon 19 due to frameshift. Such a shortened sequence would 
probably result in an inactive protein. A brief investigation was conducted to validate the 
presence of DIP rs35337982 in 20 genomic DNA sample (Chapter 2, Section 2.2.5). 
Samples were amplified by PCR and then sequenced (an example of sequenced sample is 
reported in Appendix S). None of them showed to have the insertion at the DIP 
rs35337982 (data not shown).    
 
3.4  Discussion 
 
The MTHFD1L gene has received particular attention in recent years owing to its 
association with coronary artery disease, Alzheimer’s disease and NTDs. Our previous 
study, demonstrated that the MTHFD1L rs3832406 DIP is functional by impacting on 
alternative splicing efficiency (Parle-McDermott et al. 2009). We report a new modified 
melting curve assay to genotype this functionally relevant triallelic MTHFD1L 
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polymorphism without the need for traditional capillary electrophoresis methods. We 
genotyped rs3832406 DIP and SNP rs17080476 in an Irish cleft cohort in a bid to test for 
association. Our initial analysis shows that Allele 1 of rs3832406 DIP is associated with 
CLP cases. Allele 1 as the disease risk allele is in concordance with our previous NTD 
study which showed a similar association (Parle-McDermott et al. 2009). 
 
However, adjustment of our analyses resulted in loss of statistical significance indicating 
that this variant is simply not associated with CLP or that a larger sample size is required 
to detect an effect. We did not observe statistical significance with SNP rs17080476 which 
shares a D’ value of 0.56 with DIP rs3832406 and represented the most statistically 
compelling variant from this genomic region in our NTD study (Parle-McDermott et al. 
2009). In conclusion, our analysis shows no strong association between specific 
polymorphisms within the MTHFD1L gene and risk of cleft in an Irish cohort. We suggest 
further screening of rs3832406 DIP in a larger cohort and describe a new assay that will 
facilitate this. We have demonstrated that the modified Melting Curve Analysis developed 
for DIP rs3832406 could be a valid alternative to capillary electrophoresis for the 
genotyping of multiple allele deletion/insertion polymorphisms and can be employed by 
any laboratory with a Real-Time PCR instrument with melting curve capacity.  
Finally we tried to validate the reported DIP rs35337982 of MTHFD1L. Twenty genomic 
DNA samples were genotyped without finding any trace of this DIP. The presence of this 
potential polymorphism probably leads to an inactive protein. Since MTHFD1L function is 
essential, such a DIP would exist only in a heterozygous state and it would be likely to be 
associated with serious dysfunctions of a rare disease. Hence, our sequencing data 
indicates that this variant is not common in the Irish population, but we cannot rule out that 
it is a rare variant or whether it is simply the result of a sequencing error. The recent 
increase of whole genome or exome sequencing of rare disease patients and a future 
creation of a shared database might answer this open question (Roach et al. 2010).  
 While a second DIP (rs35337982) was not validated within MTHFD1L, DIP 
rs3832406 has been shown to impact on MTHFD1L enzyme levels and is associated with 
NTD and potentially with cleft.  The molecular mechanism of how it increases risk 
remains to be elucidated but is explored further in Chapter 7.  
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Figure 3.1 Examples of Cleft Lip (left) and Cleft Plate (right) (adapted from Dixon et 
al. 2011). 
The picture on the left shows a left unilateral cleft lip case, while the picture on the right 
shows a soft cleft palate only case.  
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Figure 3.2 Linkage disequilibrium (LD) map of one associated region of the 
MTHFD1L Gene (marked region ‘‘a’’ in Chapter 1, Figure 1.6) (Parle-McDermott et 
al. 2009). 
LD plot of pairwise values of D’ for 15 markers within the region spanning introns 7–10 of 
the MTHFD1L gene. Boxed markers were associated with NTD risk. DIP rs3832406 is the 
number 3, while SNP rs17080476 is the number 9. The DIP is in LD with the SNP with a 
D’ value of 0.56 and an r2 value of 0.13. Therefore, although they are in LD, they do not 
correlate well for one another.  
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Figure 3.3 Modified Melting Curve Analysis for DIP rs3832406 (figure drawn with 
Microsoft PowerPoint).  
The Sensor probe design for detection of all three alleles of DIP rs3832406 is shown.  The 
Sensor probe is designed to perfectly match the complement of Allele 3.   
A. Sensor probe bound to Allele 1 has a Tm of 58.8°C. B. Sensor probe bound to Allele 2 
has a Tm of 60.3° C. Sensor probe bound to Allele 3 has a Tm of 63°C. 
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Figure 3.4 Peaks resulting from DIP rs3832406 Melting Curve Analysis. 
Figure a shows the peaks produced from homozygote samples, while Figure b shows the 
heterozygote sample peaks. 
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Table 3.1 Genotyping Results in Triads (Cases, Mother and Fathers) and Controls for CLP and CPO (Isolated) or with Other 
Defects (Multiple). 
 
DIPrs3832406  Isolated defects  Multiple defects    
CPL Fathers  Mothers  Cases  Fathers  Mothers  Cases  Controls 
 n %  n %  n %  n %  n %  n %  n % 
11 162 41.8  187 40.1  209 41.9  174 42.0  203 40.8  231 43.5  419 42.1 
12 102 26.3  128 27.5  149 29.9  116 28.0  140 28.1  163 30.7  267 26.8 
13 76 19.6  89 19.1  84 16.8  82 19.8  97 19.5  91 17.1  196 19.7 
22 18 4.6  24 5.2  18 3.6  18 4.3  24 4.8  18 3.4  40 4.0 
23 24 6.2  31 6.7  28 5.6  24 5.8  34 6.8  28 5.3  52 5.2 
33 6 1.5  7 1.5  11 2.2  6 1.4  7 1.4  11 2.1  21 2.1 
                     
CPO Fathers  Mothers  Cases  Fathers  Mothers  Cases    
 n %  n %  n %  n %  n %  n %    
11 98 37.3  118 38.1  134 41.7  145 40.8  154 36.9  175 41.0    
12 78 29.7  82 26.5  88 27.4  97 27.3  110 26.4  118 27.6    
13 60 22.8  69 22.3  62 19.3  77 21.7  99 23.7  86 20.1    
22 8 3.0  12 3.9  7 2.2  8 2.3  18 4.3  9 2.1    
23 18 6.8  20 6.5  23 7.2  25 7.0  26 6.2  29 6.8    
33 1 0.4   9 2.9   7 2.2   3 0.8   10 2.4   10 2.3       
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SNPrs17080476  Isolated defects  Multiple defects    
CPL Fathers  Mothers  Cases  Fathers  Mothers  Cases  Controls 
 n %  n %  n %  n %  n %  n %  n % 
AA 268 68.2  296 63.1  320 63.1  285 67.1  320 62.9  344 62.5  660 65.9 
AG 110 28.0  160 34.1  170 33.5  124 29.2  176 34.6  188 34.2  308 30.8 
GG 15 3.8  13 2.8  17 3.4  16 3.8  13 2.6  18 3.3  33 3.3 
                     
 Isolated defects  Multiple defects    
CPO Fathers  Mothers  Cases  Fathers  Mothers  Cases   
 n %  n %  n %  n %  n %  n %    
AA 173 65.5  205 65.7  214 65.6  234 65.9  274 65.6  288 66.8    
AG 86 32.6  93 29.8  100 30.7  115 32.4  127 30.4  125 29.0    
GG 5 1.9   14 4.5   12 3.7   6 1.7   17 4.1   18 4.2       
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Table 3.2 TDT and Log-Linear analysis for DIP rs3832406 in isolated and 
multiple CPL cases. Significant values are marked in bold. 
 
   TDT  Log-linear p-value 
 DIP Allele  Passed  Not Passed  P-value  Dominant  Recessive 
   n %  n %       
Isolated 
CLP 
1  197 55.0  161 45.0  0.017  0.075  0.066 
2  126 48.3  135 51.7  0.225  0.581  0.078 
3   91 43.5   118 56.5   0.073   0.024   0.368 
Multiple 
CLP 
1  219 56.0  172 44.0  0.006  0.034  0.039 
2  135 47.4  150 52.6  0.143  0.398  0.078 
3   96 42.9   128 57.1   0.045   0.017   0.593 
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Table 3.3 Logistic Regression Results for SNP rs17080476 and DIP rs3832406. OR 
= Odds Ratio CI = confidence interval 
 
 Polym Analysis Dominant Recessive Multiplicative 
   OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
 DIP  1 Case-CTRL 1.1 (0.8, 1.5) 0.6159 1 (0.8, 1.3) 0.8468 1 (0.9, 1.2) 0.7022 
  Mother-CTRL 0.9 (0.6, 1.2) 0.3917 0.9 (0.7, 1.1) 0.4774 0.9 (0.8, 1.1) 0.3476 
CLP DIP  2 Case-CTRL 1.1 (0.9, 1.4) 0.3358 0.8 (0.5, 1.4) 0.4926 1.1 (0.9, 1.3) 0.5534 
all  Mother-CTRL 1.1 (0.9, 1.4) 0.2363 1.2 (0.7, 2) 0.5077 1.1 (0.9, 1.4) 0.2176 
 DIP  3 Case-CTRL 0.9 (0.7, 1.1) 0.1928 1 (0.5, 2) 0.9158 0.9 (0.7, 1.1) 0.2349 
  Mother-CTRL 1 (0.8, 1.3) 0.9044 0.7 (0.3, 1.5) 0.3311 1 (0.8, 1.2) 0.8726 
 SNP Case-CTRL 1 (0.6, 1.8) 0.9798 0.9 (0.7, 1.1) 0.1816 0.9 (0.7, 1.1) 0.2494 
   Mother-CTRL 1.3 (0.7, 2.5) 0.4286 0.9 (0.7, 1.1) 0.2382 0.9 (0.8, 1.1) 0.4336 
 DIP  1 Case-CTRL 1 (0.7, 1.4) 0.9697 1 (0.8, 1.2) 0.9333 1 (0.8, 1.2) 0.9358 
  Mother-CTRL 0.8 (0.6, 1.2) 0.2857 0.9 (0.7, 1.2) 0.4737 0.9 (0.8, 1.1) 0.2955 
CLP DIP  2 Case-CTRL 1.1 (0.9, 1.4) 0.258 0.9 (0.5, 1.6) 0.6969 1.1 (0.9, 1.3) 0.4046 
iso  Mother-CTRL 1.1 (0.9, 1.4) 0.2396 1.3 (0.8, 2.2) 0.3264 1.1 (0.9, 1.4) 0.1809 
 DIP  3 Case-CTRL 0.9 (0.7, 1.1) 0.323 1 (0.5, 2.2) 0.9053 0.9 (0.7, 1.1) 0.3998 
  Mother-CTRL 1 (0.8, 1.3) 0.9303 0.7 (0.3, 1.7) 0.4316 1 (0.8, 1.2) 0.8883 
 SNP Case-CTRL 1 (0.5, 1.8) 0.9538 0.9 (0.7, 1.1) 0.2786 0.9 (0.8, 1.1) 0.3381 
   Mother-CTRL 1.2 (0.6, 2.3) 0.5906 0.9 (0.7, 1.1) 0.2905 0.9 (0.8, 1.1) 0.4526 
 DIP  1 Case-CTRL 1 (0.7, 1.4) 0.9498 1 (0.8, 1.2) 0.6933 1 (0.8, 1.2) 0.7915 
  Mother-CTRL 0.9 (0.6, 1.2) 0.3981 0.8 (0.6, 1) 0.0708 0.9 (0.7, 1) 0.0808 
CPO DIP  2 Case-CTRL 1 (0.8, 1.3) 0.8703 0.5 (0.2, 1.1) 0.0749 1 (0.8, 1.2) 0.6497 
all  Mother-CTRL 1 (0.8, 1.3) 0.7614 1.1 (0.6, 1.9) 0.798 1 (0.8, 1.3) 0.7284 
 DIP  3 Case-CTRL 1.1 (0.9, 1.4) 0.3873 1.1 (0.5, 2.4) 0.7843 1.1 (0.9, 1.4) 0.3963 
  Mother-CTRL 1.3 (1, 1.7) 0.0431 1.1 (0.5, 2.4) 0.7368 1.2 (1, 1.5) 0.0576 
 SNP Case-CTRL 0.8 (0.4, 1.4) 0.4111 1 (0.8, 1.3) 0.7454 1 (0.8, 1.2) 1 
   Mother-CTRL 0.8 (0.4, 1.5) 0.4739 1 (0.8, 1.3) 0.8894 1 (0.8, 1.2) 0.7186 
 DIP  1 Case-CTRL 1 (0.7, 1.5) 0.9335 1 (0.8, 1.3) 0.9081 1 (0.8, 1.2) 0.8998 
  Mother-CTRL 0.8 (0.6, 1.2) 0.3735 0.8 (0.7, 1.1) 0.2065 0.9 (0.7, 1.1) 0.1723 
CPO DIP  2 Case-CTRL 1 (0.8, 1.3) 0.8253 0.5 (0.2, 1.2) 0.1285 1 (0.8, 1.2) 0.7474 
iso  Mother-CTRL 1 (0.8, 1.3) 0.824 1 (0.5, 1.9) 0.9076 1 (0.8, 1.3) 0.882 
 DIP  3 Case-CTRL 1.1 (0.8, 1.4) 0.5704 1 (0.4, 2.5) 0.9392 1.1 (0.8, 1.4) 0.598 
  Mother-CTRL 1.2 (0.9, 1.6) 0.1179 1.4 (0.6, 3.1) 0.4179 1.2 (1, 1.6) 0.1044 
 SNP Case-CTRL 0.9 (0.5, 1.7) 0.7393 1 (0.8, 1.3) 0.9235 1 (0.8, 1.2) 0.847 
    Mother-CTRL 0.7 (0.4, 1.4) 0.3247 1 (0.8, 1.3) 0.9406 1 (0.8, 1.2) 0.6925 
 
 
 
 
 
 
 
 
 
61 
 
Table 3.4 Spielman Transmission Disequilibrium Test (TDT) and Log-Linear 
analysis for DIPrs3832406. GRR = genotype relative risk, CI =confidence interval. 
Significant values are marked in bold. 
 
 DIP rs3832406  
  
  
Spielman TDT Log Linear Model 
   Dominant Recessive 
 1 vs 2 or 3 GRR (95% CI) p-value GRR (95% CI) p-value GRR (95% CI) p-value 
 Case effect 1.3 (1.0  1.6) 0.01734 1.5 (1.0  2.2) 0.0754 1.3 (1.0  1.7) 0.0663  
 Mom effect   0.9 (0.6  1.4) 0.6663 1.0 (0.7  1.3) 0.8828 
CLPiso 
2 vs 1 or 3       
Case effect 0.9 (0.7  1.1) 0.2253 0.9 (0.7  1.2) 0.5807 0.5 (0.3  1.1) 0.0776 
 Mom effect   1.1 (0.8  1.4) 0.6009 1.3 (0.6  2.4) 0.5059 
 3 vs 1 or 2       
 Case effect 0.8 (0.6  1.0) 0.0727 0.7 (0.5  1.0) 0.0236 1.5 (0.6  3.4) 0.3677 
 Mom effect     0.9 (0.7  1.3) 0.7472 0.8 (0.3  2.7) 0.7633 
  1 vs 2 or 3       
 Case effect 1.3 (1.1  1.6) 0.0062 1.6 (1.0  2.3) 0.0337  1.3 (1.0  1.7) 0.0393 
 Mom effect   0.9 (0.6  1.3) 0.5228 1.0 (0.8  1.3) 0.9429 
CLPall 
2 vs 1 or 3       
Case effect 0.8 (0.7  1.1) 0.1432 0.9 (0.7  1.2) 0.3976 0.5 (0.3  1.1) 0.0775 
 Mom effect   1.0 (0.8  1.4) 0.7729 1.3 (0.6  1.4) 0.5059 
 3 vs 1 or 2       
 Case effect 0.8 (0.6  1.0) 0.0445 0.7 (0.5  0.9) 0.0171 1.2 (0.6  2.8) 0.5926 
 Mom effect     1.0 (0.7  1.3) 0.8751 0.8 (0.3  2.7) 0.7633 
  1 vs 2 or 3       
 Case effect 1.1 (0.8  1.4) 0.5399 1.4 (0.9  2.2) 0.1564 1.0 (0.7  1.3) 0.8062 
 Mom effect   0.9 (0.5  1.5) 0.5795 1.0 (0.7  1.4) 0.8539 
CPOiso 
2 vs 1 or 3       
Case effect 0.9 (0.7 1.2) 0.5989 1.0 (0.7  1.4) 0.9325 0.6 (0.2  1.4) 0.2307 
 Mom effect   0.9 (0.6  1.3) 0.6016 1.1 (0.4  2.9) 0.8085 
 3 vs 1 or 2       
 Case effect 1.0 (0.7  1.3) 0.8083 0.9 (0.7  1.3) 0.7549  1.1 (0.4  2.7) 0.9028 
 Mom effect     1.1 (0.8  1.6) 0.5776 6.0 (0.7 49.8) 0.0972 
  1 vs 2 or 3       
 Case effect 1.1 (0.9  1.3) 0.4866 1.4 (0.9  2.4) 0.1223  1.0 (0.7  1.2) 0.8326 
 Mom effect   0.8 (0.5  1.3) 0.4738 0.8 (0.6  1.1) 0.2436 
CPOall 
2 vs 1 or 3       
Case effect 1.0 (0.7  1.2) 0.7422 1.0 (0.8  1.4) 0.9119 0.6 (0.3  1.4) 0.2449 
 Mom effect   1.0 (0.8  1.40 0.9397 1.8 (0.7  4.2) 0.2067 
 3 vs 1 or 2       
 Case effect 0.9 (0.7  1.2) 0.5774 0.9 (0.7  1.2) 0.5666 1.0 (0.4  2.3) 0.9136 
 Mom effect     1.1 (0.8  1.5) 0.4295 2.3 (0.6  9.0) 0.2195 
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Table 3.5 Spielman Transmission Disequilibrium Test (TDT) and Log-Linear 
analysis    for SNP rs17080476. GRR = genotype relative risk, CI =confidence 
interval. Significant values are marked in bold. 
 
 SNP rs17080476   
  Spielman TDT Log Linear Model 
    Dominant Recessive 
  GRR (95% CI) p-value GRR (95% CI) p-value GRR (95% CI) p-value 
CLPiso 
Case 
effect 
0.9 (0.7  1.1) 0.2157 0.8 (0.4  1.5) 0.4495  0.9 (0.6  1.1) 0.2806 
Mom effect   1.4 (0.6  3.2) 0.4164 0.8 (0.6  1.1) 0.1917 
CLPall 
Case 
effect 
0.8 (0.7  1.1) 0.1907 0.9 (0.5  1.7) 0.8119  0.8 (0.6  1.1) 0.1629 
Mom effect   1.5 (0.7  3.3) 0.3206 0.9 (0.7  1.2) 0.3715 
CPOiso 
Case 
effect 
0.9 (0.7  1.3) 0.7006 1.0 (0.4  2.1) 0.9183  0.9 (0.7  1.3) 0.6962 
Mom effect   0.5 (0.2  1.3) 0.1438 0.9 (0.6  1.30 0.6548 
CPOall 
Case 
effect 
1.0 (0.7  1.2) 0.7411 0.7 (0.4  1.4) 0.3272  1.0 (0.8  1.3) 0.9703 
Mom effect   0.4 (0.2  1.1) 0.0825 0.9 (0.7  1.2) 0.4889 
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4.1 Introduction 
 
4.1.1  MicroRNA regulation and biogenesis 
 
MicroRNAs (miRNAs) are small endogenous noncoding RNAs (ncRNAs) that can pair 
to sites in the mRNAs of protein-coding genes to modulate their expression, playing a 
role in many biological processes. The first miRNA was discovered in yeast in 1993 
(Lee et al. 1993, Wightman et al. 1993) and since that, these ~22-nucleotide regulators 
have been thoroughly investigated, making them the best characterized group among 
ncRNAs. To date more than 2000 human miRNAs have been identified with each 
having up to hundreds of unique target mRNAs (miRBase Version 19, Griffiths-Jones 
et al. 2006, Kozomara et al. 2011). 
 
Most microRNA genes originate from intergenic regions or in anti-sense orientation to 
genes
 
and contain their own promoter (Lee et al. 2004).  The biogenesis of miRNAs 
begins with the transcription of primary transcripts (pri-miRNAs) by either RNA 
polymerase II or RNA polymerase III in the nucleus (Figure 4.1) (Winter et a. 2009). 
pri-miRNAs may be edited by adenosine deaminases acting on RNA (ADARs) which 
modifies adenosine (A) into inosine (I) enhancing their processing by Drosha 
(Kawahara et al. 2008). In the nucleus, pri-miRNAs are then processed by the 
microprocessor complex which recognises their hairpin structure. This complex is 
formed by the RNase III type endonuclease Drosha and its partner, DGCR8 (DiGeorge 
syndrome critical region 8). It produces a ~60-nucleotide stem loop called precursor 
miRNA (pre-miRNA), which is exported to the cytoplasm by exportine 5 (XPO 5) in 
complex with Ran-GTP61 (Yi et al. 2003). Once in the cytoplasm, the pre-miRNA are 
cleaved by Dicer and TAR RNA-binding protein (TRBP), generating a ~22-nucleotide 
mature miRNA duplex (Inui et al. 2010). 
 
At this stage, one strand of miRNA is usually degraded and the other strand is loaded 
into the RNA-induced silencing complex (RISC). This complex, which contains 
Argonaute (Ago) proteins, is the cytoplasmic effector machine of the miRNA pathway. 
It is guided by the single-stranded miRNA to its final target mRNAs partially 
complementing its sequence. A pairing between the seed sequence of the miRNA and 
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the seed match sequence in the 3′UTR of the mRNA is particularly important. The 
RISC can repress the target mRNA through two main mechanisms that have different 
variations (Inui et al. 2010). It can remove the polyA tail by promoting the activity of 
deadenylases (such as CCR-NOT), causing mRNA degradation. Alternatively it can 
block the translation at the initiation step or at the elongation step by causing, for 
example the ribosome stalling or the repression of initiation factor 4E (EIF4E).  
 
4.1.2 Neural Tube Defects and MTHFD1L 
 
Common birth malformations known as neural tube defects (NTDs) are severe 
craniospinal defects resulting from the failure of the neural tube to close during early 
embryonic development (Rampersaud E 2006). Low periconceptional maternal folate 
levels are well known as important risk factors for NTD, even though the mechanisms 
behind this association remains poorly understood (Kirke 2005). It is claimed that 50-
70% of NTDs in humans could be prevented if women ingest a folic acid supplement in 
the periconceptional period (Wald 1991, Czeizel and Dudas 1992, Zhang et al. 2006). 
Common genetic variation is another important risk factor for NTD, whereby genes 
involved in the transport and metabolism of folate are prime candidates for genetic 
association studies.  
 
One of these genes involved in the folate pathway is MTHFD1L, which encodes a 
mitochondrial mono-functional enzyme with a 10-formyltetrahydrofolate synthetase 
activity (Prasannan et al. 2003). This enzyme localizes to mitochondria and catalyzes 
the synthesis of formate within the highly compartmentalized one-carbon (1C) 
metabolism. In this crucial metabolism, 1C units are processed and transported through 
cytoplasm and mitochondria, generating a mostly unidirectional flow that supports 
important biological functions like de novo purine and thymidylate biosynthesis, 
methionine biosynthesis and amino acid metabolism (Prasannan and Appling 2009). 
Metabolic experiments carried out in mouse embryonic fibroblasts indicate that more 
than 75% of 1C units that enter the cytoplasmic methyl cycle derive from mitochondria 
(Pike et al. 2010). It appears that MTHFD1L is the only enzyme in both embryos and 
adults, (which catalyzes the last step in the production of formate in the mitochondria), 
which is subsequently exported to the cytoplasm. This role puts MTHFD1L under the 
spotlight for a possible involvement in human disease including cancer, which has been 
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investigated in several studies. For instance, MTHFD1L expression is upregulated in 
human colon cancer (Sugiura et al. 2004) and breast cancer (Selcuklu et al. 2012), and 
high levels of this protein are correlated with growth rate of human cancer cell lines 
(Jain et al. 2012). In addition, genome-wide association studies demonstrated that 
MTHFD1L polymorphisms are associated with coronary artery disease (Samani et al. 
2007, Bressler et al. 2010) and Alzheimer’s disease (Naj et al. 2010). 
 
In mouse models MTHFD1L is clearly linked to NTD. Where Mthfd1l knockout mice 
have been analysed, the loss of the protein was found to be lethal to developing 
embryos, causing fetal growth restriction and aberrant neural tube phenotypes with 
100% penetrance (Momb et al. 2013). All the Mthfd1l knockout embryos developed a 
clear NTD phenotype failing to close the neural tube (exencephaly or 
craniorachischisis) or displaying a wavy neural tube with a small, aberrantly formed 
head (Momb et al. 2013). Maternal supplementation with formate significantly 
decreased the incidence of NTDs and partially rescued the growth defects in mouse 
embryos lacking Mthfd1l (Momb et al. 2013).  
 
In humans MTHFD1L variants have been shown to be associated with risk of NTDs in 
an Irish cohort (Parle-McDermott et al. 2009). In our previous study, two separate 
regions (referred to as regions “a” and “b”) of the gene exhibited significant association 
signals suggesting the presence of two independent disease-causing variants (Chapter 1, 
Section 1.1.7, Figure 1.6). The “a” region at the 5′ end of the gene has already been 
investigated and a common deletion/insertion polymorphism (DIP) rs3832406 was 
proposed as a functional variant through affecting the alternative splicing of MTHFD1L 
(Parle-McDermott et al. 2009).  
 
In this chapter, we have focused on the “b” region that overlaps the 3′UTR of 
MTHFD1L (Figure 4.2) and have investigated SNP variants of this region that could 
alter microRNA regulation. MicroRNAs (miRNAs) are important regulators of gene 
expression levels, involving binding of the miRNAs (predominantly) to target sites in 
the 3′UTR of targeted genes (Bartel 2004). MTHFD1L, along with another folate-
related gene MTHFD2, has been previously identified as direct targets of miR-9 in 
MCF-7 breast cancer cells (Selcuklu et al. 2012).  Using miRNA binding prediction 
tools, in addition to the previously confirmed miR-9 binding (Selcuklu et al. 2012), we 
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found that miR-197 also has a predicted binding site on MTHFD1L 3′UTR, which 
overlaps with the miR-9 binding site and the NTD associated SNP rs7646 (Figure 
4.3a). In this chapter, we have further examined the binding efficacy of miR-9 and 
miR-197 to MTHFD1L 3′UTR and the effects on MTHFD1L expression levels in 
different genotypic backgrounds (SNP rs7646 A/G alleles). In addition, other folate 
related genes have been investigated as possible targets of miR-9 and miR-197. 
 
The majority of the data in this chapter has been submitted for publication to Human 
Mutation and is currently under review: 
Minguzzi S, Selcuklu SD, Spillane C, Parle-McDermott A: An NTD-associated 
polymorphism in the 3′ UTR of MTHFD1L can affect disease risk by altering miRNA 
binding.  
 
4.2  Materials and methods 
 
4.2.1 Constructs and LightSwitch Luciferase Assay  
 
The original full-length 3′UTR reporter construct for MTHFD1L (obtained from 
Switchgear Genomics) contained the A allele, designated as UTR-A. Four nucleotides 
were mutated in the seed position of the related miRNA within the MTHFD1L 3′UTR 
luciferase vector in order to generate a negative control (Figure 4.3b). Mutations were 
generated by using QuikChange II Site-Directed Mutagenesis Kit (Agilent Technology) 
following manufacturer’s protocol.  These negative controls are necessary to 
demonstrate that the miRNA knocks-out the gene reporter specifically binding the 
predicted sequence in the 3′UTR. In the same way, the A nucleotide in SNP7646 
position of MTHFD1L 3′UTR (UTR_snpG) was replaced with a G nucleotide. These 
constructs were designated as UTRmut9, UTRmut197 and UTR-G, respectively 
(Figure 4.3b). All the mutated constructs were generated by Duygu Selcuklu in the 
Charles Spillane’s laboratory in the National University of Ireland, Galway. 
 
HEK293 and MCF7 cells were cultured for one week (two passages) in complete 
DMEM 1640 in 75cm
3
 flasks as per Chapter 2, Section 2.2.1.1. In each well of a 24-
well plate 2 x 10
5
 cells were seeded in 500 µl of complete DMEM 1640 and they were 
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grown for 24 hours until they reached a confluency of about 80%. Cells were 
transiently transfected following pLightSwitch system protocol. Each 3′UTR or 
mutated construct (100 ng) was co-transfected with 50 nM  of Pre-miR
TM
 miRNA 
precursor (pre-9, pre-197, pre-control) or 50 nM of miRNA inhibitor oligos (anti-9, 
anti-197, anti-control) (Ambion) in 24-well plates. Pre-miR
TM
 miRNA Precursor 
Molecules are small, chemically modified double-stranded RNA molecules designed to 
mimic endogenous mature miRNAs. The negative control was composed of random 
sequence Pre-miR
TM
 molecules validated to not produce identifiable effects on known 
mRNAs.   
 
After 48 hours, transfection media was removed and 100 µl of incomplete DMEM were 
added to each well. In each well, 100 µl of LightSwitch Assay Solution containing lysis 
buffer and luciferase substrate were added. After shaking, the plate was incubated 
wrapped with tin foil at R.T. for 30 minutes. Samples were aliquoted in a 96-well plate 
to make four technical replications of 50 µl each and luminescence was read for 2 
seconds in luminometer plate reader (Glomax, Turner Biosystem). Log 2 ratios of 
targeting/non-targeting miRNA (pre-miR/pre-control or anti-miR/anti-control) 
luciferase activity for each construct were plotted. Log2 and standard deviation (SD) 
were calculated for all the normalised values using Microsoft Excel
®
. Correlations 
between relative Luciferase activities were compared using one-way ANOVA, with 
results considered significant if a two-tailed p-value was < 0.05. 
 
4.2.2 Cell transfection and RT-qPCR assay 
 
All the transfection experiments were performed as per Chapter 2, Section 2.2.1.4. RT-
qPCR assays are described in Chapter 2 Section 2.2.10 and primers and probes are 
showed in Table 2.2. In Chapter 4, Section 4.3.6, five different endogenous control 
genes (GAPDH, GUS, ACTB, RPS13 and TBT) were investigated to identify the 
control gene least affected by experimental conditions and most suitable for real-time 
PCR normalisation in cDNA samples of interest. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) endogenous control gene displayed the least amount of 
variation and was chosen as reference gene.    
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4.2.3 Thermodynamic Model for the miRNA-Target Interaction 
 
TargetScan 6.2 (http://www.targetscan.org) and MiRanda (http://www.microrna.org) 
were used to identify the miRNAs predicted to bind MTHFD1L 3′UTR region 
containing SNP rs7646. These binding prediction tools were also used to identify other 
possible miR-9 and miR-197 targets among folate related genes. The binding affinity of 
miR-197 and miR-9 for “A” and “G” alleles of SNP rs7646 was investigated using a 
parameter-free thermodynamic model (Mathews, Sabina et al. 1999; Wuchty, Fontana 
et al. 1999). ETarget is the energy of dissociated mRNA target region having no 
interaction with mRNA, EIntermediate represents the energy necessary to make the target 
region accessible for microRNA binding and EComplex is the energy of the final 
microRNA-target complex which is paired according to constraints imposed by the 
seed sequence. All ensemble free energies were computed with RNAfold or 
RNAcofold (Vienna RNA Package) using partition function folding and default 
settings. To determine EIntermediate free energy, binding parameters were modified in a 
way to leave the target nucleotides (and one additional nucleotide upstream and 
downstream) unpaired (Kertesz et al. 2007, Zhang et al. 2011).  
 
The target size used for computational analysis had a length of 80 nucleotides 
consisting of the seed sequences and flanking regions. The analysis was repeated 
increasing the target size up to 160 nucleotides and results did not change. The 
activation and binding energies were calculated to estimate the binding affinity. The 
activation energy, ΔE(a), is the difference between EIntermediate and ETarget, while the 
binding energy, ΔE(b), is the difference between EComplex and ETarget (Kertesz et al. 
2007, Zhang et al. 2011). 
 
4.3 Results 
 
4.3.1 SNP rs7646 (A/G) overlaps miR-9 and miR-197 predicted binding sites in 
the MTHFD1L 3′UTR   
 
MTHFD1L 3′UTR SNP rs7646 (A/G) has been previously identified as the only 
polymorphism (amongst those that were tested in the 3′UTR region) significantly 
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associated with Neural Tube Defects (NTD) in an Irish cohort (Parle-McDermott et al. 
2009). SNP rs7646 is a common variant with a frequency of approximately 69% for the 
A allele and 31% for the G allele in a Caucasian population (HapMap Genome Browser 
release #28). Mother control logistic regression showed an association between the G 
allele and NTD risk (OR = 1.5 [1.09-2.06], p=0.0127) (Parle-McDermott et al. 2009). 
Here, using the miRNA target prediction tools, MiRanda and TargetScan, miR-9 and 
miR-197 were predicted to bind to the MTHFD1L 3′UTR, in the region that also 
contains SNP rs7646 (Figure 4.3a). miR-9 is the only miRNA predicted by TargetScan 
to target a ‘conserved site for miRNA families broadly conserved among vertebrates’ 
within the MTHFD1L 3′UTR. Although it is identified as a ‘poorly conserved site for 
miRNA families conserved among mammals or vertebrates’, miR- 197 is also predicted 
to target MTHFD1L 3′UTR (TargetScan 6.2) at the bases 121-127 (7mer-1A). The 
SNP (rs7646) is located adjacent to the 5′ end of the miR-197 seed sequence and 5′ end 
of the miR-9 binding site (Figure 4.3a). 
 
4.3.2 Minimum Free Energy (MFE) of miR-9 and miR-197 binding to 
MTHFD1L 3′UTR differs between allelic variants of SNP rs7646 (A/G) 
 
To analyse the binding affinity of miR-9 and miR-197 to MTHFD1L 3′ UTR with 
different genotypes (A or G alleles of SNP rs7646), we generated a parameter-free 
thermodynamic model (Mathews et al. 1999, Wuchty et al. 1999). Secondary structure-
based free energies of molecules were calculated for each stage of the binding process: 
ETarget represents the energy of dissociated mRNA target region, EIntermediate is the energy 
necessary to make the target region accessible for miRNA binding and EComplex is the 
energy of miRNA-target complex. The activation energy, ΔE(a), is represented by the 
difference between EIntermediate and ETarget, while the binding energy, ΔE(b), is the 
difference between EComplex and ETarget (Kertesz, et al. 2007; Zhang et al. 2011). The 
miR-9 binding diagram displayed mild differences between SNP rs7646 genotypes, 
whereby both ΔE (a) and ΔE (b) of the A allele were slightly lower compared to G 
allele free energies (Figure 4.4a, Table 4.1). In the final microRNA-target complex, 
SNP rs7646 resides in a loop region, not part of the complementary region (Figure 4.4a, 
Table 4.1). This prediction suggests that the A allele is unlikely to have a major effect 
on the miRNA binding. However, the predicted structure highlights that miR- 197 
gains an extra match in the presence of G allele (changing from 7mer-1A to 8mer 
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match) decreasing the binding energy, ΔE (b) from -8.05 kcal/mol (A allele) to -10.79 
kcal/mol (G allele) (Figure 4.4b, Table 4.1). This analysis thereby suggests that the G 
allele generates a stronger binding of miR-197 on the MTHFD1L 3′UTR compared to 
the A allele. 
 
4.3.3 Allelic variants show no significant difference in the miR-9 directed 
suppression of MTHFD1L  
 
Previously, it has been demonstrated that miR-9 decreased the expression levels of 
MTHFD1L at both mRNA and protein levels in MCF-7 cells (Selcuklu et al. 2012). 
Ablation of the miR-9 seed region confirmed the direct binding of miR-9 to the 
MTHFD1L 3′UTR (Selcuklu et al. 2012). In this study, we have confirmed the direct 
targeting and suppression of MTHFD1L by miR-9 in both MCF-7 and HEK293 cell 
lines (Figure 4.5ab). To test whether the variants of the SNP rs7646 (A/G) affect miR-9 
regulation of MTHFD1L levels, we generated MTHFD1L 3′UTR reporter constructs 
containing each of the variants (A/G) or mutated miR-9 seed region (Figure 4.3b). 
These constructs are designated as UTR-A, UTR-G and UTRmut9, respectively. All 
three constructs were analysed for luciferase activity levels in MCF-7 (Figure 4.5a) and 
HEK293 (Figure 4.5b) cells with overexpression of miR-9 (pre-9) or a control miRNA 
(pre-ctr) that does not target any known mRNA. The luciferase analysis demonstrated 
that the expression of 3′ UTR constructs (UTR-A and UTR-G) were suppressed by 
miR-9, whilst mutation of the miR-9 seed region (UTRmut9) recovered the luciferase 
levels (Figure 4.5ab), indicating direct binding of miR-9 to this predicted site in the 
MTHFD1L 3′UTR. Comparison of the MTHFD1L 3′UTR construct that contains the A 
allele (UTR-A) with the construct with the G allele (UTR-G) suggested that although 
both could be suppressed by miR-9, there was no significant difference in the luciferase 
expression levels (Figure 4.5ab). This indicates that miR-9 binding affinity to 
MTHFD1L 3′UTR is not directly affected by the polymorphism (SNP rs7646) in a 
manner that affects MTHFD1L expression levels. 
 
4.3.4 MiR-197 directly targets the MTHFD1L 3′UTR with enhanced suppression 
observed for the G allele   
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To test whether miR-197 directly binds to the putative site on MTHFD1L 3′UTR and 
whether the presence of either of the allelic variants of the SNP rs7646 (A/G) affects 
binding efficacy; luciferase assays were performed in both MCF-7 and HEK293 cells 
using the MTHFD1L 3′UTR reporter constructs for either of the SNP variants (UTR-A 
and UTR-G) and also the construct with mutated miR-197 binding site (UTRmut197) 
(Figure 4.3b). Luciferase activity was suppressed in the wild type construct (UTR-A). 
However, ablation of the seed region (UTRmut197) recovered the luciferase activity, 
indicating that miR-197 directly binds to this predicted region in MTHFD1L 3′UTR in 
a manner that downregulates expression (Figure 4.5cd). In addition, presence of the G 
allele (UTR-G) displayed a greater level of suppression of the luciferase activity 
compared to UTR-A, indicating that miR-197 has stronger miRNA:target binding 
efficacy and therefore stronger suppression effects on the MTHFD1L 3′UTR variant 
containing the G allele (Figure 4.5cd).  
 
To determine the effect of miR-197 on the expression levels of endogenous 
MTHFD1L, miR-197 was overexpressed in MCF-7 and HEK293 cell lines. RT-qPCR 
analysis showed that, in both cell lines, miR-197 downregulated the expression levels 
of MTHFD1L (Figure 4.5cd), confirming the downregulation effect observed in the 
luciferase reporter construct assays. In addition, Western blot analysis demonstrated 
that miR-197 expression downregulated MTHFD1L at the protein level (Figure 4.5cd). 
Taken together, these results confirm that miR-197 directly regulates MTHFD1L gene 
expression levels at the mRNA and protein levels and that SNP rs7646 has a functional 
impact on miR-197 binding efficacy. 
 
4.3.5  miR-9 and miR-197 display antagonistic target suppression 
 
To understand the relative efficiencies of miR-9 or miR-197 in the regulation of 
MTHFD1L, the endogenous expression of miR-9, miR-197 and MTHFD1L were 
measured in MCF-7 and HEK293 cells. The HEK293 cells displayed a higher 
expression level of miR-9 and miR-197 compared to MCF-7 cells (Figure 4.6). In 
contrast, MTHFD1L expression was higher in MCF-7 cells compared to HEK293 cells, 
negatively correlating with miR-9 and miR-197 expression as expected. The 
endogenous expression levels of miR-197 is several orders of magnitude greater than 
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miR-9 in both cell lines (Figure 4.7). miR-9 and miR-197 binding sites partially overlap 
in the MTHFD1L 3′UTR (Figure 4.3a).  
 
To investigate the possibility that endogenous miR-9 and miR-197 may affect each 
other’s binding and consequently the target expression, we performed further luciferase 
assays in MCF-7 and HEK293 cells with exogenously added miRNA (pre-9 or pre-
197) in the presence or absence of miRNA inhibitors to deplete endogenous miR-9 or 
miR-197. Both cell lines displayed a further pre-9 mediated decrease in luciferase 
activity when endogenous miR-197 was depleted by anti-197 for either MTHFD1L 3′ 
UTR allele (Figure 4.8). A similar experiment was performed with miR-197 
overexpression (pre-197) in the presence and absence of anti-9 and showed no 
statistically significant difference for the A allele in either cell line (Figure 4.9ab). On 
the other hand, the 3′ UTR construct with the G allele showed an opposite effect in 
miR-9 depleted cells (anti-9); a slightly increased luciferase activity (p-value =0.003) in 
MCF-7 (Figure 4.9c) and a decreased luciferase activity in HEK293 cells (Figure 4.9d).  
 
4.3.6 miR-9 and miR-197 may target other folate genes  
 
Computational analysis was carried out using miRANDA and TargetScan, to predict 
other possible folate genes regulated by these miRNAs. As a result, miR-9 was 
predicted by both tools to bind DHFR, SHMT1, methionine synthase (MTR) and 
DHFR1L genes (Chapter 1, Section 1.1.4). The first three genes encode cytoplasmic 
proteins while the latter encodes a mitochondrial protein. miR-9 binding sequence in 
DHFR and DHFRL1 is conserved among primates, whereas miR-9 binding sequence in 
SHMT1 is conserved in primates, rabbits, armadillos and opossums. miR-9 binding 
sequence in MTR is highly conserved among vertebrates. On the other hand, miR-197 
analysis showed that, along with MTHFD1L, TYMS is another possible target gene. 
miR-197 binding sequence in TYMS 3′UTR is conserved among humans, macaques and 
armadillos. Transient transfection experiments in HEK293 and MCF-7 cell lines were 
performed to verify in silico predictions.  Transfection with miR-9 in HEK293 cells 
showed that all the predicted genes are significantly downregulated (Figure 4.10a) 
while in MCF-7 only MTR showed a significant downregulation (Figure 4.10b). 
Instead, miR-197 transfection inhibited TYMS expression in both the cell lines (Figure 
4.11ab). 
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4.4 Discussion 
  
Polymorphisms in miRNA target binding sites can affect the binding efficacy of 
miRNAs. Consequently, altered miRNA binding to the target can potentially alter the 
expression levels of the target gene, and can contribute to risk factors for the 
development of certain diseases. Indeed, the association of genetic polymorphisms that 
alter miRNA binding with disease risk has been reported in a number of studies (Haas 
et al. 2012, Mishra et al. 2007, Song et al. 2009, Nicoloso et al. 2010, Zhang et al. 
2011). The patho-mechanistic role of miRNAs is increasingly acknowledged (Haas et 
al. 2012). It has also been shown that SNPs are less frequent in miRNAs or their target 
sites than in other regions of the genome, suggesting some level of purifying selection 
against mutations in miRNA:target gene binding systems (Chen and Rajewsky 2006, 
Saunders et al. 2007; Yu et al. 2007). This negative selection of sequence variations 
emphasises the crucial role of miRNA regulation in pivotal cellular processes.  
 
miR-9 has been reported as an important regulator in neural development (Yuva-
Aydemir et al. 2011). In vertebrates, miR-9 modulates the proliferation, migration and 
differentiation of neural progenitor cells by targeting diverse mRNAs (Yuva-Aydemir 
et al. 2011). Moreover, some evidence suggests that miR-9 expression in post-mitotic 
neurons plays a role in neurodegenerative diseases (Yuva-Aydemir et al. 2011). Altered 
miR-9 levels have been found in postmortem Alzheimer disease hippocampus and 
hippocampal cultures (Lukiw 2007, Schonrock et al. 2012). Although most current 
evidence indicates tumour suppressor activity of miR-9 (Laios et al. 2008, Lujambio et 
al. 2008) conflicting findings exist (Khew-Goodall and Goodall 2010) and the role of 
this miRNA in cancer biology is not well understood. Thus, the importance of miR-9 in 
development and disease is emerging through its ability to regulate different targets in a 
manner that can be dependent on the cellular context and the developmental stage.  
 
In this NTD focused miRNA study, we identified a novel direct interaction between the 
MTHFD1L 3′ UTR and miR-197 in MCF-7 and HEK293 cell lines. This is the second 
miRNA to be identified as a regulator of MTHFD1L, along with miR-9 (Selcuklu et al. 
2012). Our results demonstrate that both miRNAs specifically downregulate 
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MTHFD1L at mRNA and protein levels in both cell lines. Using computational 
modelling, we predicted secondary structures of miR-197 and miR-9 binding to the 3′ 
UTR containing either an A or G allele of SNP rs7646. We found that the G allele 
significantly favours miR-197 binding, providing an extra match just beside the seed 
sequence and contributing to the pairing stability. On the other hand, SNP rs7646 
locates within an unmatched loop of the predicted secondary structure and, according to 
free energy diagrams (in silico); it should not affect miR-9 binding. These findings 
were verified in vitro using the luciferase reporter assays. Our results demonstrate that 
SNPrs7646 significantly changed miR-197 binding affinity, causing stronger 
suppression when bound to the G allele of MTHFD1L mRNA compared to the A allele, 
while it did not generate any significant variation for miR-9 binding affinity. miR-9 and 
miR-197 binding sites partially overlap in the MTHFD1L 3′UTR.  
 
We consider that the two miRNAs are unlikely to simultaneously bind to the 3′UTR 
due to secondary structure constraints. According to this hypothesis, depleting miR-197 
from the cells should leave more MTHFD1L mRNAs available for miR-9 and vice-
versa. We tested the effects of altered expression levels of miR-9 and miR-197 using 
miRNA precursors (premiR) and inhibitors (anti-miR). miR-9 overexpression (pre-9) 
led to more downregulation of the target expression when miR-197 was depleted (anti-
197) in all the conditions tested (Figure 4.8), while miR-197 overexpression (pre-197) 
in combination with miR-9 depletion (anti-9) led to differential outcomes depending on 
the genotype and the cell line (Figure 4.9). Overall, these data indicate that there is 
competition between miR-9 and miR-197 for MTHFD1L 3′ UTR binding. However, 
the differential regulatory effect observed depends on which endogenous miRNA is 
downregulated, whereby cell type and genotype could affect miRNA binding efficiency 
and endogenous miRNA abundance. The miR-9 binding site within the 3′ UTR of 
MTHFD1L is a more highly conserved site than the miR-197 site. It is possible that, 
although miR-197 is much more abundant in both cell lines compared to miR-9 (Figure 
4.7), miR-9 may preferentially bind to the 3′UTR of MTHFD1L even in the presence of 
excess miR-197. In other words, miR-9 is a more specific, efficient regulator of 
MTHFD1L and miR-197 can be outcompeted by miR-9 regardless of abundance. miR-
197 may increase its binding efficiency in the presence of G allele of the rs7647 SNP as 
we already showed that this allele appears to increase miR197 binding efficacy (Figure 
4.5cd). This can explain the differences we observe based on cell type and MTHFD1L 
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genotype. MCF-7 cells express endogenous miR-9 at a 3-fold lower level than HEK293 
cells (Figure 4.6). The increase in MTHFD1L expression in the presence of anti-9 in 
MCF-7 cells (Figure 4.9ac) indicates that the endogenous miR-9 is inhibited and 
exogenous miR-197 cannot compensate for this. In HEK293 cells endogenous miR-9 is 
expressed at a higher level. The A allele shows no change in the presence of anti-9 
(Figure 4.9b), suggesting that exogenous miR-197 cannot successfully compete with 
any residual endogenous miR-9 that has escaped anti-9 inhibition. Further 
downregulation is observed for the G allele in the presence of anti-9 (Figure 4.9d), as it 
provides a better binding site for miR-197 and can successfully compete with any 
residual endogenous miR-9. We also cannot rule out that there are differences in the 
mechanism of action of cellular miRNAs compared to precursor mimic miRNAs, as a 
previous study suggested (Haas et al. 2012). Our results can suggest that pre-9 and pre-
197 directed downregulation of MTHFD1L is affected by the competitive binding 
behaviour of both miRNAs. Therefore, the overall impact of miRNA regulation of 
MTHFD1L must be considered in the context of both of these MTHFD1L targeting 
miRNAs.  
 
Previously, it has been demonstrated that another folate related gene, MTHFD2, is 
downregulated by miR-9 (Selcuklu et al. 2012). Like MTHFD1L, MTHFD2 localizes 
to mitochondria and the two enzymes together contribute to the synthesis of formate 
that is the main source of 1C-units in the folate pathway. Moreover, our data suggested 
that miR-9 may target other folate genes including DHFR, DHFRL1, SHMT1 and 
MTR. Transfection with miR-9 in HEK293 cells showed these four genes are 
significantly downregulated (Figure 4.10a) while in MCF-7 only MTR showed a 
significant downregulation (Figure 4.10b).  The differences between cell types may be 
related to the breast cancer phenotype of MCF-7 versus the embryonic kidney cell 
phenotype of HEK293 cells. Though these data require further validation, they provide 
a hint of a possible broader regulative role of miR-9 for folate genes. This possible role 
of miR-9 along with its involvement in neurogenesis further highlights that this miRNA 
warrants further investigation in relation to NTD and other neuro-developmental 
diseases. Although our results suggest that the NTD associated SNP rs7646 does not 
influence the miR-9 mediated regulation of MTHFD1L, our data have relevance for 
how miR-9 and miR-197 compete.  
 
77 
 
In the context of functional effects in neurological tissues, miR-197 is commonly 
upregulated in Alzheimer Disease, brain parenchyma and cerebrospinal fluid (Maes et 
al. 2009). In this study, we have identified and validated MTHFD1L as a direct miR-
197 target and demonstrated that the maternal NTD-associated SNP rs7646 affects the 
miR-197 binding efficacy. The G allele, associated with an increased risk, provides 
more efficient binding that alters the expression level of MTHFD1L. Recent reports 
indicate that mthfd1l knockout mice develop NTD with 100% penetrance (Momb et al. 
2013). Thus, the impact of SNP rs7646 on the binding of miR-197 to the 3′ UTR of 
MTHFD1L provides a mechanistic explanation of the previous association of this SNP 
with NTD risk (Parle-McDermott et al. 2009). Studying the expression pattern of both 
miR-197 and miR-9 during embryogenesis will improve our understanding of the 
miRNA-mediated control of MTHFD1L and its relevance to NTD risk. Apart from 
NTD risk, it is also worth noting the relevance of miR-197 in cancer. miR-197 has been 
reported to be upregulated in human male breast cancer (Lehmann et al. 2010), lung 
cancer (Yanaihara et al. 2006, Zheng et al. 2011), and cervical carcinoma (Pereira et al. 
2010) and it has been shown to modulate the expression of the tumour suppressor gene 
FUS1 whose expression is lost in a large proportion of lung tumours (Du et al. 2009). 
We previously have showed that an increase in MTHFD1L enzyme levels through a 
separate associated genetic variant (DIP polymorphism) increases the case risk of NTD 
(Parle-McDermott et al. 2009). The DIP polymorphism within intron 7 of MTHFD1L 
impacts on alternative splicing (Parle-McDermott et al. 2009) while SNP rs7646 within 
the 3′ UTR appears to influence miRNA binding. Both studies highlight that it is the 
level of MTHFD1L enzyme that is relevant for disease as both an increase (Parle-
McDermott et al. 2009) or a decrease in MTHFD1L (this study) can be associated with 
increasing NTD case and maternal risk respectively. This suggests that maintaining 
MTHFD1L levels within an expression level “window” during development may be a 
critical factor for reducing NTD risk.  
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Figure 4.1 miRNA biogenesis and mechanisms of action (modified from Inui et al. 
2010). 
pri-miRNAs are transcribed in the nucleus and processed by the microprocessor 
complex by the RNase III type endonuclease Drosha and its partner, DGCR8. It 
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produces a 70-nucleotide stem loop called pre-miRNA, which is exported to the 
cytoplasm by exportine 5. Once in the cytoplasm, the pre-miRNAs are cleaved by 
Dicer and TRBP, generating a 20-nucleotide mature miRNA duplex. At this stage, one 
strand of miRNA is usually degraded and the other strand is loaded into the RISC 
which contains Ago proteins. The RISC is guided by the single-stranded miRNA to its 
final target mRNAs partially complementing its sequence. The RISC can repress the 
target mRNA through two main mechanisms. It can remove polyA tail by promoting 
the activity of deadenylases (such as CCR4-NOT), causing mRNA degradation in P-
bodies. Alternatively it can block the translation at the initiation step or at the 
elongation step by causing, e.g., the ribosome stalling or the repression of initiation 
factor 4E (EIF4E).  
pri-miRNAs, primary transcripts; DGCR8, DiGeorge syndrome critical region 8; pre-
miRNA, precursor miRNA; TRBP, TAR RNA-binding protein, RISC, RNA-induced 
silencing complex, Ago, Argonaute; P-bodies, Processing bodies; EIF4E, repression of 
initiation factor 4E. 
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Figure 4.2 Linkage disequilibrium (LD) map of one associated region of the 
MTHFD1L Gene (marked region ‘‘b’’ in Chapter 1, Figure 1.6). 
LD plot of pairwise values of D’ for the 26 markers within the region comprised 
between intron 26 and MTHFD1L 3′end. Boxed markers were associated with NTD 
risk. SNP rs7646 is within the 3′UTR of MTHFD1L. 
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Figure 4.3 Schematic depiction of MTHFD1L 3′UTR and miR-9 / miR-197 binding 
regions (figure drawn with Microsoft PowerPoint). 
(a) MTHFD1L 3′UTR schematic representation according to NCBI Reference 
Sequence NM_001242767. Numbering starts from the first nucleotide of the 3′UTR, 
thus, SNPrs7646 is present in position 120. Seed sequences of miR-197 and miR-9 are 
in position 121-127 and 133-139, respectively. (b) Schematic depiction of the 
constructs used for luciferase analysis. Sequences underneath show nucleotides that 
were mutated to generate SNPrs7646 G allele 3′UTR (UTR-G) and negative controls 
for miR-9 (UTRmut9) and miR-197 (UTRmut197). 
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Figure 4.4 Thermodynamic model of miR-9 and miR-197 binding to MTHFD1L 
3′UTR and the influence of SNPrs7646 (figure drawn with Microsoft PowerPoint). 
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Secondary structure prediction of (a) miR-9 and (b) miR-197, binding to MTHFD1L 
3′UTR harbouring A or G allele and the relative free energy diagrams are shown. 
Secondary structure-based free energies at different stages of the binding process 
represented by ETarget; the energy of dissociated mRNA target region, EIntermediate; the 
energy necessary to make the target region accessible for miRNA binding, and EComplex; 
the energy of miRNA-target complex. The activation energy, ΔE (a), is given by the 
difference between EIntermediate and ETarget, and the binding energy, ΔE (b), is the 
difference between EComplex and ETarget. 
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Figure 4.5 MiR-9 and miR-197 targeting effects on MTHFD1LwithSNPrs7646 
variants (A or G allele). 
85 
 
Data are presented as luciferase assays, RT-qPCR and Western blot for miR-9 in (a) 
MCF-7 and (b) HEK293cells and for miR-197 in (c) MCF-7 and (d) HEK293 cells. 
Luciferase analysis compared MTHFD1L 3′UTR A allele (UTR-A), G allele (UTR-G) 
and the mutant controls (UTRmut9 or UTRmut197). Data are represented as Log2 ratio 
of targeting to non-targeting miRNA luciferase activity (pre-miR to pre-ctr ratio). RT-
qPCR analysis of MTHFD1L is represented as relative expression in pre-9, pre-197 and 
pre-ctr transfected cells. All data were analysed by the E (Efficiency)-Method using 
GUS as an endogenous control for normalization. Statistical significance was 
calculated using Student’s t-test (*p<0.05, **p<0.001). The Western blot shows 
MTHFD1L protein in pre-9, pre-197 and pre-ctr transfected cells. Numbers represent 
relative band intensities measured by densitometry analysis normalized using PDH E1α 
as an endogenous control for mitochondrial proteins.  
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Figure 4.6 Endogenous levels of miR-9, miR197 and MTHFD1L in HEK293 and 
MCF-7 cells. 
RT-qPCR analysis of endogenous (a) miR-9, (b) miR197 and, (c) MTHFD1L in 
HEK293 and MCF-7 cells are shown. RNU6B was used to normalize miRNAs 
expression and GUS was used to normalize MTHFD1L expression.  MCF-7 values 
were used as the calibrator. 
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Figure 4.7 Endogenous levels of miR-9 compared to miR-197 in HEK293 and 
MCF-7 cells. 
RT-qPCR analysis of endogenous miR-9, miR-197 in HEK293 (a) and MCF-7 (b) cells 
are shown. RNU6B was used to normalize miRNAs expression and miR-9 is the 
calibrator. 
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Figure 4.8 Effects of miR-9 overexpression and miR-197 knockdown on 
MTHFD1L 3′ UTR with SNPrs7646 variants (A or G allele). 
The data show luciferase analysis of (a) UTR-A in MCF-7, (b) UTR-A in HEK293 
cells, (c) UTR-G in MCF-7 and (d) UTR-G in HEK293 cells with miR-9 
overexpression (pre-9) and endogenous miR-197 or miR-197 knockdown (anti-197).  
Data are represented as Log2 ratio of targeting to non-targeting miRNA luciferase 
activity. Statistical significance was calculated using Student’s t-test (*p<0.05, 
**p<0.001). 
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Figure 4.9 Effects of miR-197 overexpression and miR-9 knockdown on 
MTHFD1L 3′ UTR withSNPrs7646 variants (A or G allele). 
Data show luciferase analysis of (a) UTR-A in MCF-7, (b) UTR-A in HEK293 cells, 
(c) UTR-G in MCF-7 and (d) UTR-G in HEK293 cells with miR-197 overexpression 
(pre-197) and endogenous miR-9 or miR-9 knockdown (anti-9). Data are represented as 
Log2 ratio of targeting to non-targeting miRNA luciferase activity. Statistical 
significance was calculated using Student’s t-test (*p<0.05, **p<0.001). 
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Figure 4.10 Gene expression after transfection with miR-9 precursor. 
RT-qPCR analysis of DHFRL1, DHFR, SHMT1 and MTR in HEK293 (a) and MCF-7 
(b) cells. Data are represented as relative expression in pre-9, pre-197 and pre-ctr 
(CTR) transfected cells. All data were analysed by the E (Efficiency)-Method using 
GAPDH as an endogenous control for normalization. Statistical significance was 
calculated using Student’s t-test (*p<0.05, **p<0.001). 
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Figure 4.11 Gene expression after transfection with miR-197 precursor. 
RT-qPCR analysis of TYMS in HEK293 (a) and MCF-7 (b) cells. Data are represented 
as relative expression in pre-9, pre-197 and pre-ctr (CTR) transfected cells. All data 
were analysed by the E (Efficiency)-Method using GAPDH as an endogenous control 
for normalization. Statistical significance was calculated using Student’s t-test 
(*p<0.05, **p<0.001). 
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Table 4.1 Free Energies of miR-9 and miR-197 binding to MTHFD1L 3′UTR with 
SNP rs7646 alleles (A/G). 
 
 
       miR-9     miR-197 
Genotype
* A G A G 
F
re
e 
E
n
er
g
ie
s 
(k
ca
l/
m
o
l)
 
Target
1 -15.58 -15.74 -15.58 -15.74 
Intermediate
2 -7.25 -6.86 -6.05 -6.05 
Complex
3 -25.26 -25.14 -23.63 -26.53 
∆E(a)4 8.33 8.88 9.53 9.69 
∆E(b)5 -9.68 -9.4 -8.05 -10.79 
 
* 
SNP rs7646 alleles (A/G) in the target MTHFD1L 3′UTR 
1
Energy of dissociated mRNA target region. 
2
Energy necessary to make the target region accessible for miRNA binding  
3 
Energy of miRNA-target complex. 
4
 Activation energy is the difference between EIntermediate and ETarget,  
5 
Binding energy is the difference between EComplex and ETarget 
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CHAPTER 5 
 
Investigation of novel 
MTHFD-like sequences 
across the human genome 
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5.1 Introduction  
 
The comparison of genomic sequences within a species or between different species is 
an important genetic tool, useful for the identification of protein-coding genes, 
structural motifs, and regulatory elements such as components of promoters and 
enhancers (Margulies and Birney 2008). Throughout evolution transposable elements 
have shuffled eukaryotic genomes generating a multitude of new sequences including 
new genes and pseudogenes (Xing et al. 2006). Genome studies have revealed that 
approximately 50% of the human genome and >70% of genomes of some grass species 
like maize, consist of transposable element sequences (Wessler 2006). 
 
Pseudogenes are classified as genomic sequences resulting from either 
retrotransposition or genomic duplication of functional genes. Processed pseudogenes 
arose from the former event, while non-processed pseudogene derived from the latter 
and often retain the exon-intron structures of their parental genes (Zhang et al. 2003). 
During their evolutionary history, pseudogenes generally accumulate mutations which 
cause premature stop codons or frameshifts and consequent loss of functionality. 
Previous studies have located and annotated human pseudogenes, counting around 
20,000 sequences out of which about 8,000 show evidence of processing (Torrents et 
al. 2003). Different studies have also revealed that in mammals most of the genome, 
including numerous pseudogenes, is transcribed in both sense and antisense direction 
(Katayama et al. 2005, Carninci et al. 2005). But less than 2% of the total genome is 
transcribed into protein-coding RNA, because the large majority of transcripts are 
noncoding RNAs (ncRNAs) (Cheng and Carmicheal 2010). Over the last decade there 
has been a near-exponential growth of publications focused on ncRNAs (Taft et al. 
2010). They have been classified into various categories such as snoRNAs, siRNAs and 
miRNAs (as discussed in Chapter 4). ncRNAs have many different functions playing 
an important role in the regulation of a multitude of cellular processes. Recently, it has 
been demonstrated that expressed pseudogenes and ncRNAs can compete with their 
ancestral protein coding genes for the same pool of miRNAs (Salmena et al. 2011). 
 
The aim of this chapter was to analyze genomic sequences similar to MTHFD1 and 
MTHFD1L to determine if there is evidence for the expression. Expressed sequences 
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were then investigated further to discover possible protein coding homologous or 
regulatory elements such as ncRNAs related to MTHFD1 and MTHFD1L. 
 
5.2  Results 
 
5.2.1 MTHFD1 and MTHFD1L homologous sequence search 
 
Nucleotide BLAST (Human genome database) was used to find sequences similar to 
MTHFD1L and MTHFD1. All the sequences analysis and sequence similarity 
localization was made using mRNA transcript variant 1 of MTHFD1L (accession 
number: NM_001242767) and MTHFD1 mRNA (accession number: NM_005956) 
using default parameters. Evidence of transcription for the reported DNA sequences 
was sought in Ref seq and the EST database (Chapter 2, Sections 2.2.14.9-10) using 
default parameters. 
 
5.2.2 CHR 11 homologue sequence 
 
A sequence on Chromosome 11 (Chr11seq) (location: 11p15.1, 18892534..18895009) 
is a processed pseudogene which shows about 88% similarity with a region of 
MTHFD1L spanning between exon 21 and 3′UTR (Figure 5.1). This sequence shares 
1291 bases with MTHFD1L (position 2144-3434) out of which 939 bases come from 
the coding region. ORF FINDER analysis did not show any clear ORF due to stop 
codon mutations along the sequence. These findings suggest that no functional protein 
is encoded from Chr11seq. Since the Chr11seq sequence spans the MTHFD1L 3′UTR 
we investigated a possible expression of a ncRNA. EST and Refseq database analyses 
(Chapter 2, Sections 2.2.14.9-10) did not report any expression of this sequence; 
neither did RT-qPCR analysis using placental, HEK293 and lymphoblast RNAs 
(Chapters 2, Sections 2.2.4 and 2.2.6) (data not shown). MTHFD1L and Chr11seq 
sequence alignment along with the position of the primers used for RT-qPCR are 
shown in Appendix Z. 
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5.2.3 CHR2 and CHR9 homologue sequences 
 
5.2.3.1 Sequence analysis 
There are non-processed sequences present on both Chr2 (Chr2seq) (location: 2p11.1, 
861528..871795) and Chr9 (Chr9seq) (location: 9q12, 663889..679324) derived from a 
MTHFD1L region which includes exon 25-26 and a part of flanking introns (Figure 
5.2). Sequence similarity is about 95% with Chr2seq and 94% with Chr9seq, reaching 
for both 97% in the region corresponding to exon 25-26 (sequence alignment is shown 
in Appendix BB). An EST database search showed that two transcribed RNAs were 
reported under NEDO human cDNA sequencing project (Yudate et al. 2001). They are 
reported as ncRNAs because of the lack of a readable ORF. The expressed ncRNAs are 
spliced sequences, one originating from Chr2seq (AK074198) and the other from 
Chr9seq (AK097152). Figure 5.3 shows that both ncRNAs share exon 2, 3 and 4 while 
they have a different exon 1 which derives from an upstream sequence with no 
similarity to MTHFD1L. Exons 2 and 3 exactly match to exon 25 and 26 of MTHFD1L 
whereas exon 4 originates from intron 26 of the gene. 
  
5.2.3.2 RT-PCR assays 
Expression of the ncRNAs was assessed by RT-PCR in human placental, HEK 293 and 
lymphoblast RNA using a variety of different primer sets (Chapter 2, Sections 2.2.4 
and 2.2.6) followed by agarose gel electrophoresis. The positions of primers are shown 
in Appendix BB. The results for the assay that would detect both ncRNAs 
simultaneously, showed a clear expression of the ncRNAs in placental sample and a 
very low expression in the lymphoblast sample, whereas no expression was detected in 
the HEK 293 sample (Figure 5.3b) (for sequencing data see Appendix P). Primers to 
distinguish each ncRNA were examined in placental RNA (Figure 5.3a) and both 
ncRNAChr2 and ncRNAChr9 were detected (Figure 5.3c) (for sequencing data see 
Appendix Q and Appendix R, respectively). ncRNAChr2 and ncRNAChr9 show an 
interesting combination of exons originated from MTHFD1L preceded by an unrelated 
exon. Since the database evidence of ncRNAs expression was corroborated by these 
RT-PCR experiments we decided to investigate them as possible MTHFD1L regulation 
elements.  
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5.2.3.3 ncRNA transfection in HEK 293 cells and the impact on MTHFD1L 
expression levels 
ncRNAChr2 and ncRNAChr9 sequences were obtained in mammalian expression 
vector pME18SFL3 (Appendix A) from the Biological Resource Centre National 
Institute of Technology and Evaluation, Chiba, Japan. HEK 293 cells were transfected 
following the method described in Chapter 2, Section 2.2.1.4. mRNA and proteins were 
extracted at 3 different time points: 24 hours, 48 hours and 72 hours after transfection. 
ncRNAChr2 and ncRNAChr9 expressions were determined to verify transfection 
efficiency (Figures 5.4 and 5.5). No endogenous expression was detected in non-
transfected controls as determined by an RT-PCR assay. 
 
Eleven different endogenous control genes were previously investigated by Kirsty 
O’Brien to identify the control gene least affected by experimental conditions and most 
suitable for real-time PCR normalisation in cDNA samples of interest. Beta-
Glucuronidase (GUS) endogenous control gene displayed the least amount of variation 
and was chosen as reference gene for the ncRNA transfection. Results were calculated 
by applying the comparative CT method (2
- Ct
) to measure the fold change in gene 
expression relative to the reference gene. Transfected samples and negative control 
with only transfection reagent (-CTR) were normalized to non-transfected sample for 
each time point. Differences in relative expression ratios were compared using one-way 
ANOVA, with results considered significant if a two-tailed p-value was < 0.05. 
 
The expression of MTHFD1L long transcript was detected and results are shown in 
Figures 5.6, 5.7 and 5.8. MTHFD1L expression did not show any significant variation 
at any time point after the transfection. The same result was obtained for MTHFD1L 
protein expression detected by Western blot (Figure 5.9). This findings suggest that 
ncRNAChr2 and ncRNAChr9 does not modulate MTHFD1L expression either at 
transcriptional or at post-transcriptional level.  
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5.2.4 CHR X homologue sequence 
 
5.2.4.1 Sequence analysis  
This sequence on Chromosome X (ChrXseq) (location: Xp11.21, 57418826..57421885) 
is a processed pseudogene that shows about 93% similarity with MTHFD1 (Figure 
5.10). The 3005-base similar sequence covers almost the whole MTHFD1 gene, 
including its coding region and 3′UTR. MTHFD1 mRNA and ChrXseq sequence 
alignment along with the position of the primers used for RT-qPCR are shown in 
Appendix AA. Stop codon mutations cut off the original MTHFD1 ORF in several 
parts, the longest of which is 750 bp (black arrows in Figure 5.10). ChrXseq was 
analyzed to see if any polymorphisms may create these stop codons, but none of the 
variants overlap them. There is no evidence of ChrXseq expression in EST and Refseq 
databases.  
 
5.2.4.2 RT-PCR assay 
RT-PCR analysis showed an abundant expression of ChrXseq in placental, HEK 293 
and lymphoblast RNAs. Red arrows in Figure 5.10 show the position of the RT-PCR 
amplicons analyzed (Figure 5.11). Negative controls without enzyme in the RT step 
were performed in order to avoid possible genomic DNA contamination. All cDNA 
products were also tested for genomic contamination by an intron spanning PCR assay 
designed on the MTHFD1 gene (Chapter 2, Section 2.2.7). PCR products obtained were 
sequenced and no discrepancy with ChrXseq database sequence was found. Sequenced 
PCR products are shown in Appendix T, U, V, W, X and Y.  
 
5.2.4.3 ChrX 3′UTR overexpression in HEK293 
To verify if ChrXseq can modulate the expression of its parental gene MTHFD1, part 
of ChrXseq was cloned into the mammalian expression vector pcDNA™3.2/V5-DEST 
(Invitrogen) as explained in Chapter 2, Section 2.2.12. A preliminary test was 
performed using a cloned region from ChrXseq that overlaps MTHFD1 3′UTR (Figure 
5.12). This region was selected because of the possible miRNA regulation involvement. 
pcDNA™3.2-ChrX3′UTR was transiently transfected in a 6-well plate seeded with 
HEK293 cells as described in Chapter 2, Section 2.2.1.4. pcDNA™3.2/V5-DEST 
empty vector was employed as a control and RNA was extracted after 24, 48, and 72 
hours of transfection (Chapter 2.2.4). RT-qPCR for MTHFD1 was performed using 
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GUS as reference gene. Samples transfected with CHR3′UTR showed a lower 
MTHFD1 expression (Figure 5.13). Results were statistically significant for 48 hour (p-
value=0.031) and 72 hour (p-value =0.042) samples.   
   
5.2.4.4 Generation of a protein expression vector with ChrXseq longest ORF 
Stop codon mutations cut off the original MTHFD1 ORF in several parts, the longest of 
which is 750 bp (black arrows in Figure 5.10 and 5.12). This sequence could encode for 
a part of the 10-formyl-THF-synthethase domain of MTHFD1, which may be enough 
to retain enzymatic activity. The 750 ORF sequence was PCR amplified and cloned in 
E.coli protein expression vector Gateway
®
 pDEST™15 (Chapter 2, Section 2.2.12) 
(Figure 5.12). 
 
5.3  Discussion 
 
Sequence analysis was performed to discover homologous coding genes or regulatory 
elements like ncRNAs, related to MTHFD1 and MTHFD1L. The first similar sequence 
that we addressed was CHR11seq. For this sequence we found no evidence of 
expression either from the database or RT-PCR analysis. We therefore concluded that 
Chr11seq is probably an inactive sequence derived by transposition from MTHFD1L.  
 
We next focused on two ncRNAs expressed from Chr2 and Chr9. In this case evidence 
of expression was found from both database and RT-PCR analysis but only a 
significant level of ncRNA was detected and only in the placental samples. A deeper 
investigation did not show any association between ncRNAs expression and 
MTHFD1L regulation. These findings suggest these ncRNAs might be expressed only 
in specific tissues and/or at specific stages of development. Despite sequence similarity, 
their function, if any, appear to be unrelated to MTHFD1L regulation. 
 
ChrXseq was then studied as a pseudogene of MTHFD1. Despite the lack of annotation 
in numerous databases, this sequence was found to be highly expressed in different 
mammalian cell samples. The longest ORF, spans over less than one third of the 
parental gene. Previous reports demonstrated that expressed pseudogenes and ncRNAs 
can compete with their ancestral protein coding genes for the same pool of miRNAs 
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(Salmena et al. 2011). Circular RNA (circRNA), competing endogenous RNAs 
(ceRNAs) and pseudogene decoys share miRNA-response elements (MREs) with many 
mRNAs (Kosik 2013). To test the possibility that ChrX could act as a pseudogene 
decoy, the portion of ChrXseq corresponding to MTHFD1 3′UTR has been cloned into 
a mammalian expression vector and transfected in HEK293 cells. Results showed a 
significant downregulation of MTHFD1 expression after 48 and 72 hours of expression. 
These data suggest that the ncRNA expression could be involved in the regulation of its 
parental gene MTHFD1. Nevertheless, this regulation does not seem to occur in a 
miRNA-regulated fashion. If the ChrX3′UTR sequence had acted like a miRNA decoy 
it would have competed with MTHFD1 for binding the same pool of miRNAs leading 
to an upregulation of the gene. A possible mechanism that could explain the inhibitory 
effect of MTHFD1 is the formation of DNA-RNA triplex. Recent publications are 
reporting considerable evidence for the existence of nucleic triplexes in vivo and their 
potential participation in a variety of biological processes including chromatin 
organization, DNA repair, transcriptional regulation and RNA processing (Buske et al. 
2011). Nonetheless, the hypothesis of DNA-RNA triplex involvement is intriguing but 
remains to be tested. Further investigation, which will require the cloning of the full 
length ChrXseq transcript, may help to understand the role of this pseudogene. A 
protein expression vector containing the longest ORF in ChrXseq has also been 
generated and will be used to verify if the putative protein retain catalytic activity. In 
conclusion, this study provides interesting hints for the development of a possible 
future project.  
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Figure 5.1 Schematic representation of MTHFD1L spliced gene on Chr6.  
Arrows show exons within the coding sequence of the gene. Blue line represents 
corresponding processed pseudogene on Chr11.  
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Figure 5.2 Schematic representation of exon 25-26 flanking region of MTHFD1L 
non-spliced gene on Chr6.  
Blue lines represent corresponding non-processed pseudogenes on Chr2 and Chr9, 
while arrows on blue lines represent spliced ncRNAChr2 and ncRNAChr9 respectively.  
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Figure 5.3 RT-PCR analysis of ncRNAChr2 and ncRNAChr9.  
(a) Scheme of ncRNAs and relative position of primers (figure drawn with Microsoft 
PowerPoint). (b) cDNAs obtained from human placental (1), lymphoblast (2) and HEK 
293 (3) RNAs and relative –RT controls (4-6) were amplyfied with NCBI 2For/2Rev 
primer, and run onto an agarose gel along with 100bp ladder (7). A band of 244 bases 
was clearly detected in the placental cDNA and lymphoblast cDNA (for sequencing 
data see Appendix P). The placental sample band was the strongest in intensity. (c) 
Placental cDNA amplified by using the following primers: NCBI 5For/2Rev (9), NCBI 
AllFor/2Rev (10), producing respectively 458 and 468; 100bp ladder (8) (for 
sequencing data see Appendix R and Appendix Q, respectively). 
 
 
104 
 
 
 
Figure 5.4 RT-qPCR analysis for ncRNAChr2.  
ncRNAChr2 expression was determined to verify transfection efficiency at 24, 48 and 
72 hours. Relative expression was calculated using GUS as reference gene. Samples 
which are not transfected with ncRNAChr2 did not show any expression.  
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Figure 5.5 RT-qPCR analysis for ncRNAChr9. 
ncRNAChr9 expression was determined to verify transfection efficiency at the different 
time points. Relative expression was calculated using GUS as reference gene. No 
expression was detected in samples not transfected with ncRNAChr9.  
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Figure 5.6 Relative MTHFD1L gene expression after 24 hours of transfection. 
MTHFD1L gene expression was compared between transfected samples and negative 
control. Results were calculated by applying the comparative CT method (2
- Ct
) to 
measure the fold change in MTHFD1L expression relative to Beta-Glucuronidase (GUS) 
reference gene (Chapter 2, Section 2.2.10). Transfected samples and negative control with 
only transfection reagent (-CTR) were normalized to non-transfected sample. 
Differences in relative expression ratios were compared using one-way ANOVA, with 
results considered significant if a two-tailed p-value was < 0.05. MTHFD1L expression 
did not show any significant change after 24 hours of transfection. 
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Figure 5.7 Relative MTHFD1L gene expression after 48 hours of transfection. 
MTHFD1L gene expression was compared between transfected samples and negative 
control. Results were calculated as for the 24 hour time point. MTHFD1L expression 
was not affected by ncRNA transfection after 48 hours of transfection. 
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Figure 5.8 Relative MTHFD1L gene expression after 72 hours of transfection. 
MTHFD1L gene expression was compared between transfected samples and negative 
control. Results were calculated as for the 24 hour and 48 hour time points. Again, 
MTHFD1L expression did not show any significant change after 72 hours of 
transfection. 
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Figure 5.9 Western Blot for MTHFD1L expression at 24, 48 and 72 hour time 
points. 
Mitochondrial proteins were extracted from HEK 293 cells after 24, 48 and 72 hours of 
transfection (Chapter 2, Section 2.2.1.4). Samples were analysed by Western blotting 
and probed with antibodies against both MTHFD1L and PDH subunit E1 alpha used as 
reference protein and mitochondrial marker. MTHFD1L expected size is 102 kDa after 
cleavage of the mitochondrial targeting sequence, while PDH subunit E1 alpha 
expected size is 41 kDa. ncRNA tranfected samples did not show a variation in 
MTHFD1L expression compared to negative control samples and normalised to PDH. 
ncRNAChr2 samples showed a general lower expression of both MTHFD1L and PDH. 
This can be explained by an higher mortality of ncRNAChr2 cell samples probably due 
to an high amount of bacterial endotoxins derived from plasmid Minipreps.  2: 
ncRNAChr2, 9: ncRNAChr9, –: negative control (only transfection reagent), U: 
untransfected negative control. 
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Figure 5.10 Schematic representation of MTHFD1 spliced gene on Chr14 (figure 
drawn with Microsoft PowerPoint).  
Thick pink arrows show exons within the coding sequence of the gene flanked by 5′ 
and 3′UTR. Above exons there are corresponding catalytic domains of MTHFD1 
protein. Blue line represents corresponding processed pseudogene on ChrX, while 
black arrows underneath show ORFs along ChrXseq. Red arrows show RT-PCR 
amplicons obtained using following primer pairs: 1, ChrX 5For/5Rev (471 bases); 2, 
CHRX 6For/6Rev (431 bases); 3, CHRX 7For/4Rev (475 bases); 4, ChrX 3For/3Rev 
(418 bases); 5, ChrX 2For/2Rev (474 bases); 6, CHRX 1For/ 3′UTR 2nd Rev (453 
bases). 
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Figure 5.11 PCR products from Placental cDNA samples.  
100bp ladder (1), CHRX 7For/4Rev (475 bases) (2), ChrX 5For/5Rev (471 bases) (3), 
ChrX 3For/3Rev (418 bases) (4), CHRX 6For/6Rev (431 bases) (5), ChrX 2For/2Rev 
(474 bases) (6), CHRX 1For/3′UTR 2nd Rev (453 bases) (7). Bands were sequenced 
and data are reported in Appendix T, U, V, W, X and Y, respectively.  
The lower part of the figure shows the relative –RT controls which are all negative. 
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Figure 5.12 Schematic representation of MTHFD1 spliced gene on Chr14 (figure 
drawn with Microsoft PowerPoint).  
Thick pink arrows show exons within the coding sequence of the gene flanked by 5′ 
and 3′UTR. Above exons there are corresponding catalytic domains of MTHFD1 
protein. Blue line represents corresponding processed gene on ChrX, while black 
arrows underneath show ORFs along ChrXseq. Purple arrows represent ChrX 
sequences that were selected for recombinant cloning.  ChrX 750 ORF seq (750 bases) 
was cloned in vector Gateway
®
 pDEST™15 vector (Appendix D), while ChrX 3′UTR 
seq was cloned in pcDNA™3.2/V5-DEST vector (Appendix C). 
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Figure 5.13 MTHFD1 expression after 24, 48 and 72 hour transfection 
ChrX3′UTR. 
Data are represented as relative expression of ChrX3′UTR and CTR (empty vector) 
samples for 3 time points. All data were analysed by the E (Efficiency)-Method using 
GUS as an endogenous control for normalization. Statistical significance was 
calculated using Student’s t-test (*p<0.05). 
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CHAPTER 6 
 
MTHFD1L expression 
after cycloleucine exposure 
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6.1  Introduction 
 
Cycloleucine is a non-metabolisable amino acid formed by cyclization of leucine. This 
molecule is an inhibitor of Methionine Adenosyltransferase (MAT) which is 
responsible for the production of S-Adenosylmethionine (SAM) (Figure 6.1). The 
exposure of cells to cycloleucine decreases the cellular SAM level, which is the major 
methyl donor (Zhuge and Cederbaum 2007, Tchantchou and Shea 2008). The donation 
of a methyl group during the methylation reaction converts SAM to S-
adenosylhomocysteine (SAH) under the catalysis of S-adenosylmethionine 
methyltransferase (Finkelstein, 1998). SAH is subsequently hydrolyzed to 
homocysteine and the methyl cycle is completed by the remethylation of homocysteine 
to methionine. 
 
As explained in Chapter 1, Section 1.1.4, methyl cycle forms part of 1C metabolism. 
Cycloleucine inhibition of MAT and consequent disruption of the methyl cycle may 
have different effects on 1C metabolism regulation and the regulation of its associated 
genes. Our group recently investigated the molecular response to 1C metabolism 
inhibition by exposing human lymphoblast cell lines to the cycloleucine (Carroll et al. 
2012). Microarray analysis was carried out to examine the expression of 47,000 
transcripts. 
  
Taking advantage of this previous study, here, we specifically tested the expression of 
Short and Long MTHFD1L transcripts in response to cycloleucine exposure. As 
described in Chapter 1, Section 1.1.7, the Long transcript expresses an active protein, 
while the Short transcript, which is caused by the alternatively spliced exon 8A, is 
enzymatically inactive. Our previous study suggested that high Long/Short transcript 
ratio could be associated with the risk of NTDs and that this alternative splicing could 
have a role in the regulation of MTHFD1L (Parle-McDermott et al. 2009). Moreover, 
differences in the alternative splicing patterns are recurrent among folate-related genes 
(Duan et al. 2009). The aim of this chapter is to verify if a perturbation of the folate 
pathway by using cycloleucine could affect MTHFD1L regulation and if this regulation 
occurs through the mechanism of alternative splicing.  
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6.2  Results 
 
6.2.1  MTHFD1L Long isoform expression after cycloleucine exposure 
 
Cycloleucine time course was carried out as described in Chapter 2, Section 2.2.11. 
MTHFD1L Long transcript, was detected in Coriell lymphoblast cells after exposure to 
5mM, 7.5mM and 10mM of cycloleucine for 24, 48 and 72 hours (Carroll et al. 2012). 
Five different endogenous control genes were investigated to identify the control gene 
most suitable for real-time PCR normalisation in cDNA samples of interest. The 40S 
Ribosomal Protein S13 gene (RPS13) displayed the least amount of variation and was 
selected as reference gene. The mean and standard deviation (SD) were calculated for 
treated and non-treated samples for each time point using Microsoft Excel
®
. Results 
were calculated by applying the E-method to measure the fold change in gene 
expression relative to the reference gene. Treated samples were then normalised to non-
treated samples of each specific time point. Differences in relative expression ratios 
were compared using one-way ANOVA, with results considered significant if a two-
tailed p-value was < 0.05. 
 
Gene expression of MTHFD1L long isoform was significantly increased after 24 hours 
of exposure in samples treated with 7.5mM and 10mM of cycloleucine (p-value 0.001 
and 0.004 respectively) (Figures 6.2 and 6.3). In 5mM/24hours treated samples the 
upregulation effect is still detectable, but no longer significant (p-value = 0.103) 
(Figure 6.4). In all the treated samples MTHFD1L Long transcript expression returns to 
a level comparable to negative control after 48 and 72 hours.  
 
6.2.2 MTHFD1L Short isoform expression after cycloleucine exposure 
 
The MTHFD1L Short isoform expression showed a similar but opposite trend, 
compared to the Long isoform as expected. Samples exposed to all the concentrations 
of cycloleucine showed a significant inhibition of MTHFD1L Short transcript 
expression at 24 hour time point (Figures 6.5, 6.6 and 6.7). Consistently with Long 
isoform result, Short mRNA levels return to normal expression after 48 and 72 hours of 
exposure.  
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6.3  Discussion 
 
Results show that MTHFD1L transcript level responds to cycloleucine exposure in 
Coriell lymphoblast cells. This effect is limited in time as we detected a change in gene 
expression only after 24 hours of exposure. The upregulation of the Long transcript 
coincides with a downregulation of the Short transcript suggesting that the regulation 
operates through their alternative splicing. An increase of Long/Short transcript ratio 
results in an increment of active MTHFD1L protein in mitochondria. These findings 
continue to highlight the key role of alternative splicing in the MTHFD1L gene. The 
regulation of alternative splicing depends on the interaction between splicing factors 
and regulatory elements in the pre-mRNA, (Kornblihtt 2006). The methyl cycle forms 
part of 1C metabolism and the MTHFD1L enzyme is a key supplier of the 1C flow 
between the mitochondria and the cytoplasm. Cycloleucine inhibition of MAT and 
consequent disruption of the methyl cycle appears to lead to cascade effects resulting in 
MTHFD1L upregulation through the altered activity of a yet to be identified alternative 
splicing factor. For example, the blocking of the methyl cycle might lead to a higher 
availability of 1-C units for other reactions in the folate metabolic pathway and this can 
result in an overexpression of proteins necessary for 1-C metabolism such as 
MTHFD1L.  
 
As mentioned in Chapter 1, Section 1.1.7, we showed that MTHFD1L Long transcript 
is significantly upregulated in HEK293 cells cultured in the absence of folate. This 
cycloleucine time course experiment confirms our hypothesis that a high level of 
MTHFD1L Long transcript might be a marker for a folate pathway inhibition and, as a 
consequence, for folate deficiency. These data, in combination with our previous work 
on NTDs, further emphasise the importance of the amount of the functional MTHFD1L 
enzyme to support 1C metabolism in the mitochondria and the flow of 1Cs between the 
mitochondria and the cytoplasm.  The level of MTHFD1L enzyme responds to 
disruption of folate metabolism and this appears to operate by alternative splicing (this 
chapter) and possibly miRNA regulation (Chapter 4).  
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Figure 6.1 Pathways of methionine and homocysteine (modified from Ditscheid et 
al. 2005).  
This figure shows two metabolic pathways involving methionine and homocysteine: 
remethylation and transsulphuration. The remethylation of homocysteine into 
methionine requires 5-methyltetrahydrofolate for methyl group donation and 
cobalamine as coenzyme. 5-Methyltetrahydrofolate is formed from serine. 
Tetrahydrofolate, FAD and pyridoxalphosphate act as coenzymes. Serine, itself, is 
generated by glycine. Alternatively, betaine may act as methyl group donor. The 
second pathway results in the formation of cysteine via cystathionine. Cysteine plays an 
important role as a precursor of glutathione and taurine. This transsulphuration pathway 
requires serine as cofactor and pyridoxalphosphate as coenzyme. 
1:methionine-adenosyl-transferase, 2:S-adenosyl-homocysteine-hydrolase, 3:betaine-
homocysteine-methyltransferase, 4:methyltetrahydrofolate-reductase, 5:5-
methyltetrahydrofolate-methyl-transferase, 6:cystathionine-beta-synthase, 
7:cystathionine- -lyase; FAD=flavine adenine dinucleotide, PLP:pyridoxalphosphate. 
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Figure 6.2 Expression of  MTHFD1L mRNA Long isoform after exposure to 
10mM of cycloleucine. 
The gene relative expression was calculated using RPS13 as reference gene. Treated 
samples were normalised to negative control of each specific time point. 24 hour of 
exposure showed a significant ~5 fold increase of gene expression (p-value = 0.001) 
that returns to normal level after 48 and 72 hours (p-value = 0.35 and 0.076 
respectively).  
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Figure 6.3 Expression of  MTHFD1L mRNA Long isoform after exposure to 
7.5mM of cycloleucine. 
The gene relative expression was calculated as above. Again, 24 hour exposure point 
showed a significant ~9-fold overexpression of the gene (p-value = 0.004). After 48 
and 72 hours of exposure did not show any significant change in MTHFD1L 
expression. 
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Figure 6.4 Expression of  MTHFD1L mRNA Long isoform after exposure to 5mM 
of cycloleucine. 
The gene relative expression was calculated as above. Exposition to 5mM of 
cycloleucine showed a smaller change of MTHFD1L expression (~2 folds) with a p-
value no longer significant (p=0.103).  After 48 and 72 hours of exposure did not show 
any significant change in MTHFD1L expression (p-value = 0.217 and 0.175 
respectively). 
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Figure 6.5 Expression of  MTHFD1L mRNA Short isoform after exposure to 
10mM of cycloleucine. 
The gene relative expression was calculated using RPS13 as reference gene. Treated 
samples were normalised to negative control of each specific time point. Differently 
from MTHFD1L Long isoform, the Short transcript showed a significant 
downregulation of ~2.5 folds after 24 hours of exposition to cycloleucine (p-value = 
0.002). After 48 and 72 hours of exposure no more significant changes in gene 
expression are detected.  
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Figure 6.6 Expression of  MTHFD1L mRNA Short isoform after exposure to 
7.5mM of cycloleucine. 
The gene relative expression was calculated as above. Again, MTHFD1L Short 
transcript showed a significant downregulation of ~5 folds after 24 hours of exposure to 
cycloleucine (p-value = 0.004). After 48 and 72 hours of exposure MTHFD1L Short 
isoform expression returns to levels comparable to negative control. 
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Figure 6.7 Expression of  MTHFD1L mRNA Short isoform after exposure to 
7.5mM of cycloleucine. 
The gene relative expression was calculated as above. Similarly to MTHFD1L Long 
transcript, the exposition to 5mM of cycloleucine showed a lighter effect on the Short 
transcript expression after 24 hours of exposition. In this case the expression is 
inhibited of ~1.5 folds showing a slightly significant p-value (p = 0.036). After 24 and 
48 hours of exposure  the gene expression level returns to negative control level. 
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CHAPTER 7 
 
Proteomic analysis after 
perturbation of MTHFD1L 
expression 
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7.1 Introduction  
 
The term “proteomics” generally refers to the large-scale analysis of proteins and it is 
often specifically used for protein purification and mass spectrometry. The 
opportunities offered by proteomic tools to broaden our knowledge of disease 
mechanisms are formidable. Particularly promising areas of research include the 
development of novel biomarkers for diagnosis, the identification of new targets for 
therapeutics and the study of altered protein expression (Hanash 2003).  
 
As explained in Chapter 1, Sections 1.1.6 and 1.1.7, perturbations of MTHFD1L 
expression levels seem to be associated with disease. High expression levels of 
MTHFD1L were found in human colon adenocarcinoma (Sugiura et al. 2004) and 
significantly correlated with the growth rates of human cancer cell lines (Jain et al. 
2012). In the latter study, it has been also demonstrated that breast cancer patients with 
above-median expression levels of MTHFD1L, SHMT2 and MTHFD2, but not their 
cytosolic homologues, displayed higher mortality (Jain et al. 2012). In addition, disease 
association studies (Chapter 1, Section 1.1.7) performed in our laboratory suggested 
that higher MTHFD1L protein levels could be associated with an increased NTD risk 
(Parle-McDermott et al. 2009).  
 
On the other hand, the loss of the protein in Mthfd1l knockout mice was found to be 
lethal to developing embryos, causing fetal growth restriction and NTD phenotypes 
with 100% penetrance (Momb et al. 2013). In Chapter 4, we also showed that the 
impact of SNP rs7646 on the binding of miR-197 to the 3′UTR of MTHFD1L provides 
a mechanistic explanation of the previous association of this SNP with NTD risk 
(Parle-McDermott et al. 2009) i.e., the ‘G’ allele provides a better binding site for miR-
197. The immediate assumption is that the ‘G’ allele would lead to a decrease in 
embryonic MTHFD1L levels. However, the actual expression of miR-197 and miR-9 
during embryogenesis and their competition for the binding of MTHFD1L 3′UTR 
require further investigation to prove this assumption. What is clear from the data in the 
literature and in this thesis is that the MTHFD1L functional enzyme levels are of 
particular significance given that increased or decreased levels are consistently 
observed across a number of human diseases. Maintaining MTHFD1L levels within an 
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expression level “window”, especially during cell proliferation, may be crucial for the 
maintenance of healthy cells. 
 
In this chapter, the role of an altered MTHFD1L expression in disease will be assessed 
by a proteomic analysis. This will be performed on cells that have been manipulated to 
‘knock-down’ expression of MTHFD1L and to overexpress it providing an 
understanding of how the expression level of MTHFD1L is significant in disease. 
Changes in protein expression of such cell lines will be assessed by means of label-free 
liquid chromatography–mass Spectrometry (LC-MS).    
 
7.2 Material and methods  
 
7.2.1 MTHFD1L knockdown by shRNA Lentiviral transduction and generation 
of stable HEK293 cell lines 
 
MTHFD1L knockdown in HEK293 cells was performed using the MISSION
TM
 TRC 
lentiviral shRNA vectors. Five different constructs, targeting different regions of 
MTHFD1L, and a non-target shRNA control were purchased from Sigma-Aldrich. Two 
different kind of Isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible vectors were 
used for the experiment. pLKO_IPTG_3xLacO vector (Appendix G) contains three lac 
operon sequences (two in the U6 promoter and one 3′ of the promoter) affording a tight 
gene regulation. Whereas, the pLKO_IPTG_1xLacO (Appendix F) vector contains a 
single lac operon sequence in the U6 promoter, which allows a stronger shRNA 
expression, but looser control of the promoter when it is not induced. Constructs and 
vectors are reported in Table 7.1. Constructs number 3 and 5 were already validated for 
knocking down MTHFD1L by Sigma.  
HEK 293 cells were cultured as explained in Chapter 2, Section 2.2.1.1. Cells were 
counted and 1.6 x 10
4
 cells were seeded in a 96 well plate in 120 µl of complete media 
and incubated at 37
o
C for about 20 hours until ~70% confluency was obtained. Media 
was removed from wells and 110 µl media and Hexadimethrine bromide, at a final 
concentration of 8 mg/ml, were added to each well to enhance transduction. The plate 
was gently swirled to mix. A range of volume (2, 5, 10, and 15 µl) of each lentiviral 
construct was added to appropriate wells. The plate was gently swirled and incubated at 
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37
o
C for about 20 hours. Then the media containing viral particles replaced with 120 µl 
of fresh media particles and the plate was incubated at 37
o
C for 24 hours. Media was 
then replaced with fresh media containing 5 µg/ml of puromycin and resistant cells 
were selected for 1 week. Media with 5 µg/ml puromycin was also tested in non-
transduced cells and all died within 4 days. Resistant transducted cells were then 
cultured for 2 weeks in 5 µg/ml puromycin media until 75cm
3
 flasks were obtained and 
used for making backup frozen stocks and for preliminary downregulation test.  
 
7.2.2 Preliminary shRNA downregulation test 
 
A preliminary test was run to determine the best concentration of IPTG to use and to 
select two shRNA constructs for the proteomic analysis. A 100% confluent 75cm
3 
flask 
for each of the 6 shRNA was split in 4 flasks and cells were grown in 10 ml of 5 µg/ml 
puromycin DMEM with 0 µM, 10 µM, 50µM or 100 µM of IPTG. To confirm that 
non-target shRNA does not affect MTHFD1L expression, normal non-transduced 
HEK293 cells were also grown in DMEM with 100 µM of IPTG. After 3 days cells 
were collected and MTHFD1L expression was tested. For RNA extraction and RT-
qPCR analysis see Chapter 2, Sections 2.2.4 and 2.2.10, respectively.   
 
7.2.3 Generation of HEK293 stable cell line overexpressing MTHFD1L 
 
A modified version of MTHFD1L coding sequence with attB-flanked in pMA-RQ 
vector was purchased from Invitrogen
®
. MTHFD1L coding sequence in this clone was 
modified without changing the resulting amino acid sequence in order to optimize the 
protein expression in mammalian cells. The sequence was cloned in the mammalian 
expression vector pcDNA™3.2/V5-DEST (Appendix C) using Invitrogen® Gateway 
cloning system as explained in Chapter 2, Section 2.2.12. HEK293 cells were 
transfected in a 6-well plate with pcDNA3.2-MTHFD1Lopt plasmid and 
pcDNA™3.2/V5-DEST empty vector (used negative control for the experiment) as 
described in Chapter 2, Section 2.2.1.4. After 3 days of transfection, media was 
replaced with fresh media containing 500 µg/ml of G418 antibiotic and resistant cells 
were selected for 2 weeks. Media with 500 µg/ml of G418 antibiotic was also tested in 
non-transfected cells, that all died within 10 days. Stable transfected cells were then 
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cultured for 2 weeks in 500 µg/ml G418 until 75cm
3 
flasks were obtained and used for 
making backup frozen stocks and for single clone selection.     
 
 
 
7.2.4 Single clone selection 
 
Single clone cell lines were generated using three different shRNAS: 1(-CTR), 3 and 7 
for knock-down and pcDNA3.2-MTHFD1Lopt and pcDNA™3.2/V5-DEST empty 
vector for overexpression. Serial dilutions 1:5 were made with each cell line in a 96-
well plate and incubated for 24 hours at 37
o
C. Clones were screened by microscopy and 
wells containing single cells were marked. At least 3 single clones for each cell line 
were then subcultured from the 96-well plate into larger vessels following this order: 
24-well plate, 6-well plate, 25cm
3
 flask and 75cm
3
. The process required 30-40 days 
depending on the cell line. Two clones for each cell line were grown in 75cm
3
 flasks 
for 5 days in media with 200 µM  IPTG. Cell pellets were then collected and tested for 
MTHFD1L expression by RT-qPCR as per Chapter 2 Sections 2.2.4 and 2.2.10. A 
specific RT-qPCR UPL assay was designed for MTHFD1Lopt sequence (Chapter 2, 
Section 2.2.10).  
 
7.2.5 MTHFD1L overexpression and downregulation experiments 
 
Single clone cell lines named shRNA1-1 (CTR), shRNA3-3 and shRNA7-4 were 
selected for the downregulation experiment. A 100% confluent 75cm
3
 flask for each 
cell line was split into five 75cm
3
 flasks and cells were grown for 5 days in 5 µg/ml 
puromycin media with 200 µM IPTG. Cells were collected and washed 5 times in 1ml 
of 1x PBS buffer and cell pellets were stored at -80°C until required for use.  
Similarly, single clone cell lines named 1L-1 and CTR-1 were selected for the 
overexpression experiment. A 100% confluent 75cm
3
 flask for each cell line was split 
in five 75cm
3
 flasks and cells were grown for 5 days in 500 µg/ml G418 media. Cells 
were collected and washed 5 times in 1ml of 1x PBS buffer and cell pellets were stored 
at -80°C until required for use. One cell pellet was used for RNA extraction and RT-
qPCR detection of MTHFD1L mRNA (Chapter 2, Section 2.2.10). A second cell pellet 
was used for mitochondrial protein extraction (Chapter 2, Section 2.2.13.1) and 
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Western Blotting using anti MTHFD1L anti PDH antibodies (Chapter 2, Sections 
2.2.13.4-5). The three remaining cell pellets were used for label-free LC-MS analysis 
as reported below.     
 
 
7.2.6 Sample preparation for label-free LC-MS analysis  
 
Sample preparation and label-free and LC-MS analysis were performed by our 
collaborators Michael Henry and Paula Meleady in the National Institute for Cellular 
Biology in Dublin. Cell pellets were lysed with 300uL of lysis buffer consisting 300uL 
of lysis buffer (7 M urea, 2M thiourea, 30 mM Tris, 4% CHAPS, pH 8.5), and then 
homogenised by carefully passing the samples through a 20 gauge needle 5 times 
(avoid sample frothing). Samples were left on a shaker for 1 hr at room temp to allow 
extraction to take place, and then centrifuged at approximately 10000 g for 15 minutes 
at 4°C to remove insoluble material. The supernatant was removed and protein 
concentrations determined using the thiourea-compatible Quick Start Bradford assay 
(Bio-Rad) and stored at -80°C until required for use.  
To remove any trace of detergent, 100 g of sample were cleaned using the Ready Prep 
2-D clean up kit (Bio-Rad). The protein pellet was resuspended in detergent free buffer 
of 6M Urea, 2M thiourea, 10mM tris, pH 8.0 and protein concentration was determined 
again using Quick Start Bradford assay (Bio-Rad). Protein concentration was then 
adjusted to 2μg/μL using the same buffer. Proteins were then digested in the following 
way. Ten micrograms of protein sample (5 l) were added to 35.4 μL of 50 mM 
ammonium bicarbonate and 0.5µl of 1% Protease MAX™ Surfactant (Promega). 
 
Reduction was performed by adding DTT to a final concentration of 5 mM, at 56 °C for 
20 min, and allowed to cool to room temperature for approximately 20 min. Samples 
were alkylated by adding Iodoacetamide 15mM to a final concentration and then 
incubated for 15 minutes in the dark at room temperature. Digestion with sequence 
grade Lys-C (Promega) was carried out at a ratio of 1:20 (w/w) Lys-C:Protein at 37 °C 
for 6 h, followed by a second digestion with sequence grade Trypsin (Promega) at a 
ratio of 1:25 (w/w) Trypsin:Protein  overnight at 37 °C. To stop the digestion, 2µL of a 
50% TFA/50% water solution was added. Samples were then cleaned up using Pep-
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clean C18 spin columns (Thermo Fisher Scientific), dried under a vacuum and stored at 
−80 °C. Prior to mass spectrometry analysis dried peptides were resuspended in 50 μL 
of 0.1% trifluoroacetic acid (TFA) in 2% acetonitrile (ACN), vortexed and sonicated to 
ensure an even suspension. 
 
 
7.2.7 Label-free LC-MS quantitative profiling  
 
Nano LC–MS/MS analysis was carried out using an Ultimate 3000 nano LC system 
(Dionex) coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap 
XL; Thermo Fisher Scientific). Five microlitres of digest were loaded onto a C18 trap 
column (C18 PepMap, 300 μm ID × 5 cm, 5 μm particle size, 100 Å pore size; Thermo 
Fisher) and desalted for 10 min using a flow rate of 25 μL/min in 0.1% TFA. The trap 
column was then switched online with the analytical column (PepMap C18, 75 μm ID 
× 500 mm, 3 μm particle and 100 Å pore size; Thermo Fisher) and peptides were eluted 
with the following binary gradients of solvent A and B: 0–25% solvent B in 240 
minutes and 25–50% solvent B in a further 60 minutes, where solvent A consisted of 
2% ACN and 0.1% formic acid in water and solvent B consisted of 80% ACN and 
0.08% formic acid in water. Column flow rate was set to 300 nL/min.  Data were 
acquired with Xcalibur software, version 2.0.7 (Thermo Fisher Scientific). The mass 
spectrometer was operated in data-dependent mode and externally calibrated. Survey 
MS scans were acquired in the Orbitrap in the 300–2000 m/z range with the resolution 
set to a value of 60,000 at m/z 400. Up to seven of the most intense ions (1+, 2+ and 
3+) per scan were CID fragmented in the linear ion trap. A dynamic exclusion window 
was applied within 40 s. All tandem mass spectra were collected using a normalised 
collision energy of 35%, an isolation window of 3 m/z, and one microscan. 
 
7.2.8 LC–MS Data analysis  
 
Label-free LC–MS analysis was carried out using Progenesis label-free LC–MS 
software version 3.1 (NonLinear Dynamics), essentially as recommended by the 
manufacturer (see www.nonlinear.com for further background to alignment, 
normalisation, calculation of peptide abundance, etc.). The software processed the raw 
data in two steps. Firstly each sample run was subjected to alignment which involved 
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aligning the data based on the LC retention time of each sample; this allows for any 
drift in retention time giving an adjusted retention time for all runs in the analysis. The 
sample run that yielded most features (i.e. peptide ions) was used as the reference run, 
to which retention time of all of the other runs were aligned and peak intensities were 
normalised. The Progenesis peptide quantification algorithm calculates peptide 
abundance as the sum of the peak areas within its isotope boundaries. Each abundance 
value is then transformed to a normalised abundance value by applying a global scaling 
factor. Protein abundance was calculated as the sum of the abundances of all peptide 
ions which have been identified as coming from the same protein.  A number of criteria 
were used to filter the data before exporting the MS/MS output files to MASCOT 
(www.matrixscience.com) for protein identification; peptide features with ANOVA < 
0.05 between experimental groups, mass peaks (features) with charge states from +1 to 
+3, and greater than 3 isotopes per peptide. All MS/MS spectra were exported from 
Progenesis software as a MASCOT generic file (mgf) and used for peptide 
identification with MASCOT (version 2.2) searched against the UniProtKB–SwissProt 
database (taxonomy, Mammals). The search parameters used were as follows: peptide 
mass tolerance set to 20 ppm, MS/MS mass tolerance set at 0.5 Da; up to two missed 
cleavages were allowed, carbamidomethylation set as a fixed modification and 
methionine oxidation set as a variable modification. Only peptides with ion scores of 
30 and above were considered and re-imported back into Progenesis LC–MS software 
for further analysis. An ANOVA p-value of ≤0.05 between experimental groups was 
used as cut-off. Protein function and network analysis was performed using IPA 
Ingenuity software (Qiagen).  
 
7.3 Results 
 
7.3.1 Preliminary shRNA downregulation test 
 
MTHFD1L is an essential gene (Momb et al. 2013) and a severe downregulation could 
cause cell death, hence, IPTG inducible vectors were used to allow a certain control on 
MTHFD1L downregulation. Out of five shRNA constructs, we selected the two 
constructs that showed the best MTHFD1L downregulation. Two different shRNA 
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constructs were employed to combine the final proteomic data for the purpose of 
excluding possible off-target effects.  
Thus, a preliminary test was performed to determine the best concentration of IPTG 
and to select two shRNA constructs for the proteomic analysis. RT-qPCR results are 
shown in Figure 7.1. Normal non-transduced HEK293 cells and the non-target shRNA1 
control showed a similar value confirming that the latter does not affect MTHFD1L 
expression. shRNA4 did not change MTHFD1L mRNA level, while shRNA5 and 
shRNA6 showed a moderate downregulation. shRNA3 and shRNA7 produced the best 
downregulation effect, ~80% and ~75% respectively, and therefore they were selected 
for the proteomic analysis. As expected, increasing the IPTG dosage leads to a better 
MTHFD1L downregulation. Both the inducible vectors (3xLacO and 1xLacO) showed 
a limited leakage with no IPTG induction (~20%) and a tight control of the regulative 
effect. 
   
7.3.2 Single clone selection for downregulation and overexpression experiments 
 
Due to the random integration of vectors into the host genome, varying levels of target 
gene knockdown may be seen with different resistant colonies. Testing a number of 
colonies allows the optimal degree of knockdown to be determined. Two clones for 
each cell line were then tested for MTHFD1L expression by RT-qPCR. Results are 
shown in Figure 7.2. shRNA 7-4 and shRNA 3-3 single clones which presented the best 
downregulation levels were selected for the proteomic analysis (Figure 7.2a and b). 
Regarding the upregulation experiment, 1L-1 single clone was selected for the 
proteomic analysis as it showed the highest expression of MTHFD1Lopt sequence 
(Figure 7.2c).      
 
7.3.3 MTHFD1L overexpression and downregulation experiments 
 
MTHFD1L Overexpression Experiment 
Prior to carry out LC-MS analysis, MTHFD1L expression level was verified by RT-
qPCR and Western Blot (Figure 7.3a). RT-qPCR confirmed a high expression level of 
MTHFD1Lopt sequence (Figure 7.3a) while Western Blot showed a 2.89 fold 
overexpression of MTHFD1L protein. In the MTHFD1L overexpression experiment, 
LC-MS data analyzed with Progenesis3.1 software reported a total of 92 significant 
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proteins of which 17 upregulated (Table 7.2) and 75 downregulated (Table 7.3). 
MTHFD1L was first in the list of upregulated proteins (7.04 fold change) proving the 
effectiveness of the experiment.   
 
MTHFD1L Knockdown Experiment 
MTHFD1L downregulation was also confirmed by RT-qPCR and Western Blot (Figure 
7.3b). LC-MS analysis resulted in 83 significant proteins for shRNA3-3 sample and 79 
for shRNA7-4 sample, while the two samples shared 50 proteins. MTHFD1L protein 
showed a 31.62 fold downregulation in shRNA3-3 and a 10.51 fold downregulation in 
shRNA7-4 sample confirming RT-qPCR and Western Blot results. Sample datasets 
were combined and all the proteins listed in only one group (62) or displaying opposite 
regulation (2) were discarded. Among the resulting 48 proteins that were shared 
between the two lines, 18 were upregulated (Table 7.4) and 30 were downregulated 
(Table 7.5).  
 
Six proteins were present in both MTHFD1L overexpression and knockdown lists 
(Table 7.6) and showed opposite trend of expression as expected. Specifically, all these 
proteins showed an opposite regulation compared with MTHFD1L expression. Many of 
the proteins affected by MTHFD1L expression are involved in nucleic acid metabolism 
and DNA replication, recombination and repair (Table 7.7). Almost all these proteins 
seem to follow a clear expression trend, they are downregulated when MTHFD1L level 
is high and upregulated when MTHFD1L level is low. Protein networks have been 
drawn using IPA Ingenuity software and they are shown in Figures 7.4 and 7.5. Four 
proteins, whose expression is associated with DNA damage prevention, are an 
exception to this trend (CRYZ, HSPB1, PRKDC, and SMARCA1). According to the 
literature an inhibition of these proteins should increase DNA damage.    
 
IPA analysis also showed that MTHFD1L overexpression data significantly match with 
an increased signal of cell death (necrosis, apoptosis, apoptosis of tumour cell line, 
neural cell death and apoptosis of neurons). In particular the downregulation of 7 
proteins (PRDX3, PRDX2, MSH2, XRCC5, HSD17B10, XRCC6 and NEFL) is 
associated with an increased apoptotic signal in neurons. Among these proteins there is 
neurofilament, light polypeptide (NEFL) that was one of the proteins most affected by 
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MTHFD1L expression. It showed a 27.88 fold downregulation when MTHFD1L levels 
was high and a 9.29 fold upregulation when MTHFD1L level was low.  
 
7.4 Discussion 
 
In this chapter, the role of altered MTHFD1L expression in disease was assessed by a 
proteomic analysis. Such analysis has been accurately designed to produce different 
datasets that can be compared to each other in order to strengthen the final outcome. 
Single clone cell lines were sub-cultured to guarantee a stable MTHD1L expression 
among cell population. In addition to this, two different inducible shRNA constructs 
have been employed for protein inhibition. MTHFD1L is essential for cell viability, 
therefore it was important to downregulate it enough to induce appreciable proteomic 
changes, but not too much to utterly damage the cell stability. shRNA3-3 and shRNA7-
4 datasets were combined and 64 proteins were omitted as appearing in only one 
dataset or showing opposite regulation. These omitted proteins presumably were the 
result of off-target shRNA regulation. MTHFD1L downregulation and upregulation 
results were compared with the aim to identify proteomic patterns directly related to 
MTHFD1L expression. 
 
Interestingly, many proteins affected by MTHFD1L expression are involved in nucleic 
acid metabolism and DNA replication, recombination and repair (Table 7.7). Almost all 
these proteins are downregulated when MTHFD1L is overexpressed while they are 
upregulated when MTHFD1L is inhibited. An example of proteins displaying this 
expression trend is given by the DNA replication licensing factor MCM proteins. They 
form a complex (MCM2-7) with replicative helicase activity essential for 'once per cell 
cycle' DNA replication initiation and elongation in eukaryotic cells (Tsuji et al. 2006). 
Another protein in this list (Table 7.7) is the folate related TYMS, which ubiquitously 
localizes to the nucleus, cytoplasm and mitochondria, and it is responsible for the 
synthesis of thymidylate (Anderson et al. 2012). The enzymes that constitute the de 
novo thymidylate pathway include TYMS, DHFR and SHMT1. These enzymes, along 
with other proteins like MTHFD1, form a nuclear complex that is associated with the 
nuclear lamina during S and G2/M phases (Anderson et al. 2012). This complex 
provides thymidylate for DNA replication and repair, and it is important to prevent 
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uracil accumulation in the nuclear DNA (MacFarlane et al. 2011). SHMT1 serves as a 
scaffold protein that is essential for complex formation. In 2012 Anderson et al. 
investigated further the nature of this nuclear complex seeking for the involvement of 
other proteins. By using co-immunoprecipitation experiments and tandem affinity 
purification they identified a number of proteins associated with SHMT1 and the 
nuclear complex. Intriguingly, in addition to TYMS, three of these proteins (PCNA, 
LMNA and LMNB1) also appeared in our proteomic experiment and they followed the 
same regulation trend, opposite to MTHFD1L expression direction (Table 7.7). 
Proliferating cell nuclear antigen (PCNA), which acts as a processivity factor for DNA 
replication (Shumaker et al. 2008), was previously identified as a SHMT interacting 
partner (Woeller et al. 2007, Li et al. 2004). PCNA was shown to co-precipitate with 
SHMT1, TYMS and DHFR in nuclear extracts but not in cytoplasmic extracts 
(Anderson et al. 2012). Both Lamin A/C (LMNA) and Lamin B1 (LMNB1) also co-
precipitate with SHMT1. LMNB1, which is a component of the nuclear lamina, 
exhibited co-localization with TYMS, DHFR and SHMT1 in filament-like linear 
structures during the S and G2/M phase of the cell cycle. LMNB1 directly binds 
SHMT1 anchoring the complex to the nuclear lamina (Anderson et al. 2012).  
 
Our findings suggest that MTHFD1L levels might be inversely proportional to the 
levels of the proteins involved in the nuclear thymidylate biosynthesis complex level. 
The stability of this complex is important to prevent uracil misincorporation into 
genomic DNA (MacFarlane et al. 2011). Thymidine nucleotides differ from the other 
nucleotides in that they are not crucial during DNA replication. DNA polymerases 
typically fail to distinguish between dTTP and dUTP during DNA replication and 
repair and can incorporate dUTP into DNA when dTTP is limiting (Stover et al. 2012). 
Moreover, while the synthesis of cytosine and purine nucleosides occurs in the 
cytoplasm, the salvage and folate-dependent de novo synthesis of thymidylate, 
catalyzed by thymidine kinase (TMPK) and TYMS respectively, occurs in the nucleus 
at sites of DNA synthesis (Chen et al. 2010 and Anderson et al. 2012). Cellular dTTP 
pools are normally maintained at very low levels and when they are depleted or 
expanded DNA integrity and human health can be affected (Samsonoff et al. 1997). 
There is strong evidence that dTTP is synthesized “on-site and on-demand”, and a 
diminished dTTP synthesis results in dU accumulation in DNA, causing genomic 
instability through futile cycles of DNA synthesis and repair (Blount et al 1997). 
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Elevated uracil misincorporation and chromosome breaks contribute to the increased 
risk of cancer and cognitive defects associated with folate deficiency in humans 
(Blount et al 1997). Indeed, the inhibition of SHMT1, which is an essential scaffold for 
the formation of the thymidylate biosynthesis complex, leads to increased uracil 
misincorporation in DNA, increased risk of intestinal cancer (MacFarlane et al. 2011), 
and NTDs (Beaudin et al. 2011) in mice. In our analysis, MTHFD1L overexpression 
seems to inhibit the presence of the proteins belonging to the nuclear thymidylate 
biosynthesis complex. This should result in an increased uracil accumulation in the 
DNA. Thus, this mechanism provides an explanation to the association of increased 
MTHFD1L levels with NTDs (Parle-McDermott et al. 2009) and cancer (Sugiura et al. 
2004, Jain et al. 2012). In agreement with this mechanism, also proteins involved in the 
repair of the double-strand breaks (DSBs) showed to be downregulated by MTHFD1L 
overexpression. The XRCC5 and XRCC6 proteins form a dimer that is involved in 
stabilizing broken DNA ends and bringing them together (Tuteja et al. 1994). ATP-
dependent RNA helicase DDX1 and DDX11 also play a role in the RNA clearance 
DSBs, thereby facilitating the template-guided repair of transcriptionally active regions 
of the genome (Li et al. 2008). Defects in the cellular response to DSBs underpin many 
human diseases, including cancer and neurodegeneration (McKinnon et al. 2007).  
 
The effect of MTHFD1L expression on the nuclear thymidylate biosynthesis complex 
and other proteins involved in DNA replication and repair is probably linked to the 
formate production within mitochondria. It appears that the majority of 1C units for 
cytoplasmic processes are derived from mitochondrial formate produced by MTHFD1L 
(Momb et al. 2013). Moreover, the identification of MTHFD1 (the cytoplasmic 
paralogue of MTHFD1L) as a component of the nuclear thymidylate biosynthesis 
complex indicates that formate can be an important source of nuclear methylene-THF 
for de novo thymidylate biosynthesis (Anderson et al. 2012). Another point to consider 
is the toxicity of formate to respiration via inhibition of cytochrome c oxidase, which 
was proven in an early study (Nicholls 1975). More recently, Kapur et al. (2007) 
reported that a formate concentration as low as 1 mM induced neurotoxicity in rat 
hippocampal brain slices. Here, we corroborated those findings by showing that 
cytochrome c oxidase subunit 7A2 (COX7A2) is downregulated by MTHFD1L 
overexpression (Table 7.3). Thus, an impaired production of formate may affect the cell 
at different levels. MTHFD1L, along with the mitochondrial proteins SHMT2 and 
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MTHFD2, were correlated with the growth rates of human cancer cell lines (Jain et al. 
2012). Thus, in healthy cells, an increasing formate production may be a signal for 
uncontrolled cell proliferation that triggers defensive mechanisms like the inhibition of 
nuclear thymidylate biosynthesis and DNA replication and repair. Augmented uracil 
misincorporation and DNA breaks may eventually lead to apoptosis.           
 
This possible explanation is in concordance with the increased signal of cell death 
reported upon MTHFD1L overexpression. Specifically, the downregulation of PRDX2 
(Boulos et al.2007), PRDX3 (Hattori et al. 2003), MSH2 (Francisconi et al. 2006), 
XRCC5, XRCC6 (Gu et al. 2000), HSD17B10 (Lustbader et al. 2004) and NEFL (Lee 
et al. 1994, Cluskey et al. 2001) have been associated with increased apoptosis in 
neurons.  
 
Among these proteins NEFL showed the strongest response to MTHFD1L upregulation 
and overexpression. Neurofilament medium polypeptide (NEFM) was also highly 
downregulated (5.19 fold change) by the overexpression of MTHFD1L. 
Neurofilaments comprise the axoskeleton and functionally maintain neuronal calibre 
(Lalonde et al. 2003). They may also play a role in intracellular transport to axons and 
dendrites. In mouse, depletion of NEFL causes massive selective motor neuron death 
(Lee et al. 1994, Cluskey et al. 2001). These proteins are commonly used as a 
biomarker of neuronal damage and they have been proposed to be involved in the onset 
and progression of amyotrophic lateral sclerosis, mainly characterized by motor neuron 
atrophy and paresis (Lalonde et al. 2003). Another protein associated with 
neurodegenerative disease is the Aβ-binding alcohol dehydrogenase HSD17B10, which 
has been proven to directly link Aß to mitochondrial toxicity in Alzheimer's Disease 
(AD) (Lustbader et al. 2004). In mice, XRCC5 and XRCC6 deficiency results in 
dramatically increased death of neurons in developing embryos and adults (Gu et al. 
2000). Thus, our protein expression results might provide a link for the former genetic 
association of MTHFD1L with AD (Naj et al., 2010) and NTD risk (Parle-McDermott 
et al. 2009).  
 
SMARCA1, CRYZ, HSPB1, and PRKDC, which are associated with DNA damage 
prevention, showed to be downregulated by MTHFD1L knockdown. SMARCA1 
protein, though present in the control sample, was totally depleted in shRNA3-3 and 
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shRNA7-4 samples. This protein is annotated as probable global transcription activator 
of SNF2L1 that is a chromatin remodeling gene expressed in diverse tissues, cancers, 
and derived cell lines, contributes to the chromatin remodeling complex and facilitates 
transcription (Ye et al. 2009). A reduction of SNF2L1 protein level induced growth 
inhibition, DNA damage and phosphorylation of checkpoint proteins and marked 
apoptosis. This effect was detected in cancer cells but not in normal cells (Ye et al. 
2009). SMARCA1 may be also involved in brain development by regulating En-1 and 
En-2. Quinone oxidoreductase CRYZ has been shown to decrease oxidative damage of 
genomic DNA in mouse mammary gland (Krishnamurthy et al. 2012). Heat shock 
protein beta-1 (HSPB1) has been shown to provide neuroprotection against ischemic 
injury (Stetler et al. 2012). Its phosphorylation is required to decrease DNA damage in 
primary rat cortical neurons (Stetler et al. 2012). Inactivation of PPKDC in human cells 
increases damage of DNA enhanced by ionizing radiation (Dziegielewski et al. 2002). 
Taken together, these available data suggest that the downregulation of MTHFD1L and 
the consequent decrease of formate may cause DNA damage. This hypothesis is 
supported by the evidence of RNRR1 upregulation in MTHFD1L knocked-down 
samples (Table 7.7). Ribonucleoside-diphosphate reductase (RNRR1 protein, RRM1 
gene) catalysis the production of dADP, dGDP, dCDP and dUDP from their 
corresponding NDPs, whereas the synthesis of dTDP is unique because it requires 
TMPK (Hu et al. 2012). RNRR1 is recruited to sites of DNA damage and without the 
coordination of TMPK can lead to dUTP incorporation during repair (Hu et al. 2012).  
 
In summary, we demonstrated that MTHFD1L levels affect the nuclear thymidylate 
biosynthesis complex and other proteins involved in DNA replication and repair. We 
proposed that an increased formate production may be a signal for uncontrolled cell 
proliferation that triggers defensive mechanisms like the inhibition of nuclear 
thymidylate biosynthesis and DNA replication and repair. On the other hand, a 
downregulation of MTHFD1L has been linked with an increased DNA damage.  
 
In conclusion, these data suggest that nucleotide biosynthesis and DNA replication and 
repair are sensitive to changes in the expression level of mitochondrial MTHFD1L, 
which is likely to correspond to a change in formate production from the mitochondria. 
Formate supply may act as a ‘sensor’ to ensure that there is a balanced supply of 
nucleotides for DNA replication and repair and to prevent uracil misincorporation. This 
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findings further highlight the importance of MTHFD1L levels and, consequently, of 
formate abundance inside mitochondria, the cytoplasm and the nucleus.   
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Figure 7.1  Relative MTHFD1L gene expression in shRNA transduced cell lines.  
MTHFD1L gene expression was analysed in shRNA transduced samples and compared 
to the negative control. shRNA 3 and shRNA 7 samples produced the highest 
MTHFD1L downregulation. Relative expression was calculated using GUS as 
reference gene and normalized against shRNA1 (-CTR) sample. 
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Figure 7.2 Single clone selection for proteomic analysis. 
MTHFD1L gene expression was analysed in single clone samples and compared to the 
respective negative control sample. (a) shRNA 3-2 and shRNA3-3 showed similar 
levels of downregulation and the latter was selected for the proteomic experiment. (b) 
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shRNA 7-4 presented a better downregulation than shRNA 7-3, thus it was selected for 
the proteomic experiment. (c) 1L-1 upregulation was about 100 times higher than 1L-2 
one. Therefore, 1L single clone was selected for the proteomic analysis. Relative 
expression was calculated using GUS as reference gene and normalized against the 
respective negative control sample. 
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Figure 7.3 Validation of MTHFD1L expression for proteomic analysis.  
MTHFD1L expression was analysed at mRNA and protein level in samples for 
overexpression (a) and downregulation (b) experiments. Relative expression was 
calculated using GUS as reference gene and normalized against shRNA1 (-CTR) 
sample. In Western blotting analysis samples were probed with antibodies against both 
MTHFD1L and PDH subunit E1 alpha used as reference protein and mitochondrial 
marker. MTHFD1L expected size is 102 kDa after cleavage of the mitochondrial 
targeting sequence, while PDH subunit E1 alpha expected size is 41 kDa.  
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Figure 7.4  Protein network designed from MTHFD1L overexpression data. 
Protein network was drawn using IPA Ingenuity software with proteins classified as 
involved in nucleic acid metabolism, small molecule biochemistry and DNA 
replication, recombination and repair. Colour legend: light blue = mild downregulation, 
green = strong downregulation, pink = mild upregulation, red = strong upregulation. 
Uncoloured proteins are not affected by MTHFD1L expression and they were used 
only to complete the network.   
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Figure 7.5  Protein network designed from MTHFD1L downregulation data. 
Protein network was drawn using IPA Ingenuity software with proteins classified as 
involved in Developmental disorders, Hereditary disorders and DNA replication, 
recombination and repair. Colour legend: light blue = mild downregulation, green = 
strong downregulation, pink = mild upregulation, red = strong upregulation. 
Uncoloured proteins are not affected by MTHFD1L expression and they were used 
only to complete the network.   
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Table 7.1 shRNA constructs used in MTHFD1L downregulation experiment.   
Name
a
  Cat. no. TRC number Target Vector Validated
b
 Vector map 
shRNA 1 
(-CTR) SHC002V  
 
None
c
 pLK0.1 Yes Appendix E  
shRNA 3 
SHCLNV-
NM_015440 
TRCN0000045400 
     MTHFD1L 
pLKO_IPTG_
1xLacO Yes Appendix F 
shRNA 4 
SHCLNV-
NM_015440 
TRCN0000045398 
     MTHFD1L 
pLKO_IPTG_
3xLacO No Appendix G 
shRNA 5 
SHCLNV-
NM_015440 
TRCN0000045399 
    MTHFD1L 
pLKO_IPTG_
3xLacO Yes Appendix G 
shRNA 6 
SHCLNV-
NM_015440 
TRCN0000217958 
     MTHFD1L 
pLKO_IPTG_
1xLacO No Appendix F 
shRNA 7 
SHCLNV-
NM_015440 
TRCN0000229790  
    MTHFD1L 
pLKO_IPTG_
3xLacO No Appendix G 
 
a 
Name used in this study  
b
 Some shRNAs have already been validated by Sigma-Alright  
c
 The negative control shRNA is design to not target any known mammalian gene.  
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Table 7.2 List of proteins with increased expression following overexpression of 
MTHFD1L in HEK293 cells.  
Accession 
No.
a
 
Gene 
Name
b
 Protein Description 
Pepti-
des
c
 Score
d
 
Anova                       
p-value 
Fold
change 
Q6UB35 MTHFD1L 
Monofunctional C1-tetrahydrofolate 
synthase, mitochondrial  6 238.52 1.11E-05 7.04 
P13797 PLS3 Plastin-3  3 147.45 0.01 2.55 
Q9Y617 PSAT1 Phosphoserine aminotransferase  3 139.75 0.01 1.57 
P08107 HSPA1A  Heat shock 70 kDa protein 1A/1B  2 102.14 9.43E-05 3.65 
P50225 SULT1A1 Sulfotransferase 1A1  2 68.05 9.41E-05 3.18 
P22695 UQCRC2 
Cytochrome b-c1 complex subunit 2, 
mitochondrial  1 63.01 0.02 1.32 
O00410 IPO5 Importin-5  1 61.01 0.02 1.19 
O95373 IPO7 Importin-7  1 53.84 0.02 1.62 
P41252 IARS Isoleucine--tRNA ligase, cytoplasmic  1 53.79 0.03 1.27 
P39687 ANP32A 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member A  1 46.77 0.02 1.63 
O43175 PHGDH D-3-phosphoglycerate dehydrogenase  1 42.33 0.01 1.25 
P08195 SLC3A2 4F2 cell-surface antigen heavy chain  1 41.43 0.03 2.19 
P50991 CCT4 T-complex protein 1 subunit delta  1 36.66 0.05 1.22 
P09661 SNRPA1  U2 small nuclear ribonucleoprotein A'  1 36.33 0.03 1.19 
Q5QNW6 HIST2H2BF Histone H2B type 2-F  1 36.22 0.05 2.91 
P00338 LDHA  L-lactate dehydrogenase A chain  1 33.91 0.04 1.47 
Q99832 CCT7  T-complex protein 1 subunit eta  1 33.55 0.05 1.24 
 
a
 Uniprot accession number from MASCOT search of UniProtKB-SwissProt, taxonomy Homo sapiens.  
b
 Official recommended gene name taken from UniProtKB-SwissProt. 
c
 Number of peptides used to identify the protein.  
d
 The Mascot Score is a statistical score for how well the experimental data match the database sequence. 
It corresponds to the summed score, calculated with an algorithm, for the individual peptides.   
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Table 7.3 List of proteins with decreased expression following overexpression of 
MTHFD1L in HEK293 cells.  
Accession 
No.
a
 
Gene 
Name
b
 Protein Description 
 
Pepti-
des
c
 Score
d
 
Anova                       
p- value 
Fold 
change 
P07197 NEFM 
Neurofilament medium 
polypeptide  4 187.29 1.38E-05 5.19 
P12004 PCNA Proliferating cell nuclear antigen 3 166.36 3.32E-04 1.56 
P04181 OAT 
Ornithine aminotransferase, 
mitochondrial  2 132.83 1.21E-03 1.39 
P12236 SLC25A6 ADP/ATP translocase 3  2 127.02 1.20E-03 1.71 
P00918 CA2 Carbonic anhydrase 2  3 108.65 9.60E-08 17.91 
P13796 LCP1 Plastin-2  2 99.6 5.07E-04 1.48 
P49327 FASN Fatty acid synthase  2 93.3 0.02 1.28 
Q12906 ILF3 
Interleukin enhancer-binding 
factor 3  2 89.26 0.02 1.32 
P08670 VIM Vimentin 2 81.72 0.01 1.54 
P37802 TAGLN2 Transgelin-2  1 79.73 0.01 1.29 
Q9NVI7 ATAD3A 
ATPase family AAA domain-
containing protein 3A  2 75.3 7.28E-04 1.32 
P00387 CYB5R3 NADH-cytochrome b5 reductase 3  1 73 0.03 1.55 
P37837 TALDO1 Transaldolase  1 72.41 0.05 1.53 
Q99714 HSD17B10 
3-hydroxyacyl-CoA 
dehydrogenase type-2  1 71.4 0.02 1.43 
Q15102 PAFAH1B3 
Platelet-activating factor 
acetylhydrolase IB subunit gamma 1 70.39 9.22E-04 1.31 
P62318 SNRPD3 
Small nuclear ribonucleoprotein 
Sm D3  1 69.43 1.73E-03 1.24 
Q16658 FSCN1 Fascin  2 69.2 0.01 1.52 
Q99623 PHB2 Prohibitin-2  1 67.77 0.02 1.44 
P33992 MCM5 
DNA replication licensing factor 
MCM5  1 65.91 0.04 1.89 
P07196 NEFL Neurofilament light polypeptide  2 64.7 6.03E-05 27.88 
P25705 ATP5A1 
ATP synthase subunit alpha, 
mitochondrial  1 62.67 0.05 1.27 
P06576 ATP5B 
ATP synthase subunit beta, 
mitochondrial  1 61.71 0.05 1.49 
P20700 LMNB1 Lamin-B1  1 61.17 0.05 1.54 
Q96CX2 KCTD12 
BTB/POZ domain-containing 
protein KCTD12 1 59.69 4.60E-07 12.10 
P49736 MCM2  
DNA replication licensing factor 
MCM2 1 58.75 0.01 1.92 
Q13162 PRDX4 Peroxiredoxin-4  1 57.14 0.01 1.33 
P40926 MDH2 
Malate dehydrogenase, 
mitochondrial  1 55.73 0.01 1.33 
A8MWD9 
 
Small nuclear ribonucleoprotein 
G-like protein  1 55.65 0.04 1.74 
A6NHG4 DDTL 
D-dopachrome decarboxylase-like 
protein  1 50.41 0.03 2.43 
Q7Z4W1 DCXR L-xylulose reductase 1 50.35 3.34E-03 1.51 
Q9BVA1 TUBB2B Tubulin beta-2B chain  1 50.13 7.63E-04 1.77 
Q04760 GLO1 Lactoylglutathione lyase  1 49.27 0.02 1.31 
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P51649 ALDH5A1 
Succinate-semialdehyde 
dehydrogenase, mitochondrial  1 47.57 2.13E-03 1.36 
Q13838 DDX39B 
Spliceosome RNA helicase 
DDX39B  1 46.94 0.02 1.43 
P11142 HSPA8 Heat shock cognate 71 kDa protein  1 46.86 0.03 1.49 
P12956 XRCC6 
X-ray repair cross-complementing 
protein 6  1 45.17 0.03 1.29 
P09211 GSTP1 Glutathione S-transferase P  1 44.65 0.03 1.21 
Q13310 PABPC4  Polyadenylate-binding protein 4 1 43.58 0.02 1.27 
Q15233 NONO 
Non-POU domain-containing 
octamer-binding protein  1 42.99 0.05 1.64 
Q13263 TRIM28 
Transcription intermediary factor 
1-beta  1 42.95 1.07E-03 1.67 
P15311 EZR Ezrin  1 42.42 0.02 1.28 
P31939 ATIC  
Bifunctional purine biosynthesis 
protein PURH 1 41.57 0.03 1.26 
P00505 GOT2 
Aspartate aminotransferase, 
mitochondrial  1 41.23 0.02 1.36 
Q92499 DDX1 
ATP-dependent RNA helicase 
DDX1  1 41.21 0.03 1.39 
P14406 COX7A2 
Cytochrome c oxidase subunit 
7A2, mitochondrial  1 41.02 0.02 2.13 
Q9BPW8 NIPSNAP1 Protein NipSnap homolog 1  1 40.92 0.01 1.59 
Q99460 PSMD1 
26S proteasome non-ATPase 
regulatory subunit 1 1 40.57 0.04 1.41 
Q14152 EIF3A  
Eukaryotic translation initiation 
factor 3 subunit A  1 39.86 0.01 1.13 
P17980 PSMC3  
26S protease regulatory subunit 
6A  1 39.62 0.02 1.41 
P33993 MCM7 
DNA replication licensing factor 
MCM7  1 38.96 0.02 1.52 
Q9Y277 VDAC3 
Voltage-dependent anion-selective 
channel protein 3  1 37.74 2.92E-04 1.85 
P14678 SNRPB 
Small nuclear ribonucleoprotein-
associated proteins B and B'  1 37.45 0.01 1.33 
P32119 PRDX2  Peroxiredoxin-2 1 37.1 0.01 1.59 
P30048 PRDX3 
Thioredoxin-dependent peroxide 
reductase, mitochondrial  1 36.79 0.01 1.30 
P46060 RANGAP1 Ran GTPase-activating protein 1  1 36.71 0.01 1.32 
P07910 HNRNPC 
Heterogeneous nuclear 
ribonucleoproteins C1/C2  1 36.13 0.02 1.64 
Q9HC38 GLOD4 
Glyoxalase domain-containing 
protein 4  1 35.45 0.03 1.45 
P14625 HSP90B1 Endoplasmin OS=Homo sapiens  1 35.35 2.64E-04 1.31 
P25788 PSMA3 Proteasome subunit alpha type-3 1 35.06 0.03 1.30 
Q12931 TRAP1 
Heat shock protein 75 kDa, 
mitochondrial  1 34.18 0.02 1.39 
P31150 GDI1 
Rab GDP dissociation inhibitor 
alpha  1 34.12 0.03 1.70 
Q6ZU15 SEPT14 Septin-14  1 33.74 2.08E-03 1.26 
Q92841 DDX17 
Probable ATP-dependent RNA 
helicase DDX17  1 33.52 0.02 1.39 
P55072 VCP 
Transitional endoplasmic 
reticulum ATPase 1 33.33 0.03 1.84 
P13010 XRCC5 
X-ray repair cross-complementing 
protein 5  1 33.07 4.45E-03 2.19 
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P14868 DARS 
Aspartate--tRNA ligase, 
cytoplasmic  1 33 0.05 1.69 
P45880 VDAC2 
Voltage-dependent anion-selective 
channel protein 2  1 32.88 0.01 1.55 
P35579 MYH9 Myosin-9  1 32.64 0.04 1.41 
P14174 MIF 
Macrophage migration inhibitory 
factor  1 32.58 0.01 1.61 
O95336 PGLS 6-phosphogluconolactonase  1 32.38 0.02 1.47 
O43390 PGLS 
Heterogeneous nuclear 
ribonucleoprotein R  1 32.02 0.03 1.25 
Q2TAY7 SMU1 
WD40 repeat-containing protein 
SMU1  1 31.33 0.02 1.32 
P62249 RPS16  40S ribosomal protein S16  1 31.14 0.04 1.40 
O75348 ATP6V1G1 V-type proton ATPase subunit G 1  1 30.7 0.02 1.68 
P43246 MSH2 
DNA mismatch repair protein 
Msh2  1 30.42 0.01 1.49 
 
a
 Uniprot accession number from MASCOT search of UniProtKB-SwissProt, taxonomy Homo sapiens.  
b
 Official recommended gene name taken from UniProtKB-SwissProt (for A8MWD9 there is no official 
gene name available so it has not been included).  
c
 Number of peptides used to identify the protein. 
d
 The Mascot Score is a statistical score for how well the experimental data match the database sequence. 
It corresponds to the summed score, calculated with an algorithm, for the individual peptides.   
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Table 7.4 List of proteins with increased expression following downregulation of MTHFD1L in HEK293 cells.  
 
 
   
shRNA 3-3 
 
shRNA 4-7 
Accession 
No.
a
 
Gene 
Name
b
 Protein Description 
Average 
Fold 
Change
c
 
Pepti-
des
d
 Score
e
 
Anova                       
p- value 
Fold
change   
Pepti-
des
d
 Score
e
 
Anova                       
p- value 
Fold
change 
P07196 NEFL  Neurofilament light polypeptide 9.29 6 339.63 8.37E-08 17.23 
 
6 339.63 0.03 1.36 
P55786 NPEPPS Puromycin-sensitive aminopeptidase  2.50 5 235.19 5.78E-04 2.75 
 
5 235.19 0.01 2.24 
O75131 CPNE3 Copine-3  2.02 3 180.52 8.13E-05 1.98 
 
3 180.52 2.08E-03 2.06 
P33993 MCM7 
DNA replication licensing factor 
MCM7 2.20 2 150.99 1.34E-03 2.10 
 
2 150.99 2.70E-03 2.30 
P25205 MCM3 
DNA replication licensing factor 
MCM3 2.69 2 120.25 0.01 2.12 
 
2 120.25 3.64E-03 3.27 
P31939 ATIC  
Bifunctional purine biosynthesis 
protein PURH  1.81 2 117.67 1.30E-03 2.01 
 
2 117.67 0.01 1.60 
P17844 DDX5  
Probable ATP-dependent RNA helicase 
DDX5  1.56 2 111.99 9.14E-04 1.83 
 
2 111.99 0.01 1.30 
Q14566 MCM6 
DNA replication licensing factor 
MCM6  2.31 2 102.86 0.01 1.52 
 
2 102.86 5.99E-04 3.10 
P02545 LMNA Prelamin-A/C  1.42 1 94.36 0.01 1.16 
 
1 94.36 0.02 1.67 
Q92945 KHSRP Far upstream element-binding protein 2  2.28 1 84.23 2.57E-03 2.15 
 
1 84.23 4.39E-04 2.41 
P51649 ALDH5A1 
Succinate-semialdehyde 
dehydrogenase, mitochondrial 1.94 1 81.28 4.23E-03 2.33 
 
1 81.28 0.02 1.55 
P33992 MCM5 
DNA replication licensing factor 
MCM5  2.29 1 74.25 0.01 2.38 
 
1 74.25 4.52E-03 2.20 
Q9H2H8 PPIL3  
Peptidyl-prolyl cis-trans isomerase-like 
3  4.78 1 71.88 4.43E-03 4.16 
 
1 71.88 2.58E-03 5.39 
P62993 GRB2 Growth factor receptor-bound protein 2  2.01 1 68.8 0.03 1.92 
 
1 68.8 0.02 2.09 
Q8TBC5 ZSCAN18  
Zinc finger and SCAN domain-
containing protein 18  3.66 1 67.6 0.03 2.82 
 
1 67.6 4.91E-03 4.49 
Q15084 PDIA6 Protein disulfide-isomerase A6  1.83 1 67.24 4.74E-03 1.98 
 
1 67.24 0.01 1.69 
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O75436 VPS26A 
Vacuolar protein sorting-associated 
protein 26A  1.41 1 66.59 3.49E-03 1.46 
 
1 66.59 0.02 1.36 
P23921 RRM1 
Ribonucleoside-diphosphate reductase 
large subunit  1.45 1 65.83 0.03 1.59 
 
1 65.83 0.02 1.31 
Q9UQ35 SRRM2  
Serine/arginine repetitive matrix 
protein 2  1.50 1 63.08 1.91E-03 1.40 
 
1 63.08 0.04 1.59 
P30520 ADSS Adenylosuccinate synthetase isozyme 2  1.51 1 62.2 0.03 1.48 
 
1 62.2 0.02 1.53 
P48147 PREP Prolyl endopeptidase  1.63 1 61.38 1.11E-03 1.61 
 
1 61.38 0.03 1.64 
O60664 PLIN3 Perilipin-3 OS=Homo sapiens 2.02 1 59.64 0.01 2.25 
 
1 59.64 0.01 1.79 
O00233 PSMD9 
26S proteasome non-ATPase 
regulatory subunit 9  1.66 1 59.5 0.02 1.62 
 
1 59.5 0.03 1.69 
P08238 HSP90AB1 Heat shock protein HSP 90-beta  1.70 1 54.2 0.02 1.95 
 
1 54.2 0.02 1.46 
P49736 MCM2 
DNA replication licensing factor 
MCM2 2.12 1 45.84 0.01 1.90 
 
1 45.84 0.01 2.33 
P30419 NMT1 
Glycylpeptide N-
tetradecanoyltransferase 1  1.43 1 41.96 0.02 1.59 
 
1 41.96 0.05 1.27 
Q9UHD8 SEPT9  Septin-9  1.84 1 41.65 1.49E-03 1.73 
 
1 41.65 0.02 1.94 
P33991 MCM4  
DNA replication licensing factor 
MCM4  2.89 1 37.19 3.93E-03 3.14 
 
1 37.19 0.01 2.64 
O43633 CHMP2A Charged multivesicular body protein 2a  3.69 1 32.85 4.43E-03 4.28 
 
1 32.85 8.54E-04 3.11 
P04818 TYMS Thymidylate synthase  2.40 1 31.82 0.01 2.28 
 
1 31.82 0.01 2.52 
 
a
 Uniprot accession number from MASCOT search of UniProtKB-SwissProt, taxonomy Homo sapiens.  
b
 Official recommended gene name taken from UniProtKB-SwissProt.  
c
 Average fold change calculated form shRNA3-3 and shRNA4-7 values. 
d
 Number of peptides used to identify the protein. 
e
 The Mascot Score is a statistical score for how well the experimental data match the database sequence. It corresponds to the summed score, calculated with an 
algorithm, for the individual peptides.  
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Table 7.5 List of proteins with decreased expression following downregulation of MTHFD1L in HEK293 cells.  
 
 
   
shRNA 3-3 
 
shRNA 4-7 
Accessio
n No.
a
 
Gene 
Name
b
 Protein Description 
Average 
Fold 
Change
c
 
Pepti-
des
d
 Score
e
 
Anova                       
p- value 
Fold
change   
Pepti-
des
d
 Score
e
 
Anova                       
p- value 
Fold
change 
P26639 TARS  
Threonine--tRNA ligase, 
cytoplasmic 1.58 4 166.70 4.81E-05 1.70 
 
4 166.70 2.09E-04 1.46 
Q9P2J5 LARS Leucine--tRNA ligase, cytoplasmic 1.60 3 134.07 0.01 1.67 
 
3 134.07 0.02 1.53 
Q14677 CLINT1 Clathrin interactor 1  1.38 1 75.53 0.04 1.26 
 
1 75.53 0.02 1.49 
P04792 HSPB1 Heat shock protein beta-1  1.99 1 69.13 0.02 2.44 
 
1 69.13 0.03 1.53 
Q08257 CRYZ Quinone oxidoreductase  1.51 1 68.71 0.02 1.54 
 
1 68.71 0.04 1.48 
P78527 PRKDC 
DNA-dependent protein kinase 
catalytic subunit 1.98 2 68.04 3.07E-03 1.81 
 
2 68.04 0.00 2.15 
P30825 SLC7A1 
High affinity cationic amino acid 
transporter 1 3.16 1 66.99 0.03 3.22 
 
1 66.99 0.02 3.09 
P55809 OXCT1 
Succinyl-CoA:3-ketoacid 
coenzyme A transferase 1, 
mitochondrial  2.41 1 62.33 0.05 2.71 
 
1 62.33 0.03 2.11 
Q6UB35 MTHFD1L 
Monofunctional C1-
tetrahydrofolate synthase, 
mitochondrial  21.06 1 58.66 5.65E-05 31.62 
 
1 58.66 4.83E-04 10.51 
Q13428 TCOF1 Treacle protein  1.77 1 57.69 4.53E-04 1.73 
 
1 57.69 1.17E-04 1.80 
O43592 XPOT  Exportin-T  2.61 1 56.94 0.01 2.47 
 
1 56.94 4.09E-03 2.75 
P50402 EMD Emerin  1.39 1 53.16 3.88E-03 1.38 
 
1 53.16 0.02 1.39 
P28370 SMARCA1 
Probable global transcription 
activator SNF2L1  Infinity 1 52.50 8.14E-04 Infinity 
 
1 52.50 0.01 Infinity 
Q8TEQ6 GEMIN5 Gem-associated protein 5  1.82 1 46.87 0.05 1.61 
 
1 46.87 0.01 2.04 
P55060 CSE1L  Exportin-2  1.75 1 41.01 0.04 1.53 
 
1 41.01 0.04 1.96 
Q92598 HSPH1 Heat shock protein 105 kDa  1.88 1 40.55 0.01 1.77 
 
1 40.55 0.01 1.99 
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Q5TDH0 DDI2 Protein DDI1 homolog 2 5.98 1 38.34 0.03 4.20 
 
1 38.34 0.01 7.76 
Q15149 PLEC  Plectin 2.20 1 36.53 0.02 2.79 
 
1 36.53 0.02 1.62 
a
 Uniprot accession number from MASCOT search of UniProtKB-SwissProt, taxonomy Homo sapiens.  
b
 Official recommended gene name taken from UniProtKB-SwissProt.  
c
 Average fold change calculated form shRNA3-3 and shRNA4-7 values.  
d
 Number of peptides used to identify the protein.  
e
 The Mascot Score is a statistical score for how well the experimental data match the database sequence. It corresponds to the summed score, calculated with an 
algorithm, for the individual peptides.   
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Table 7.6 List of proteins presents in both MTHFD1L overexpression and downregulation groups.  
 
Accession 
No. 
Gene 
Name Protein Description Function 
MTHFD1L 
Overexpression     
(Fold change) 
MTHFD1L 
Downregulation 
(Fold change) 
P49736 MCM2 DNA replication licensing factor MCM2 unwinding DNA -1.92 2.12 
P33992 MCM5 DNA replication licensing factor MCM5  unwinding DNA -1.89 2.29 
P33993 MCM7 DNA replication licensing factor MCM7  unwinding DNA -1.52 2.20 
P31939 ATIC 
Bifunctional purine biosynthesis protein 
PURH metabolism of nucleotide acid component or derivate -1.26 1.81 
P07196 NEFL Neurofilament light polypeptide maintenance of neuronal caliber -27.88 9.29 
P51649 ALDH5A1 
Succinate-semialdehyde dehydrogenase, 
mitochondrial 
Catalyzes one step in the degradation of the inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA) -1.36 1.94 
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Table 7.7 List of proteins involved in nucleic acid metabolism and DNA replication, recombination and repair.  
Gene Name Protein Description Functions annotation 
MTHFD1L 
Overexpression     
(Fold change) 
MTHFD1L 
Downregulation 
(Fold change) 
ATP5A1 ATP synthase subunit alpha, mitochondrial  metabolism of purine nucletide -1.27 - 
ATP5B ATP synthase subunit beta, mitochondrial  metabolism of purine nucletide -1.49 - 
ATP6V1G1 V-type proton ATPase subunit G 1  metabolism of purine nucletide -1.68 - 
HSPA8 Heat shock cognate 71 kDa protein  metabolism of purine nucletide -1.49 - 
MSH2 DNA mismatch repair protein Msh2  metabolism of purine nucletide -1.49 - 
MYH9 Myosin-9  metabolism of purine nucletide -1.41 - 
PSMC3  26S protease regulatory subunit 6A  metabolism of purine nucletide -1.41 - 
VCP Transitional endoplasmic reticulum ATPase metabolism of purine nucletide -1.84 - 
DDX17 Probable ATP-dependent RNA helicase DDX17  double-stranded DNA break repair -1.39 - 
XRCC5 X-ray repair cross-complementing protein 5  double-stranded DNA break repair -2.19 - 
XRCC6 X-ray repair cross-complementing protein 6  double-stranded DNA break repair -1.29 - 
DDX1 ATP-dependent RNA helicase DDX1  double-stranded DNA break repair -1.39 - 
PCNA Proliferating cell nuclear antigen processivity factor for DNA replication -1.56 - 
TRIM28 Transcription intermediary factor 1-beta  repair of DNA -1.67 - 
VIM Vimentin morphology of nuclear matrix -1.54 - 
GSTP1 Glutathione S-transferase P  joining of DNA -1.21 - 
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2  annealing of RNA -1.64 - 
HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2  metabolism of DNA -1.43 - 
LMNB1 Lamin-B1  interaction with chromatine -1.54 - 
DCXR L-xylulose reductase metabolism of purine nucletides -1.51 - 
MYH9 Myosin-9  catabolism of ATP -1.41 - 
LDHA  L-lactate dehydrogenase A chain  concentration of ATP 1.47 - 
FASN Fatty acid synthase  metabolism of nucleotide -1.28 - 
TALDO1 Transaldolase  metabolism of nucleotide -1.53 - 
PGLS 6-phosphogluconolactonase  pentose shunt of D-glucose -1.47 - 
VDAC3 Voltage-dependent anion-selective channel transport of adenin -1.85 - 
158 
 
protein 3  
ATIC  Bifunctional purine biosynthesis protein PURH  
metabolism of nucleotide acid 
component or derivate -1.26 1.808694803 
MCM2 DNA replication licensing factor MCM2 unwinding DNA -1.92 2.118732976 
MCM5 DNA replication licensing factor MCM5  unwinding DNA -1.89 2.289314331 
MCM7 DNA replication licensing factor MCM7 unwinding DNA -1.52 2.200014921 
MCM3 DNA replication licensing factor MCM3 unwinding DNA - 2.694198068 
MCM4  DNA replication licensing factor MCM4  unwinding DNA - 2.892855431 
MCM6 DNA replication licensing factor MCM6  unwinding DNA - 2.308368053 
ADSS Adenylosuccinate synthetase isozyme 2  
purine Nucleotides De Novo 
Biosynthesis II 
- 
1.506368023 
LMNA Prelamin-A/C  fragmentation of heterochromatin DNA - 1.415791614 
RRM1 
Ribonucleoside-diphosphate reductase large 
subunit  depletion of mitocondrial DNA 
- 
1.450368774 
CHMP2A Charged multivesicular body protein 2a  segregration of chromosomes  - 3.694267782 
TYMS Thymidylate synthase  thymidylate synthesis - 2.400240441 
CRYZ Quinone oxidoreductase  DNA damage - -1.507881316 
HSPB1 Heat shock protein beta-1  DNA damage - -1.986877817 
PRKDC DNA-dependent protein kinase catalytic subunit DNA damage - -1.97900253 
SMARCA1 Probable global transcription activator SNF2L1  DNA damage - -Infinity 
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CHAPTER 8 
 
Conclusion  
and  
Future Work  
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8.1  Conclusion 
 
This project is focused on the characterization of the folate-related gene MTHFD1L 
starting from its previous association with NTD risk (Parle-McDermott et al. 2009). Figure 
8.1 depicts a schematic representation of the project that started from the NTD associated 
polymorphisms clustered in two regions of MTHFD1L. Region “a” inspired the cleft risk 
association study and the cycloleucine experiment. SNP rs7646 within region “b” led to 
the miRNA and ncRNA investigation. The final protein expression experiment was 
performed to corroborate our results and provide a better insight into MTHFD1L’s role in 
disease. 
 
In summary, MTHFD1L polymorphisms have been studied in relation to cleft disease. 
TDT analysis showed an association between DIP rs3832406 and CLP cases. However, 
adjustment of our analyses resulted in loss of statistical significance indicating that this 
variant is simply not associated with CLP or that a larger sample size is required to detect 
an effect. We suggest further screening of rs3832406 DIP in a larger cohort and describe a 
new assay that will facilitate this. We also demonstrated that the modified Melting Curve 
Analysis developed for DIP rs3832406 is a valid alternative to capillary electrophoresis for 
the genotyping of multiple allele deletion/insertion polymorphisms.  
 
We identified a novel direct interaction between the MTHFD1L 3′ UTR and miR-197 in 
MCF-7 and HEK293 cell lines. This is the second miRNA to be identified as a regulator of 
MTHFD1L, along with miR-9 (Selcuklu et al. 2012). We verified that miR-197 
downregulates MTHFD1L and that SNPrs7646 within MTHFD1L 3′UTR significantly 
changes miR-197 binding affinity. This provides a functional explanation as to why we 
previously found SNP rs7646 to be associated with NTDs in an Irish population (Parle-
McDermott et al. 2009) (Figure 8.1). Our results also suggested that pre-9 and pre-197 
directed downregulation of MTHFD1L could be affected by the competitive binding 
behaviour of both miRNAs. Moreover, our data also indicates that miR-9 may target other 
folate genes including DHFR, DHFRL1, SHMT1 and MTR. This putative role of miR-9 
along with its involvement in neurogenesis further highlights that this miRNA warrants 
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further investigation in relation to NTD and other neuro-developmental diseases. miRNA 
regulation provides an elegant mechanism to co-ordinately regulate enzymes from the 
same pathway and the association of rs7636 with NTDs emphasises the importance of this 
regulation during development.   
 
Sequence analysis was performed to discover and characterize MTHFD1 and MTHFD1L 
similar sequences. A ncRNA transcribed from CHRX was shown to downregulate 
MTHFD1 mRNA and the formation of DNA-RNA triplex could have a role in this effect. 
This part of the project brought interesting cues for future work.  
 
We also demonstrated that MTHFD1L expression is affected by a 24-hour exposure to 
cycloleucine in lymphoblast cells. Results suggest that this regulation operates through the 
alternative splicing of the gene (Figure 8.1). These findings further support our hypothesis 
of the pivotal role played by alternative splicing in controlling the level of MTHFD1L.  
  
Finally, a proteomic analysis demonstrated that MTHFD1L levels affect the nuclear 
thymidylate biosynthesis complex and other proteins involved in DNA replication and 
repair. We proposed that an increased formate production may be a signal for uncontrolled 
cell proliferation that triggers defensive mechanisms like the inhibition of nuclear 
thymidylate biosynthesis and DNA replication and repair. On the other hand, a 
downregulation of MTHFD1L has been linked with an increased DNA damage. These data 
suggest that nucleotide biosynthesis and DNA replication and repair are sensitive to 
changes in formate production from the mitochondria. Formate supply may act as a 
‘sensor’ to ensure that there is a balanced supply of nucleotides for DNA replication and 
repair and to prevent uracil misincorporation.  
 
Formate is a pivotal component of 1C metabolism and, despite its importance, our 
knowledge of its direct involvement with disease is still limited. A 7-fold increase in 
formate was detected in the serum and urine of vitamin B12 deficient rats and a similar 
increase predicted for folate deficiency (Lamarre et al. 2012). Furthermore, increased 
formate levels have been identified in advance stage oesophageal cancer compared to 
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normal mucosae (Wang et al. 2013). Another key factor to understand the role of formate 
is the mechanism that transports this metabolite through the cellular compartments. Little 
is known about formate transport across the mitochondrial inner membrane. Formate is 
known to enter intact mitochondria, as suggested by swelling assays. It also effluxes 
rapidly from mitochondria, both in vivo (in yeast) and in vitro (Tibbets and Appling 2010). 
High concentrations of formate in mitochondria is likely to be toxic to mitochondrial 
respiration via inhibition of cytochrome c oxidase (Nicholls 1975, Kapur et al. 2007, this 
study) suggesting that formate transport is carrier mediated. Therefore, to better understand 
the role of formate in disease it is fundamental to increase our comprehension on how 
formate is transported and compartmentalised. 
 
Altogether, our findings suggest that maintaining MTHFD1L and, consequently, formate 
levels within a determined range might be crucial for the health of the cell. This prompts 
further investigation into how this signal, via subcellular formate concentration, is 
translated into a wide cellular response. The study of broad cellular regulators like c-myc 
oncogene and E2F1 transcription factor may provide an answer to this question. Indeed, 
bioinformatic analysis on the proteomic data showed a significant match between c-myc 
and E2F1 targeted proteins and the protein dataset resulting from MTHFD1L inhibition 
(IPA software) (Figure 8.2). The c-myc oncogene, which is a crucial transcription factor in 
the control of cell proliferation, differentiation, and apoptosis, was proposed as an 
MTHFD1L regulator by Sugiura et al. (2004). Both mitochondrial proteins SHMT2 
(Nikiforov et al. 2002) and MTHFD1L (Tavtigian et al. 1994, Sugiura et al. 2004) seem to 
be responsive to the expression of c-myc in mammalian cells. A c-myc consensus 
sequence (CACGTG) is also present in the first intron of both SHMT2 and MTHFD1L 
genes. Evidence of c-myc regulation of the cytosolic MTHFD1 has also been reported 
(Mao et al. 2003, Carroll et al. 2009). Thus, studying the impact of formate levels in 
different cellular compartments on c-myc and E2F1 regulation may explain how 
MTHFD1L expression changes result in a wide cellular response. This could add another 
piece to the puzzle of understanding folate-mediated 1C metabolism and its relationship to 
disease.  
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In conclusion, this study investigated MTHFD1L common genetic variants in relation to 
cleft disease and how polymorphisms can affect regulation of MTHFD1L levels and the 
subsequent risk of disease. The impact of alternative splicing on MTHFD1L expression 
and the potential function of additional homologous sequences has also been investigated. 
These data have been corroborated by proteomic analysis on samples with different 
MTHFD1L expression levels. On the tenth anniversary of the first characterisation of 
MTHFD1L (Prasannan et al. 2003), these findings provide relevant insights into the role 
played by MTHFD1L inside the cell and pave the way for future investigations on the 
signalling effect of formate.  
 
8.2 Future work 
 
8.2.1 Transcription factors responsive to formate levels  
 
The future work will address the open issues mentioned above. Bioinformatic analysis will 
be performed to select possible candidates for the role of a formate transporter, taking 
advantage of our proteomic data and other folate related analysis. In a similar way, 
database analysis will focus on potential transcription factors and regulators, such as c-myc 
and E2F1. Depending on the results of in silico analysis, we will decide which experiments 
to carry out in the wet lab.   
 
8.2.2 Putative thymidylate biosynthesis complex in mitochondria 
 
In the nucleus, SHMT1, TYMS, DHFR, MTHFD1 and other proteins form a thymidylate 
biosynthesis complex associated with the nuclear lamina (Anderson et al. 2012, Chapter 7, 
Section 7.4). Similarly, we will investigate a possible formation of a multi enzymatic 
complex in the mitochondria by using co-immunoprecipitation experiments and tandem 
affinity purification. For these experiments we will employ monoclonal antibodies for 
MTHFD1L and DHFRL1 and we will carry out LC-MS analysis to identify the proteins 
belonging to the complex. DHFRL1 was a formerly annotated pseudogene and, only 
recently, was proven to be a functional protein by our laboratory, in a publication that I 
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made a major contribution to (McEntee, Minguzzi et al. 2011). Taking advantage of the 
work already accomplished, we will generate single cell clones with DHFRL1 knocked-
down and overexpressed. Proteomic analysis will be carried out in the same way as for 
MTHFD1L. Mitochondrial and nuclear protein extracted from DHFRL1 and MTHFD1L 
may be also specifically screened using LC-MS analysis. LC-MC instrument may be also 
used for metabolic analysis using the above-mentioned samples. 
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Figure 8.1 Schematic representation of the whole project (figure drawn with 
Microsoft PowerPoint). 
The scheme represents the project starting from the previous NTD risk association study 
(Parle-McDermott et al. 2009). DIP rs3832406 within region “a” inspired the cleft risk 
association study and the cycloleucine experiment. SNP rs7646 within region “b” led to 
the miRNA and ncRNA investigation. The final protein expression experiment was 
performed to corroborate our results and provide a better insight of MTHFD1L in relation 
to disease. 
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Figure 8.2 Bioinformatic analysis on the MTHFD1L overexpression dataset using 
IPA software. 
The table shows a list of cellular regulators predicted to regulate the proteins affected by 
MTHFD1L overexpression. The regulators are listed in order of significance.  
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Appendix A  
Vector map for pME1SFL3. The image was taken from Invitrogen and it is available at 
http://www.nbrc.nite.go.jp/vector_FIG.html 
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Appendix B  
Vector map for pDONR™221. The image was taken from Invitrogen and it is available 
at http://tools.invitrogen.com/content/sfs/vectors/pdonr221_pdonrzeo_map.pdf  
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Appendix C  
Vector map for pcDNA™3.2/V5-DEST. The image was taken from Invitrogen and it is 
available at http://tools.invitrogen.com/content/sfs/vectors/pcdnav5dest_map.pdf 
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Appendix D  
Vector map for Gateway® pDEST™15 Vector. The image was taken from Invitrogen 
and it is available at http://tools.invitrogen.com/content/sfs/vectors/pdest15_map.pdf 
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Appendix E  
Map for non target shRNA in pLK0.1 vector. The image was taken from Sigma and it is 
available at 
http://www.sigmaaldrich.com/catalog/product/sigma/shc002v?lang=en&region=IE  
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Appendix F  
Vector map for non target pLK_IPTG_1xLac0 vector. The image was taken from 
Sigma and it is available at http://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/Sigma-Aldrich/Vector/1/plko_iptg_1xlaco.pdf  
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Appendix G  
Vector map for non target pLK_IPTG_3xLac0 vector. The image was taken from 
Sigma and it is available at http://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/Sigma-Aldrich/Vector/1/plko_iptg_3xlaco.pdf  
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Appendix H  
Nucleotide sequence of MTHFD1L optimized for protein expression in mammalian 
cells. 
The sequence, which is cloned in pMA-RQ vector, was purchased from Invitrogen
®
 
(Chapter 2, Section 2.2.12). In bold there are the start codon and the stop codon of protein 
coding sequence. attB regions, necessary for Gateway recombination, are highlighted in 
yellow. Shine-Dalgarno and Kozak consensus sequence are highlighted in green and blue 
respectively. Inclusion of the Shine-Dalgarno and Kozak consensus sequence allows 
protein expression in both E. coli and mammalian cells.  
5′- 
gagctctctagaggggacaagtttgtacaaaaaagcaggcttcgaaggagatagagccaccatgggcaccagactgcccctggtgctgcggcagctgaga
aggcctccacagccccctggcccccctagaaggctgagagtgccttgcagagccagcagcggcggaggcggaggtggaggcggcggaagagaaggac
tgctgggccagagaaggccccaggacggccaggccagaagcagctgtagccctggcggcagaacccctgccgccagagacagcatcgtgcgggaagt
gatccagaacagcaaagaggtgctgagcctgctgcaggaaaagaaccccgccttcaagcccgtgctggccatcatccaggccggcgacgacaacctgatg
caggaaatcaaccagaacctggccgaggaagccggcctgaacatcacccacatctgcctgccccccgacagcagcgaggccgagatcatcgacgagatc
ctgaagatcaacgaggacacccgggtgcacggcctggccctgcagatcagcgagaacctgttcagcaacaaggtgctgaacgccctgaagcccgagaag
gacgtggacggcgtgaccgacatcaacctgggcaagctcgtgcggggcgacgcccacgagtgtttcgtgtctccagtggccaaggccgtgatcgagctgct
ggaaaagtccggcgtgaacctggacggcaagaaaatcctggtcgtgggagcccacggcagcctggaagccgccctgcagtgcctgttccagcggaaggg
cagcatgaccatgagcatccagtggaaaacccggcagctgcagagcaagctgcacgaggccgacatcgtggtgctgggctcccccaagcccgaggaaat
ccccctgacctggatccagcccggcaccaccgtgctgaactgcagccacgactttctgagcggcaaagtgggctgtggcagccccagaatccacttcggcg
gcctgatcgaagaggacgacgtgatcctgctggccgctgccctgagaatccagaacatggtgtccagcggcagacggtggctgagagagcagcagcaca
gaagatggcggctgcactgcctgaagctgcagcccctgagccccgtgcccagcgacatcgagatcagcagaggccagacccctaaggccgtggatgtgct
ggccaaagagatcggactgctggccgacgagatcgagatctacggcaagagcaaggccaaagtgcggctgagcgtgctggaacggctgaaggaccagg
ccgacggcaaatacgtgctggtggccggcatcacccccacccctctgggcgagggcaagagcaccgtgaccatcggactggtgcaggccctgaccgccc
acctgaacgtgaacagcttcgcctgcctgcggcagcccagccagggccctacatttggagtgaagggcggagccgctggcggcggatatgcccaggtcat
ccccatggaagagttcaacctgcacctgaccggcgacatccacgccatcaccgccgccaacaatctgctggctgccgccatcgacacccggatcctgcacg
agaacacccagaccgacaaggccctgtacaaccggctggtgcccctggtcaacggcgtgcgcgagttcagcgagatccagctggcccggctgaagaagc
tgggcatcaacaagaccgaccccagcaccctgaccgaggaagaggtgtccaagttcgcccggctggacatcgacccctccaccatcacctggcagcgggt
gctggataccaacgaccggttcctgcggaagatcaccatcggccagggcaacaccgagaagggccactaccggcaggcccagttcgatatcgccgtggcc
agcgagatcatggccgtgctggcactgaccgacagcctggccgacatgaaggcccggctgggcagaatggtggtggcctccgataagagcggccagccc
gtgaccgccgacgatctgggagtgacaggcgccctgaccgtgctgatgaaggacgccatcaagcccaatctgatgcagaccctggaaggcacccccgtgtt
cgtgcacgccggacccttcgccaatatcgcccacggcaacagcagcgtgctggccgataagattgccctgaagctcgtgggcgaagagggcttcgtggtca
ccgaggccggctttggcgccgacatcggcatggaaaagttcttcaacatcaagtgccgggccagcggcctggtgcccaacgtggtggtgctggtcgccaca
gtgcgggccctgaagatgcacggcggaggcccatctgtgacagccggcgtgcccctgaagaaagagtacaccgaagagaacatccagctggtggctgac
ggctgctgcaacctgcagaagcagatccagatcacccagctgttcggcgtgcccgtggtggtggctctgaacgtgttcaagaccgataccagagccgagatc
gacctcgtgtgcgagctggccaagcgggctggcgccttcgatgccgtgccctgctatcattggagcgtgggcggcaagggcagcgtggacctggccagag
ccgtcagagaggccgccagcaagcggagccggttccagttcctgtacgacgtgcaggtccccatcgtggacaagatccggacaatcgcccaggccgtgta
cggcgccaaggacatcgagctgagccccgaggcccaggccaagatcgacagatacacccagcagggcttcggcaacctgcccatctgcatggccaagac
ccacctgagcctgagccaccagcccgacaagaaaggcgtgccccgggacttcatcctgcccatcagtgacgtgcgggccagcatcggagccggcttcatct
accccctcgtgggcaccatgagcaccatgcccggcctgcccacccggccctgcttctacgacatcgacctggacaccgagacagagcaggtcaaaggcct
gttctaagacccagctttcttgtacaaagtggtcccctctagaggtacc -3′ 
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Appendix I  
Sanger sequencing result for pcDNA3.2- MTHFD1Lopt using T7 For primer (Table 2.4).  
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Appendix J  
Sanger sequencing result for pcDNA3.2- MTHFD1Lopt using MTHFD1Lopt2 For primer (Table 2.4).  
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Appendix K   
Sanger sequencing result for pcDNA3.2- MTHFD1Lopt using MTHFD1Lopt For primer (Table 2.4).  
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Appendix L   
Sanger sequencing result for pcDNA3.2- MTHFD1Lopt using MTHFD1Lopt4 For primer (Table 2.4).  
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Appendix M  
Sanger sequencing result for pDEST15-750 ORF using T7 Promoter For primer (Table 2.4).  
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Appendix N  
Sanger sequencing result for pDEST15-750 ORF using T7 Terminator Rev primer (Table 2.4).  
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Appendix O  
Sanger sequencing result for pcDNA3.2-CHRX 3′UTR using T7 Promoter For primer (Table 2.4).  
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195 
 
Appendix P  
Sanger sequencing result for NCBI 2 For/Rev PCR product using NCBI 2 For primer (Table 2.4).  
The amplified sequence spans exon 3 and 4 which are present in both ncRNAChr2 and ncRNAChr9 (Chapter 5, Figure 5.3a). The arrow 
marks the hedge between exon 3 and 4. 
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Appendix Q  
Sanger sequencing result for ncRNAChr2 using NCBI All For primer (Table 2.4). 
The sequence was amplified using NCBI All For/ NCBI2 Rev primers (Chapter 5, Figure 5.3). 
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Appendix R  
Sanger sequencing result for ncRNAChr9 using NCBI 5 For primer (Table 2.4). 
The sequence was amplified using NCBI 5 For/ NCBI2 Rev primers (Chapter 5, Figure 5.3). 
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200 
 
Appendix S  
Sanger sequencing result for DIP rs35337982 validation (Chapter 3, Section 3.3.3) using A insertion For For primer (Table 2.4). The 
arrow indicates the position of the hypothetical polymorphism, namely the insertion of an extra ‘A’.  
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Appendix T   
Sanger sequencing result for CHRX 7For/4Rev band (Chapter 5, Figure 5.11) using CHRX 7For primer (Table 2.4). 
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Appendix U  
Sanger sequencing result for CHRX 5For/5Rev band (Chapter 5, Figure 5.11) using CHRX 5For primer (Table 2.4). 
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Appendix V  
Sanger sequencing result for CHRX 3For/3Rev band (Chapter 5, Figure 5.11) using CHRX 3For primer (Table 2.4). 
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Appendix W  
Sanger sequencing result for CHRX 6For/6Rev band (Chapter 5, Figure 5.11) using CHRX 6For primer (Table 2.4). 
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Appendix X  
Sanger sequencing result for CHRX 2For/2Rev band (Chapter 5, Figure 5.11) using CHRX 2For primer (Table 2.4). 
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Appendix Y  
Sanger sequencing result for CHRX 1For/3′UTR 2nd Rev band (Chapter 5, Figure 5.11) using CHRX 1For primer (Table 2.4). 
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Appendix Z  
MTHFD1L and Chr11seq sequence alignment made using CLUSTALW (Chapter 2, 
Section 2.2.14.3).  
Position of the primer CHR11 AFor and CHR11 ARev are highlighted in yellow and 
green, respectively. 
SeqA Name           Len(nt)  SeqB   Name           Len(nt)  Score 
================================================================== 
1    CHR11           1287     2    MTHFD1L           1291     88   
================================================================== 
 
 
CHR11           CTGATGCAGACCCTGGAATGGACACCTGTATTCATGCACGTGGGCCCTTTTGCTAACATC 60 
MTHFD1L         CTGATGCAGACCCTGGAAGGGACACCTGTGTTCGTGCATGCGGGCCCTTTTGCTAACATT 60 
                ****************** ********** *** **** * ******************  
 
CHR11           ACCCATGGCAATTCTTCAGTGTTGGCTGACAAAATTGCCCTGAAACTGGTTGGTGAAGAA 120 
MTHFD1L         GCTCACGGCAACTCTTCAGTGTTGGCTGATAAAATTGCCCTGAAACTGGTTGGTGAAGAA 120 
                 * ** ***** ***************** ****************************** 
 
CHR11           GGATTTGTAGTGACTGAAGCTGGCTTTGGTGCTGACATTGAAATGGAGAAATTTTTCAAC 180 
MTHFD1L         GGATTTGTAGTGACCGAAGCTGGCTTTGGTGCTGACATCGGAATGGAGAAATTCTTCAAC 180 
                ************** *********************** * ************ ****** 
 
CHR11           A---AGTGTCAAGCTTCCAGCTTGGTGCCCAGTGTGGTTGTGTTGGTGGCAACGGTGCAA 237 
MTHFD1L         ATCAAGTGCCGAGCTTCCGGCTTGGTGCCCAACGTGGTTGTGTTAGTGGCAACGGTGCGA 240 
                *   **** * ******* ************  *********** ************* * 
 
CHR11           GCTCTGAAGATGCACAGTGGCGGGCCAAGTGTAACTGCTGGTGTTCCTCTGAAGAAAGAA 297 
MTHFD1L         GCTCTGAAGATGCATGGAGGCGGGCCAAGTGTAACGGCTGGTGTTCCTCTTAAGAAAGAA 300 
                **************  * ***************** ************** ********* 
 
CHR11           CATAAAGAAAAGAACATCCAGTTGGTGGCAGATGGCTGCCGTAACCTCTAGCAGCAAATT 357 
MTHFD1L         TATACAGAGGAGAACATCCAGCTGGTGGCAGACGGCTGCTGTAACCTCCAGAAGCAAATT 360 
                 *** ***  *********** ********** ****** ******** ** ******** 
 
CHR11           CAGATTGCTCAGCTCTTTGGGGTTCCCATTATGGTGACTCTGAAGGTCTTCAAGATCCAC 417 
MTHFD1L         CAGATCACTCAGCTCTTTGGGGTTCCCGTTGTGGTGGCTCTGAATGTCTTCAAGACCGAC 420 
                *****  ******************** ** ***** ******* ********** * ** 
 
CHR11           ACCGGTGCTGAGATTGACTTGGTGTGTGAGCTCACAAAACGGGCTGGTGCCTTTGATGCA 477 
MTHFD1L         ACCCGCGCTGAGATTGACTTGGTGTGTGAGCTTGCAAAGCGGGCTGGTGCCTTTGATGCA 480 
                *** * **************************  **** ********************* 
 
CHR11           GTCCCTTGCTATCACTGGTCAGTTGGTAGAAAACGGTTG-CGGACTTGGCTTGGGCTTTG 536 
MTHFD1L         GTCCCCTGCTATCACTGGTCCGTTGGTGGAAAAGGATCGGTGGACTTGGCTCGGGCTGTG 540 
                ***** ************** ****** ***** * * *  ********** ***** ** 
 
CHR11           AGAGAAGCTGCAAGTAAAAGAAGTTGATTCCATTTCCCGTATGATGTTCAGCTTCCAATT 596 
MTHFD1L         AGAGAGGCTGCGAGTAAAAGAAGCCGATTCCAGTTCCTGTATGATGTTCAGGTTCCAATT 600 
                ***** ***** ***********  ******* **** ************* ******** 
 
CHR11           GTGGAAAAGATAAGAACCATGGCCCTGGCTGTCTATGGAGCCAACGATATCCAGCTCTCT 656 
MTHFD1L         GTGGACAAGATAAGGACCATTGCTCAGGCTGTCTATGGAGCCAAAGATATTGAACTCTCT 660 
                ***** ******** ***** ** * ****************** *****  * ****** 
 
CHR11           CCTGAGGCACAAACCAAAATAGATTGTTAACACTCAACAGGGTTTCAGAAATTTGCCCAT 716 
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MTHFD1L         CCTGAGGCACAAGCCAAAATAGATCGTTA-CACTCAACAGGGTTTTGGAAATTTGCCCAT 719 
                ************ *********** **** ***************  ************* 
 
CHR11           CTGCATGGCAAGGACCCACCTTTCTCTGTCTCACCAACCTGCCAAAAAAT-TGTGCCAAG 775 
MTHFD1L         CTGCATGGCAAAGACCCACCTTTCTCTATCTCACCAACCTGACAAAAAAGGTGTGCCAAG 779 
                *********** *************** ************* *******  ********* 
 
CHR11           GGACTTCATTGTACCTCTCAGTGATGTCAAGGCCAGCATAGGTGCTGGGTTCATTGGCCC 835 
MTHFD1L         GGACTTCATCTTACCTATCAGTGACGTCCGGGCCAGCATAGGCGCTGGGTTCATTTACCC 839 
                *********  ***** ******* ***  ************ ************  *** 
 
CHR11           TTTGGTTAGAACAATGAGCATCGTGCCAGGACTGCC-ACTTGGCCCTGCTTTCATGACAT 894 
MTHFD1L         TTTGGTCGGAACGATGAGCACCATGCCAGGACTGCCCACCCGGCCCTGCTTTTATGACAT 899 
                ******  **** ******* * ************* **  *********** ******* 
 
CHR11           AGACCTTGATATGGAAACAGAACAAATTAAAGCCTTGTTCTAAGTGAACAAGGCTTTCAT 954 
MTHFD1L         AGATCTTGATACCGAAACAGAACAAGTTAAAGGCTTGTTCTAAGTGGACAAGGCTCTCAC 959 
                *** *******  ************ ****** ************* ******** ***  
 
CHR11           AGGAATTGATTCAGGTTCCTGAAACAGACTCCTCCTTGCCTTTTTGCTGCAGTTAGAGAA 1014 
MTHFD1L         AGGACCCGATGCAGACTCCTGAAACAGACTACTCTTTGCCTTTTTGCTGCAGTTGGAGAA 1019 
                ****   *** ***  ************** *** ******************* ***** 
 
CHR11           GAAACTGAATTTTAAAAATGTCCTTTATGCAATGTTGGAGAAATGGTGAAATAGGTCAAG 1074 
MTHFD1L         GAAACTGAATTTGAAAAATGTCTGTTATGCAATGCTGGAGACGTGGTGAAATAGGCCAAA 1079 
                ************ *********  ********** ******  ************ ***  
 
CHR11           GATTTCTTCCTCATTGAAGGTGTATCCTATTCACAACAGAGTATAGTGTTCAGCAAAAGG 1134 
MTHFD1L         GATTTCTTCTTCGTTCAAGATGAATTCTGTTCACAGTGGAGTATGGTGTTCGGCAAAAGG 1139 
                ********* ** ** *** ** ** ** ******   ****** ****** ******** 
 
CHR11           ACCTCCACCAAGTCTGAAAAAAAATAATTTACTTAAGTTTCAATAGAGTTTACATTATTT 1194 
MTHFD1L         ACCTCCACCAAGACTGAAAGAAACTAATTTATTTCTGTTTCTGTGGAGTTTCCATTATTT 1199 
                ************ ****** *** ******* **  *****  * ****** ******** 
 
CHR11           CTACTGCTTACACTTTAGAATGTTAATTTTATGGG-ACTAAGGGATTAAAAGAGTGTGAA 1253 
MTHFD1L         CTACTGCTTACACTTTAGAATGTTTATTTTATGGGGACTAAGGGATTA--GGAGTGTGAA 1257 
                ************************ ********** ************   ********* 
 
CHR11           CTACAAGGTAACATTTTCCACTCTTGAGTTTTCT 1287 
MTHFD1L         CTAAAAGGTAACATTTTCCACTCTCAAGTTTTCT 1291 
                *** ********************  ******** 
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Appendix AA  
MTHFD1 mRNA and ChrXseq sequence alignment performed using CLUSTALW 
(Chapter 2, Section 2.2.14.3).  
Position of the primers are highlight as follows: ChrX 5For (gray), ChrX 6For/ ChrX 5Rev 
(purple), ChrX 7For/ ChrX 6Rev (red), ChrX 3For/ ChrX 4Rev (light blue), ChrX 2For/ 
ChrX 3Rev (green), ChrX 1For/ ChrX 2Rev (yellow),  ChrX 3′UTR For (gold), ChrX 
3′UTR 2nd Rev (underlined). All the reverse primers were designed on the antisense strand. 
CLUSTAL 2.1 Multiple Sequence Alignments 
 
Sequence 1: MTHFD1      3466 bp 
Sequence 2: ChrXseq     3005 bp 
 
 
MTHFD1          AATTACGGCCGGATTCCGGAGTCCTTTCCAGCTCCCTCTTCGGCCGGGTTTCCCGCCGAA 
ChrXseq         ------------------------------------------------------------ 
                                                                             
 
MTHFD1          TACAAAGGCGCACTGTGAACTGGCTCTTTCTTTCCGCCAATCATTTCCGCCAGCCATTCA 
ChrXseq         ------------------------------------------------------------ 
                                                                             
 
MTHFD1          TCACCGATTTTCTTCATCTTCCCCTCCCTCTTCCGTCCCGCAGTCCCCGACCTGTTAGCT 
ChrXseq         ------------------------------------------------------------ 
                                                                             
 
MTHFD1          CTCGGTTAGTTAAGGGACTCGGGTCCTTCCGAACTGCGCATGCGCCACCGCGTCTGCAGG 
ChrXseq         ------------------------------------------------------------ 
                                                                             
 
MTHFD1          GGGAGAAGCGGGCAGGGGCGCAGGCGCAGTAGTGTGATCCCCTGGCCAGTCCCTAAGCAC 
ChrXseq         ------------------------------------------------------------ 
                                                                             
 
MTHFD1          GTGGGTTGGGTTGTCCTGCTTGGCTGCGGAGGGAGTGGAACCTCGATATTGGTGGTGTCC 
ChrXseq         --------------------------------------------GATATTGGTGGTGTCC 
                                                            **************** 
 
MTHFD1          ATCGTGGGCAGCGGACTAATAAAGGCCATGGCGCCAGCAGAAATCCTGAACGGGAAGGAG 
ChrXseq         ATCGTGGGCAGCAGACTAATAAAGGCCATGGCACCAGCAGAAATCCTGAACAGGAAGGAG 
                ************.*******************.******************.******** 
 
MTHFD1          ATCTCCGCGCAAATAAGGGCGAGACTGAAAAATCAAGTCACTCAGTTGAAGGAGCAAGTA 
ChrXseq         ATCTCCGCACAAATAAGGGCGAGACTGAAGAATCAAGTCACTCAGTTGAAG-GACAAGTA 
                ********.********************.********************* ..****** 
 
MTHFD1          CCTGGTTTCACACCACGCCTGGCAATATTACAGGTTGGCAACAGAGATGATTCCAATCTT 
ChrXseq         CCTGGTTTCACACCAGGCCTGGCAATATTACAGGTTGGCAACAGAGATGATTCCAATCTT 
                *************** ******************************************** 
 
MTHFD1          TATATAAATGTGAAGCTGAAGGCTGCTGAAGAGATTGGGATCAAAGCCACTCACATTAAG 
ChrXseq         TATATAATG-TGAAGCTGAAGGCTGCTGAAGAGATTGGGATGAAAGCCACTGACATTAAG 
                *******:  ******************************* ********* ******** 
 
MTHFD1          TTACCAAGAACAACCACAGAATCTGAGGTGATGAAGTACATTACATCTTTGAATGAAGAC 
ChrXseq         TTACCAAGAACAACCACAGAATCTGAGGTGATCAAGTACATCATATCTTTGAATGAAGAC 
212 
 
                ******************************** ******** * **************** 
 
MTHFD1          TCTACTGTACATGGGTTCTTAGTGCAGCTACCTTTAGATTCAGAGAATTCCATTAACACT 
ChrXseq         TCTACTGTACACGGGTTCGTAGTGCAGCTATCTCTAGACTCAGACAAT-------ACACT 
                *********** ****** *********** ** **** ***** ***       ***** 
 
MTHFD1          GAAGAAGTGATCAATGCTATTGCACCCGAGAAGGATGTGGATGGATTGACTAGCATCAAT 
ChrXseq         GAAGGAGTGATCAATGCTATTGCACCTGAAAAGGATGTGGATGGATTGACTAGCATCAGT 
                ****.********************* **.****************************.* 
 
MTHFD1          GCTGGGAAACTTGCTAGAGGTGACCTCAATGACTGTTTCATTCCTTGTACGCCTAAGGGA 
ChrXseq         GCTGGGAAACTTGCTAGAGGTGACCTAAATGACTGTTTCATTCCTTGTATGCCTAAAGGA 
                **************************.********************** ******.*** 
 
MTHFD1          TGCTTGGAACTCATCAAAGAGACAGGGGTGCCGATTGCCGGAAGGCATGCTGTGGTGGTT 
ChrXseq         TGCTTGGAACTCATGAAAGAGACAGGGGTGCAGATTGCCAGAAGGCATGCTGTGGTGGTT 
                ************** ****************.*******.******************** 
 
MTHFD1          GGGCGCAGTAAAATAGTTGGGGCCCCGATGCATGACTTGCTTCTGTGGAACAATGCCACA 
ChrXseq         GGGTGCAGTAAAATAGTCAGGGCCCTGATGCGTGACTTGCTTCTGTGGAACAATGCCACA 
                *** ************* .****** *****.**************************** 
 
MTHFD1          GTGACCACCTGCCACTCCAAGACTGCCCATCTGGATGAGGAGGTAAATAAAGGTGACATC 
ChrXseq         GTGACCACCTGCCACTCCAAGACTGCCAATCTGGATGAGGAGGTAAATAAAGGCGACATC 
                ***************************.************************* ****** 
 
MTHFD1          CTGGTGGTTGCAACTGGTCAGCCTGAAATGGTTAAAGGGGAGTGGATCAAACCTGGGGCA 
ChrXseq         CTGGTGGTTGCAACTGGTCGGCCTGAAATGGTTAAAGGGGAATGGATCAAACCTAG--CA 
                *******************.*********************.************.*  ** 
 
MTHFD1          ATAGTCATCGACTGTGGAATCAATTATGTCCCAGAT-GATAAAAAACCAAATGGGAGAAA 
ChrXseq         ATAGTCATCAACTGTGGAATCAATTATGTCCCAGATGATAAAAAAAACAAATGGGAGAAA 
                *********.************************** .::******.************* 
 
MTHFD1          AGTTGTGGGTGATGTGGCATACGACGAGGCCAAAGAGAGGGCGAGCTTCATCACTCCTGT 
ChrXseq         AGTTGTGGGTGATGTGGCATACGACGAG--------------------------GCCCGT 
                ****************************                           ** ** 
 
MTHFD1          TCCTGGCGGCGTAGGGCCCATGACAGTTGCAATGCTCATGCAGAGCACAGTAGAGAGTGC 
ChrXseq         TCCTGGTGGCTTAGGGCTCATGACGGTTGCAATGCTCATGCAGAGCACTGTAGAGAGTGC 
                ****** *** ****** ******.***********************:*********** 
 
MTHFD1          CAAGCGTTTCCTGGAGAAATTTAAGCCAGGAAAGTGGATGATTCAGTATAACAACCTTAA 
ChrXseq         CAAGCGTTTCCTGGAGAAATTTAAGCCAGGAAAGTGGATGATTCAGTATAACAACCTTAA 
                ************************************************************ 
 
MTHFD1          CCTCAAGACACCTGTTCCAAGTGACATTGATATATCACGATCTTGTAAACCGAAGCCCAT 
ChrXseq         CCTCAAGACACCTGTTCCAAGTGACATTGATATATCACGATCTTGTAAACCGAAGCCCAT 
                ************************************************************ 
 
MTHFD1          TGGTAAGCTGGCTCGAGAAATTGGTCTGCTGTCTGAAGAGGTAGAATTATATGGTGAAAC 
ChrXseq         TGGTAAGCTGGCTTGAGTAATTGGTCTGCTGTCTGAAGAGGTAGAATTATATGGTGAAAC 
                ************* ***:****************************************** 
 
MTHFD1          AAAGGCCAAAGTTCTGCTGTCAGCACTAGAACGCCTGAAGCACCGGCCTGATGGGAAATA 
ChrXseq         AAAGGCCAAAGTTCTGCTGTCAGCACTAGAACGCCTGAAGCACCAGCCTGTTGGGAAATA 
                ********************************************.*****:********* 
 
MTHFD1          CGTGGTGGTGACTGGAATAACTCCAACACCCCTGGGAGAAGGGAAAAGCACAACTACAAT 
ChrXseq         TCAGGTGGTGACTGGAATAACTCCAACACCCCTGGGAGAAGGGAAAAGCACGACTACAAT 
                  :************************************************.******** 
 
MTHFD1          CGGGCTAGTGCAAGCCCTTGGTGCCCATCTCTACCAGAATGTCTTTGCGTGTGTGCGACA 
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ChrXseq         CGGGCTGGTGCAAGCCCTTCTTGCCCATCTTTACCAGAACTTTTTTATGTGTGTGCGACA 
                ******.************  ********* ********  * ***. ************ 
 
MTHFD1          GCCTTCTCAGGGCCCCACCTTTGGAATAAAAGGTGGCGCTGCAGGAGGCGGCTACTCCCA 
ChrXseq         GCCTTCTCAGGGCCCCACCTTTGGAATAAAAGGTGGTGTTGCAGGAGGCGGCTACTCCCA 
                ************************************ * ********************* 
 
MTHFD1          GGTCATTCCTATGGAAGAGTTTAATCTCCACCTCACAGGTGACATCCATGCCATCACTGC 
ChrXseq         GGTCATTCCTATGGAAGAGTTTAATCTTCACCTCACAGGTGACATCCATGCCATCACTGT 
                *************************** *******************************  
 
MTHFD1          AGCTAATAACCTCGTTGCTGCGGCCATTGATGCTCGGATATTTCATGAACTGACCCAGAC 
ChrXseq         ATCTAATAACCTTGTTGCTGCGGCTATTGATGCTCAGATATTTCATGAACTGACCCAGAC 
                * ********** *********** **********.************************ 
 
MTHFD1          AGACAAGGCTCTCTTTAATCGTTTGGTGCCATCAGTAAATGGAGTGAGAAGGTTCTCTGA 
ChrXseq         AGACAAGGCTACCTTTACTCATTTGGTGCCATCAGTAAATGGAGTGAGAAAGTTCTCTGA 
                **********. *****.**.*****************************.********* 
 
MTHFD1          CATCCAAATCCGAAGGTTAAAGAGACTAGGCATTGAAAAGACTGACCCTACCACACTGAC 
ChrXseq         TATCCACATACAAAGGTTAAACAGACTAGGCATTGACAAGACTGACTCTACCACACTGAC 
                 *****.**.*.********* **************.********* ************* 
 
MTHFD1          AGATGAAGAGATAAACAGATTTGCAAGATTGGACATTGATCCAGAAACCATAACTTGGCA 
ChrXseq         AGATGAAGAGATAAACAGATTTGCAAGATTGGACATTGATCCAGAAACCATAGCTTGGCA 
                ****************************************************.******* 
 
MTHFD1          AAGAGTGTTGGATACCAATGATAGATTCCTGAGGAAGATCACGATTGGACAGGCTCCAAC 
ChrXseq         AAGAGTGTTGAATACCAATGATAGATTCCTGAGGAAGATCACGATTGGACAGGCTCCAAC 
                **********.************************************************* 
 
MTHFD1          GGAGAAGGGTCACACACGGACGGCCCAGTTTGATATCTCTGTGGCCAGTGAAATTATGGC 
ChrXseq         GAAGAAAAGTCACACACAGACGGTCCACTTTGATATCTCTGTGGCCAGTGAAATTATGGC 
                *.****..*********.***** *** ******************************** 
 
MTHFD1          TGTCCTGGCTCTCACCACTTCTCTAGAAGACATGAGAGAGAGACTGGGCAAAATGGTGGT 
ChrXseq         TGTCCTGGCTCTCACCACTTCTCTAGAAGACAGGAGAGAGAGACTGGGCAAAATGGTGGT 
                ******************************** *************************** 
 
MTHFD1          GGCATCCAGTAAGAAAGGAGAGCCCGTCAGTGCCGAAGATCTGGGGGTGAGTGGTGCACT 
ChrXseq         GGCATCCAGTAAGAAAGGAGACCCCGTCAGTGCTGAAGATCTGGGGGTGAGTGGTGCATT 
                ********************* *********** ************************ * 
 
MTHFD1          GACAGTGCTTATGAAGGACGCAATCAAGCCCAATCTCATGCAGACACTGGAGGGCACTCC 
ChrXseq         GATAGTGCTTATGAAGGACACAATCAAGCCCAATCTCATGCAGAGATTGGAGGGCACTCC 
                ** ****************.************************ * ************* 
 
MTHFD1          AGTGTTTGTCCATGCTGGCCCGTTTGCCAACATCGCACATGGCAATTCCTCCATCATTGC 
ChrXseq         AGTGTTTGTCCATGCAGGCCCATTTGCCATCATCGCACACGGCAATTCCTCTATCATTGC 
                ***************:*****.*******:********* *********** ******** 
 
MTHFD1          AGACCGGATCGCACTCAAGCTTGTTGGCCCAGAAGGGTTTGTAGTGACGGAAGCAGGATT 
ChrXseq         AGACCGGATCACACTCTAGCTTGTTGGCCCAGAAGGGTTTGTAGTGACGGAGGCGGGATT 
                **********.*****:**********************************.**.***** 
 
MTHFD1          TGGAGCAGACATTGGAATGGAAAAGTTTTTTAACATCAAATGCCGGTATTCCGGCCTCTG 
ChrXseq         TGGAGCAGACATTGGAATAGAAAAGTTTCTTAACATCAAATCCCAGTATTCCGGTCTCCA 
                ******************.********* ************ **.********* *** . 
 
MTHFD1          CCCCCACGTGGTGGTGCTTGTTGCCACTGTCAGGGCTCTCAAGATGCACGGGGGCGGCCC 
ChrXseq         CCCTCACGTGGTGGTGCTTGTTGCCACTGTCAGCGCTCTAAAGATGCACAGGGGTGGCCC 
                *** ***************************** *****.*********.**** ***** 
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MTHFD1          CACGGTCACTGCTGGACTGCCTCTTCCCAAGGCTTACATACAGGAGAACCTGGAGCTGGT 
ChrXseq         TATGGTCACTGCTGGAATGCCTCTTCCCAAGGCTTACATAGAGGAGAACCTGGAGCTGGT 
                 * *************.*********************** ******************* 
 
MTHFD1          TGAAAAAGGCTTCAGTAACTTGAAGAAACAAATTGAAAATGCCAGAATGTTTGGAATTCC 
ChrXseq         TGAAAAAGGCTTCAGTAACTTGAAGAAACAAACTGAAAATGCCAGAATGTTTGGAATTCC 
                ******************************** *************************** 
 
MTHFD1          AGTAGTAGTGGCCGTGAATGCATTCAAGACGGATACAGAGTCTGAGCTGGACCTCATCAG 
ChrXseq         AGTAGTAGTGGCCGTGAATGCATTCAAGACAGATACAGAGACTGAGCTGGACCTCATCGG 
                ******************************.*********:*****************.* 
 
MTHFD1          CCGCCTTTCCAGAGAACATGGGGCTTTTGATGCCGTGAAGTGCACTCACTGGGCAGAAGG 
ChrXseq         CTGCCTTTCCAGAGAACAGAGGGCTTTTGATGCCGTGAAGTGCACTCACTGG-CAGAAGG 
                * **************** .******************************** ******* 
 
MTHFD1          GGGCAAGGGTGCCTTAGCCCTGGCTCAGGCCGTCCAGAGAGCAGCACAAGCACCCAGCAG 
ChrXseq         GGGCAAGGGTACCTTAGCCCTGGCTCAGGCTGTCCAGAGAGCAGGACAAGCACCCAGCAG 
                **********.******************* ************* *************** 
 
MTHFD1          CTTCCAGCTCCTTTATGACCTCAAGCTCCCAGTTGAGGATAAAATCAGGATCATTGCACA 
ChrXseq         CTTCCAACTCCTTTATGACCTCAAGCTCCCAGTTGAGGATAAAATCAGGATCATTGCACA 
                ******.***************************************************** 
 
MTHFD1          GAAGATCTATGGAGCAGATGACATTGAATTACTTCCCGAAGCTCAACACAAAGCTGAAGT 
ChrXseq         GAAGATCTATGGAGCAGACAACATTGAATTACTCCTCAAAGCTCAACACAAAGCTGAAGT 
                ****************** .************* * *.********************** 
 
MTHFD1          CTACACGAAGCAGGGCTTTGGGAATCTCCCCATCTGCATGGCTAAAACACACTTGTCTTT 
ChrXseq         CTACACAAAGCAGGGCTTTGGGAATCTCCCCATCTGCATGGCCAAAACACACTTGTCCTT 
                ******.*********************************** ************** ** 
 
MTHFD1          GTCTCACAACCCAGAGCAAAAAGGTGTCCCTACAGGCTTCATTCTGCCCATTCGCGACAT 
ChrXseq         GTCTCACAACCCAGAGCGAAAAGGTGTCCCTACAGGATTCATTCTGCCCATTCGCAACAT 
                *****************.******************.******************.**** 
 
MTHFD1          CCGCGCCAGCGTTGGGGCTGGTTTTCTGTACCCCTTAGTAGGAACGATGAGCACAATGCC 
ChrXseq         CCATGCCAGCATCGGGGCTGGTTTTCTGTACCCTTTAGTAGGAACGATGAGCACAAT--- 
                **. ******.* ******************** ***********************    
 
MTHFD1          TGGACTCCCCACCCGGCCCTGTTTTTATGATATTGATTTGGACCCTGAAACAGAACAGGT 
ChrXseq         -GGACTCCCCACCCAGCCCTGTTTTTATGATACTGATTTGGACCCTGAAACAGAACAGGT 
                 *************.***************** *************************** 
 
MTHFD1          GAATGGATTATTCTAAACAGATCACCATCCATCTTCAAGAAGCTACTTTGAAAGTCTGGC 
ChrXseq         GAATGGATCATTCTAAACAGATCATCATCCATCTTCAAGAAGCTACTTTGAAAATCTGGC 
                ******** *************** ****************************.****** 
 
MTHFD1          CAGTGTCTATTCAGGCCCACTGGGAGTTAGGAAGTATAAGTAAGCCAAGAGAAGTCAGCC 
ChrXseq         CAGTGTCTATTCAGGCCCACTGGGAGTTAGGAAGTATAAGGCAGCCAAGA---GTCAGCC 
                **************************************** .********   ******* 
 
MTHFD1          CCTGCCCAGAAGATCTGAAACTAATAGTAGGAGTTTCCCCAGAAGTCATTTTCAGCCTTA 
ChrXseq         CCTGCCCAGAAGATCTGAAACTAATAGTAGGAGTTTTCCCGGATGTCATTTTCAGCCTTA 
                ************************************ ***.**:**************** 
 
MTHFD1          ATTCTCATCATGTATAAATTAACATAAATCATGCATGTCTGTTTACTTTAGTGACGTTCC 
ChrXseq         ATTCTCATCGTGTATAAATTAACATAAATCATGC-------------------------- 
                *********.************************                           
 
MTHFD1          ACAGAATAAAAGGAAACAAGTTTGCCATCAAAAAAAAAAAAAAAAAA 
ChrXseq         ----------------------------------------------- 
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Appendix BB  
CLUSTALW alignment (Chapter 2, Section 2.2.14.3) of the following sequences: 
Chr9seq, Chr2seq, part of MTHFD1L.  
Chr9seq and Chr2seq were aligned with the part of MTHFD1L with similar sequence that 
correspond to exon 25, exon 26 and a part of flanking intron 26 (see Chapter 5, Figure 5.2). 
Position of the primers are highlight as follows: NCBI 5For (gray), NCBI All For (light 
blue), NCBI 2Rev (green), NCBI 2For (yellow). NCBI AllFor/Rev primers were designed 
to amplify both Chr2seq and Chr9seq but not MTHFD1L mRNA as NCBI 2Rev sits on 
MTHFD1L intronic region (underlined). NCBI All For/2Rev primers specifically amplify 
Chr2seq while NCBI 5For/2Rev primers specifically amplify Chr9seq (Chapter 5, Figure 
5.3a). 
CLUSTAL 2.1 Multiple Sequence Alignments 
 
Sequence 1: Chr9seq     2574 bp 
Sequence 2: Chr2seq     2028 bp 
Sequence 3: MTHFD1L     1937 bp 
 
 
Chr9seq         AGTGCTCCTGCTGACCTTCCCTGTCTGCAGCCCAGCTTTGGACTGTGGAGATGCCCTCAG 
Chr2seq         ------------------------------------------------------------ 
MTHFD1L         ------------------------------------------------------------ 
                                                                             
 
Chr9seq         CCTCTACTCAGTGGCTCCAGCCTCATATTTGCGTGCTATACCTTTAACCTCAAGTTCTCT 
Chr2seq         ------------------------------------------------------------ 
MTHFD1L         ------------------------------------------------------------ 
                                                                             
 
Chr9seq         TGCTGCTAACTTAAGCTGTGACTGTCCAGGACCTGCACACACACATACATGCACGCATGC 
Chr2seq         ------------------------------------------------------------ 
MTHFD1L         ------------------------------------------------------------ 
                                                                             
 
Chr9seq         ACACACACACACACACACACACACACACACACACAGAAGGTGAACACACAGGATGAGGCC 
Chr2seq         ------------------------------------------------------------ 
MTHFD1L         ------------------------------------------------------------ 
                                                                             
 
Chr9seq         CTGAAAACTCATTTCACCCGTGTACCTCACCCAAAAATTCCCCTTTGTACTCCTATCTTT 
Chr2seq         ------------------------------------------------------------ 
MTHFD1L         ------------------------------------------------------------ 
                                                                             
 
Chr9seq         ATCTCTAACTGACAGCATGAAGGTAGCCCGAAGTCCCCTCACCCTGTCTGTCCTCCTGAT 
Chr2seq         ------------------------------------------------------------ 
MTHFD1L         ------------------------------------------------------------ 
                                                                             
 
Chr9seq         TCTCTAGCCCAGTTCCCTCTAGCTCCAGCACAGACTCTTATCTCCAGCCCTGACTGCTGA 
Chr2seq         ------------------------------------------------------------ 
MTHFD1L         ------------------------------------------------------------ 
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Chr9seq         AACCCTCCAGCCCCAGCTCCAGCCCCTCAGGAGGGGACTGCGTGGGAGGAATGACTCCAG 
Chr2seq         ------------------------------------------------------------ 
MTHFD1L         ------------------------------------------------------------ 
                                                                             
 
Chr9seq         CAAGCCGGCAGCTGACCCGTCTCTGGCCTGCATGCCTCCCCCTGTGGTCCACTGCCGGTG 
Chr2seq         ------------------------------------------------------------ 
MTHFD1L         ------------------------------------------------------------ 
                                                                             
 
Chr9seq         GTCTTCAGCTCTCTCCTCGTCCCACCCCC-ATGGTCTGCTGACAGCCCAGCCCAGTGCAT 
Chr2seq         ----GCTGGTGCCACTTGAACCAAGTTCAGATGCACTGCCCAAAATAACATCCCTCGT-- 
MTHFD1L         ------------------------------------------------------------ 
                                                                             
 
Chr9seq         CCCTGCCATCTCTGCTCTACCGCTGGTCCTCCCAA-CAACCAACTTACAGCTTCCAATTG 
Chr2seq         -CCGGCCAGCAGTGCCGTGGAGACCGAGTTCTGAAGCAGGCCTTTGTGAGCTTCCAATTG 
MTHFD1L         --------------------------------------------------GTTCCAATTG 
                                                                   ********* 
 
Chr9seq         TGGACAAGATAAGGACCATTGCCCAGGCTGTCTATGGAGCCAAAGATATCGAACTCTGTC 
Chr2seq         TGGACAAGATAAGGACCATTGCCCAGGCTGTCTGTGGAGCCAAAGATATCGAACTCTGTC 
MTHFD1L         TGGACAAGATAAGGACCATTGCTCAGGCTGTCTATGGAGCCAAAGATATTGAACTCTCTC 
                ********************** ********** *************** ******* ** 
 
Chr9seq         CTGAGGCACAAGTCAAAATAGATCGTTACACTCAGCAGGGTTTTGGAAATTTGCCCATCT 
Chr2seq         CTGAGGCACAAGTCAAAATAGATCGTTACACTCAGCAGGGTTTTGGAAATTTGCCCATCT 
MTHFD1L         CTGAGGCACAAGCCAAAATAGATCGTTACACTCAACAGGGTTTTGGAAATTTGCCCATCT 
                ************ ********************* ************************* 
 
Chr9seq         GCATGGCAAAGACCGATCTTTCTCTGTCTCACCAACCTGACAAAAAAGGTGTGCCAAGGG 
Chr2seq         GCATGGCAAAGACCGACCTTTCTCTGTCTCACCAACCTGACAAAAAAGGTGTGCCAAGGG 
MTHFD1L         GCATGGCAAAGACCCACCTTTCTCTATCTCACCAACCTGACAAAAAAGGTGTGCCAAGGG 
                ************** * ******** ********************************** 
 
Chr9seq         ACTTCATCTTACCTATCAGTGATGTCCGGGCCAGCATAGGTGCTGGGTTCATTTACCCTT 
Chr2seq         ACTTCATCTTACCTATCAGTGATGTCCGGGTCAGCACAGACGCTGGGTTCATTTACCCTT 
MTHFD1L         ACTTCATCTTACCTATCAGTGACGTCCGGGCCAGCATAGGCGCTGGGTTCATTTACCCTT 
                ********************** ******* ***** **  ******************* 
 
Chr9seq         TGGTCGGAACGGTGCACCACTGACATCATGGCTCGGCTGGACTCTGGAAAGCAGGAAATT 
Chr2seq         TGGTCGGAACGGTGCACCACTGACATCATTGCTCGGCTGGACTCTGGAAAGCAGGAAATT 
MTHFD1L         TGGTCGGAACGGTGCACCACTGACATCATCGCTTGGCTGGACTCTGGAAAGCAGGAAACT 
                ***************************** *** ************************ * 
 
Chr9seq         GCTGGAGCATGTTTGGG-CATCAATGATGTCACCCGCTACGAATGCCGGGTGGGGTTACT 
Chr2seq         GCTGGAGCATGTTTGGGGCATCAGTGATGTCACCCGCTACGAATGCCGGGTGGGGTTACT 
MTHFD1L         GCTGGAGCGTGTTTGGGGCATCAGTGATGTCACCCGCTACAAATGCTGGGTGGGGTTACT 
                ******** ******** ***** **************** ***** ************* 
 
Chr9seq         GGACTGAGGGCCATGAAAAAAGAAAGCTGCGGCCCTGCCCCGTGGACTCACTGCCATTCT 
Chr2seq         GGACTGAGGGCCATGAAAAAAGAAAGCTGCGGCCCTGCCCCGTGGACTCACTGCCATTCT 
MTHFD1L         GGACTGAGGGCCATGAAAAAAGAAAGCTGCGGCCCCGGCCCGTGGACTCACTGCCATTCT 
                *********************************** * ********************** 
 
Chr9seq         GTTCTTTCTCACGTTTCAGTTCAGCTCACTTTGTTTTCCGTCCCCCTCCCTCTACTGTAA 
Chr2seq         GTTCTTTCTCACGTTTCAGTTCAGCTCACTTTGTTTTCCGTCCCCCTCCCCCTACTGTAA 
MTHFD1L         GCTCTTTCTCACGTTTCAGTTCAGCTCGGTTTGTTTTCCGTCCCCCTCCCTCTACTGTAA 
                * *************************  ********************* ********* 
 
Chr9seq         AAGTATGTACTCATTGTTTCATTTCCTGCTGGATCTGATTCAGGTCAGTGATGAAGTTCT 
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Chr2seq         AATTATGTACTCAGTGTTTCATTTCCTGCTGGATCTGATTCAGGTCAGTGATGAAGTTCT 
MTHFD1L         AAGTATGTACTCAGTGTTTCGTTTCCTGCTGGATCTGATTCAGGTCAGTGATGAAGTTAT 
                ** ********** ****** ************************************* * 
 
Chr9seq         TTGCGAGCTCAGTGGGGAGGCGTTTCCTCCCTTTCATACCGGCCCTGCTTAGGGATGCAT 
Chr2seq         TTGTGAGCTCAGTGGGGAGGCGTTTCCTCCCCTTCATACCGGCCCTGCTTAGGGATGCAT 
MTHFD1L         TTGTGAACTCAGTGGGGAGGTGTTTCCTCCCCTTTGTACCGGCCCTACTTAGGGATGCAC 
                *** ** ************* ********** **  ********** ************  
 
Chr9seq         GGTTGGTTATATACTTGCTTCACTCGGTTAGGCATGGAGGAGAATTCATTCAGACCTCAT 
Chr2seq         GGTTGGTTATATACTTGCTTCACTCGGTTAGGCATGGAGGAGAATTCATTCAGACCTCAT 
MTHFD1L         GGTTGGTTATACGCTTGCTTCACTCGGTTAGGCATGGAGGAGAATTCATTCAGCCCTCAT 
                ***********  **************************************** ****** 
 
Chr9seq         AGGTTTAAATCAAATGCATGACCCTTCACATTTTCCAGAGATTTA--GACAGTTACAGTG 
Chr2seq         AGGTTTAAATCAAATGCATGACCCTTCAGATTTTCCAGAGATTTA--GACAGTTACAGTG 
MTHFD1L         AGGTTTAAATCAAATGCATGACCCTTCACATTTTCCAGAGATTTACGGCCAGTTACAATG 
                **************************** ****************  * ******** ** 
 
Chr9seq         AGACAATTAAACATTCACCCCCC----AAGCTGCACTTGGAGATGTGTAAGCAGTAATGT 
Chr2seq         AGACAATTAAACATTCACCCCCC----AAGCTGCACTTGGAGATGTGTAAGCAGTAATGT 
MTHFD1L         AGACAATTAAACATTCACCCCCCCGCCAAGCTGCACTTGGAGATGTGTAAGCAGTAATGT 
                ***********************    ********************************* 
 
Chr9seq         AGTCATGCGCTCCCCATGATATGAGAGTGTGCAGAATGCCACTCCCCACAGCAGGTCCAC 
Chr2seq         AGTCATGCGCTCCCCATGATATGAGAGTGTGCAGAATGCCACTCCCCACAGCAGGTCCAC 
MTHFD1L         AGTCATGCGCTCCCCATGATGTGAGAGCGTGCAGAACGCCACTCCCCCCAGCAGGTCCGC 
                ******************** ****** ******** ********** ********** * 
 
Chr9seq         CAGGACCTCCTCAGGGAGCATCTTGCCTACAAAATCACCCATCCCTTTTCCCCCACTTTC 
Chr2seq         CAGGACCTCCTCAGGGAGCATCTTGCCTACAAAATCACCCATCCCTTTTTCCCCACTCTC 
MTHFD1L         CAGGACCTCCGCAGGGAGCATCTTGCCTGCAAAATCACACATCCCTTTTTCCCC-CTCTC 
                ********** ***************** ********* ********** **** ** ** 
 
Chr9seq         TTCACTTTCCCTACG---TTTCCACTCCCACACCCACAAATAAACAAAGAAACTTTGAGC 
Chr2seq         TTCACTTTCCCTACG---TTTCCACTCCCACACCCACAAATAAACAAAGAAGCTTTGAGC 
MTHFD1L         TCCACTTTCCCTACTACTTTTCCACTCCCACACCCACAAATAAACAAAGAAACCTTGAGC 
                * ************    ********************************* * ****** 
 
Chr9seq         TTATTTTACAAAAGTCTTTGAAATGGCCCTCCTCTCTCCGATGCTCCTGGGCCCTGGTTT 
Chr2seq         TTATTTTACAAAAGTGTTTGAAATGGCCCTCCTCTCTCTGATGCTCCTGGGCCCTGGTTT 
MTHFD1L         TTATTTTACAAAAGTCTTTGAAATGGCCCTCGTCTCTCCAATGCTCCTGGGTCCTGGTTT 
                *************** *************** ******  *********** ******** 
 
Chr9seq         GGCCCCATCTGTGCAGTCTCTCTGATGAGTGTGAAATAAGCCAGGTTTGGCTCATGCTCT 
Chr2seq         GGCCCCATCTGTGCAGTCTCTCTGATGAGTGTGAAATAAGCCAGGTTTGGCTCATGCTCT 
MTHFD1L         GGCCCCATCTGTGCAATCTCTCTGATGAGTGTGAAATAAGCCAGGTTTGGCTCATGCTCT 
                *************** ******************************************** 
 
Chr9seq         CCCTGTGAGCTTGCTCTCCCCGTGAGCCTGCCCTCTCCATCTGGCCTCACTTTGTTTGTG 
Chr2seq         CCCTGTGAGCTTGCTCTCCCCGTGAGACTGCCCTCTCCATCTGGCCTCACTTTGTTTGTG 
MTHFD1L         GCCGGTGAGCTTGCCCTCCCCATGAGCCTGTCCTCTCCATCTGGCCTCACTTTGTTTGTG 
                 ** ********** ****** **** *** ***************************** 
 
Chr9seq         TCCCTGGGTCCTTTGTCTCTGATCCTGGGATCCTGGTGGTTTCCTCCTCCCCGCCCAGCT 
Chr2seq         TCCCTGTGTCCTTTATCTCTGATCCTGGGATCCTGGTGGTTTCCTCCTCCCCGCCCAGCT 
MTHFD1L         TCCCTGTGTCCTTTGTCTCCCATCCTGGGATCCTGGTGGTTTCCTCCTCCCCTCCCAGCA 
                ****** ******* ****  ******************************* ******  
 
Chr9seq         TGGGTCCTTTTCCCCAGGGTTCTTCCCTATCTCTACATCAGAATTTCCTGCTTTCTCCCA 
Chr2seq         TGGGTACTTTTCCCCAGGGTTCTTCCCTATCTCTACATCAGAATTTCCTGCTTTCTCCCA 
MTHFD1L         TGAGTCCTTTTCCCCAGGGTTCTTCCCTATCTCTACATCAGAATTTCCTGCTTTCTCCCA 
                ** ** ****************************************************** 
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Chr9seq         AATATGCATTTCCCTGGCCCAGGCATCCATTGCTTCCTCTCATCGTGAGGTCCCTGCAGC 
Chr2seq         GATATGCATTTCCCTGGCCCAGGCATCCATTACTTCCTCTCATCGTGAGGTCCCTGCAGC 
MTHFD1L         AATATGCATTTCCCTGGCCCAGGCATCCACTGCTTCCTCTCATCGTGAGGTCCCTGCCGC 
                 **************************** * ************************* ** 
 
Chr9seq         AGACTGCCAATGGTGTTGTGGCCATGCCTTCCTCCACAACCCAGGGAAAGCTACATGTGT 
Chr2seq         AGGCTGCCGATGGTGTTGTGGCCATGCCTTCCTCCACAACCCAAGGAAAGCTACATGTGT 
MTHFD1L         AGGCTGCTGATGGTATTGTGGCCGTGCCTTCCTCCACAACCCAGGGAAAGCTACGTGTGT 
                ** ****  ***** ******** ******************* ********** ***** 
 
Chr9seq         GTCTGTCCCATAGGGAAGGAGTCATCCCTGTCTCTTCAGTGTGGCATGTTCAGGAGGAAG 
Chr2seq         GTCTGTCCCATAGGGAAGGAGTCATCCCTGTCTCTTCAGTGTGGCATGTTCAGGAGGAAG 
MTHFD1L         GTCTGTCCCATAGGGAAGGAGTCATCCCTGTCTCCTCAGTGTGGTGTGTTCAGGAGGAAG 
                ********************************** *********  ************** 
 
Chr9seq         GAAAGTAACCAGCGTCATTCTCAATTTCCGGAAACTGTTTATCATATTGACAAGAAGAAG 
Chr2seq         GAAAGTAACCAGCGTCATTCTCAATTTCCGGAAACTGTTTATCATATTGACAAGAAGAAG 
MTHFD1L         GAAAGTAACCAGCGTCGTTCTCAATTTCCAGAAACTGTTTATCATATTGACAAGAAGAAG 
                **************** ************ ****************************** 
 
Chr9seq         AAAGCTTTGCGACTCATGAGAATGATGTTTTCCTCTCTGGTACATAAGGTTATGTAGGTC 
Chr2seq         AAAGCTTTGTGACTCATGAGAATGATGTTTTCCTCTCTGGTACATAAGGTTATGTAGGTA 
MTHFD1L         AAAGCTTTGTGACTCATGAGAATGATGTTTTCCTCTCTGGTACATAAGGTTATCTAGGTC 
                ********* ******************************************* *****  
 
Chr9seq         CAATCCATT-GTGTAGAAGATCTTTTCTCCCTTAATGGGATGTACACTTATTTTTAGCAC 
Chr2seq         CAATCCATTTGTGTAGAGGATCTTTTCTCCCTTAATGTGATGTACAC--ATTTTTAGCAC 
MTHFD1L         CAATCCATTTGTGTAGAGGATCTTCTCTCCCCTAGTGTGATATGCACTTATTTTTAGCAC 
                ********* ******* ****** ****** ** ** *** * ***  *********** 
 
Chr9seq         AAGTATAAAACTACTTTAAATGAAGTCAGCCTCAGCCAGGGAAATATGCTGAGTAATAAT 
Chr2seq         AAGTATAAAACTACTTTAAATGAAATCAGCCTCAGCCAGGGAAATATGCTGAGTAATAAT 
MTHFD1L         AAGTATAAAACTACTTTAAATGAAATCAGCCTCAGCCAGGGAAATATGCTGAGTAATAAT 
                ************************ *********************************** 
 
Chr9seq         GTTGCCAGGTACTATACCACTGAGTTGAGTTTGCAATTCACTGCTATTAATCCCTGCATG 
Chr2seq         GTTGCCAGGTACTATACCACTGAGTTGAGTTTGCAATTCACTGCTATTAATCCCTGTGTG 
MTHFD1L         GTTGCCAGGTACTATACCACTGAGTTGAGTTTGTAATTCACTGCTATTAATCCCTGTGTA 
                ********************************* **********************  *  
 
Chr9seq         TTAGTTCTGAATTTTTACTCTTTGCATACGTAGAAAAAATGGTGTTTCTCTTCAGAGTCA 
Chr2seq         TTAGTTCTGAATTTTTACTCTTTGCATACGTAGAAAAA-TGGTGTTTCTCTTCAGAGTCA 
MTHFD1L         TTAGTTCTGATTTTTTACTCTTTGCATACATAGAAAAA-TGGTGTTTCTCTTCAGAGTCA 
                ********** ****************** ******** ********************* 
 
Chr9seq         AGGAGGGAAAAAA-GAAAAGTTAAAAGACACTTATAACACTTTTGTGTCCACCCCTAAAA 
Chr2seq         AGGAGGGAAAAAA-GAAAAGATAAAAGACGCTTATAACACCTTTGTGTCCACCCCTAAAA 
MTHFD1L         AGGAGGGAAAAAAAGAAAAGATAAAAGATGCTTATAACACTTTTGTGTCCACCCCTAAAA 
                ************* ****** *******  ********** ******************* 
 
Chr9seq         TCAGCATATTGATCTACTATTTTT-CTAGGTATTGATGGAATATTGACTCATATACTTTC 
Chr2seq         TCAGCATATTGATCTATTACTTTT-CTAGGTATTGATGGAATATTGACTCATATACTTTC 
MTHFD1L         TCAGCATATTGATCTATTATTTTTTCTAGGTATTGATGAGATGTTGACTCATATACTTTC 
                **************** ** **** *************  ** ***************** 
 
Chr9seq         ATACAACTG 
Chr2seq         ATAAAACTG 
MTHFD1L         ATACAACTG 
                *** ***** 
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